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General introduction
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INCIDENCE AND AETIOLOGY
Colorectal cancer (CRC) is the third most common cancer and is one of the major con-
tributors to cancer-related deaths worldwide 1;2. Approximately 20-25% of patients with 
CRC already have metastatic disease at the time of diagnosis and 20-25% of patients 
will develop metastases during disease progression as well, resulting in a 40-45% high 
mortality rate 3;4. CRC can be divided in colon cancer, where the development of tumors 
ranges from the caecum to the sigmoid, and rectal cancer,  that ranges from the recto-
sigmoid to the anus. Approximately one third of all colorectal cancers constitutes of 
rectal cancer.
CRC originates most often sporadically, is inherited in only 5% of the cases and evolves 
from benign pre-neoplastic lesions, such as adenomatous polyps or adenomas. The 
adenoma-carcinoma sequence, a series of well-defined histological stages, is respon-
sible for progression of these benign lesions to malignant carcinomas 5. Hanahan and 
Weinberg established six biological capabilities which tumors must acquire during the 
multistep development of human cancers, also called the hallmarks of cancer 6. These 
hallmarks are sustaining proliferative signaling, evading growth suppressors, activating 
invasion and metastasis, enabling replicative immortality, inducing angiogenesis and 
resisting cell death. More recently, they added two emerging hallmarks; reprogramming 
of energy metabolism and evading immune recognition and recognized the importance 
of the tumor-microenvironment, a repertoire of recruited normal cells around the tumor 
that contributes to the acquisition of these hallmarks as well 7.
Underlying these hallmarks are genome instability, which generates the genetic 
diversity responsible for the acquisition of these hallmarks, and inflammation 7. In CRC, 
three major mechanisms of genetic instability responsible for tumor development and 
progression have been identified (Figure 1). The first mechanism is through mutations in 
DNA mismatch repair (MMR) genes, which results in a failure to repair errors that occur 
during DNA replication, followed by alteration of the length of short, repetitive DNA 
sequences, called microsatellites, that occur in the human genome. This failure leads 
to the microsatellite instability (MSI) phenotype and is the hallmark of the hereditary 
Lynch Syndrome 8. In addition, in 12-15% of sporadic CRCs MSI has been found as well, 
but here hypermethylation of the hMLH1 promotor has been associated with this MSI 
phenotype 8. MSI tumors are more frequently right-sided, poorly differentiated, display 
more often the mucinous cell-type, show more peritumoral lymphocytic infiltration 
and are associated with an improved survival 9. Second, most CRCs arise through the 
chromosomal instability (CIN) pathway, which is also involved in CRC pathogenesis. 
CIN is observed in 65-70% of sporadic CRC and is characterized by allelic losses (loss of 
heterozygosity), chromosomal amplifications, and translocations in CRC cells 9;10. More 
recently, the existence of a new pathway for CRC development has gained attention. 
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These tumors are classified as having the CpG island methylator phenotype (CIMP), 
which involves the transcriptional silencing of tumor suppressor genes by hypermethyl-
ation of CpG islands of the promoter region of various genes 11. Approximately one-third 
to one-half of all CRCs may evolve through this pathway 12.
Recently, three main molecularly distinct subtypes of colon cancer, each associated 
with unique clinical and molecular features, were demonstrated 13. The first subtype 
demarcates the well characterized MSI/CIMP+ subset of colon cancers, which is mainly 
located on the right side of the colon. The second subtype, mostly left-sided, is largely 
devoid of MSI/CIMP+, but is typically associated with KRAS and/or TP53 mutations, 
suggesting to represent the well-described CIN tumors. The third subtype is evenly 
distributed throughout the colon, enriched with histologically poorly differentiated 
tumors, heterogeneous with respect to MSI or MSS and CIMP status, and contains a large 
proportion of KRAS and BRAF mutations as well. This subtype is associated with a poor 
prognosis and poor response to anti-epidermal growth factor receptor (EGFR) therapy. 
The enhanced expression of epithelial mesenchymal transition (EMT) and matrix remod-
Figure 1: Global overview of major mechanisms of genetic instability responsible for tumor development 
and progression in CRC.
Abbreviations; CRC colorectal cancer, MSI microsatellite instability, MSS microsatellite stability, CIN chro-
mosomal instability, CIMP CpG island methylator phenotype, BER base excision repair machinery, MMR 
mismatch repair, MLH1 MutL homolog 1, APC adenomatous polyposis coli, TP53 tumor protein 53, KRAS 
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, MUTYH mutY Homolog, PolE DNA polymerase e, 
PolD1 DNA polymerase d. + indicates mutation, - indicates wildtype.
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eling in these tumors provides a possible explanation for their poor prognosis and why 
these tumors metastasize more frequently as compared to subtype 2.  Furthermore, 
evidence showed that this subtype is highly related to serrated adenomas as serrated 
precursor lesions are thought to progress in this subtype of colon cancer 13.
TREATMENT
Treatment choices are nowadays influenced by the tumor, node and metastasis (TNM) 
classification, which aims to provide an exact prediction system for prognosis, to guide 
therapy choices and to create uniformity in cancer language 14;15. The survival of CRC pa-
tients largely depends on disease stage at diagnosis and varies widely between stages. 
In stage I, a five-year survival rate of 93.6% is seen, which drastically drops to 8.1% in 
stage IV patients 16.
The treatment of colon cancer comprises surgical resection of the primary tumor and 
regional lymph nodes. The last two decades, the role of adjuvant chemotherapy has 
gained importance and resulted in the introduction of a chemotherapy regimen in the 
Netherlands, consisting of oxaliplatin, fluorouracil and leucovorin, in stage III (lymph 
positive) and high-risk stage II colon cancer patients 17.
Nowadays, patients with rectal cancer are treated with pre-operative (chemo) radia-
tion (5x5 Gy) followed by surgical resection using the total mesorectal excision (TME) 
technique. Before the introduction of the TME technique the 5-year local recurrence rate 
of rectal cancer with conventional surgery was over 20% 18.  The last decades these local 
recurrence rates have decreased drastically, mainly influenced by the introduction of the 
TME technique and the introduction of pre-operative radiotherapy since the Dutch TME 
trial, which investigated the effect of short-term preoperative radiotherapy in combina-
tion with TME surgery compared to TME surgery alone between 1996 and 2000 19;20. The 
role of adjuvant chemotherapy in rectal cancer is still debatable. The use of adjuvant 
chemotherapy in patients not treated with pre-operative radiotherapy or chemotherapy 
seems beneficial 21, however, in patients treated pre-operatively no survival benefit has 
been reported 22-24.
ASPIRIN TREATMENT
The last decade aspirin is gaining ground in the treatment of CRC patients. There is a 
significant amount of evidence demonstrating that aspirin has anti-cancer effects 25-32. 
The first evidence comes from large cardiovascular prevention trials assessing the 
cardiovascular benefits of aspirin 29-32. In a pooled analysis of five large trials aspirin 
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taken for several years at doses of at least 75 mg daily has shown to reduce long-term 
incidence and mortality due to CRC 29.  Furthermore, aspirin showed to significantly 
reduce adenoma formation in patients with a history of CRC 33. More recently, aspirin 
has shown to be beneficial as adjuvant treatment as well. Aspirin taken after diagnosis 
significantly improved overall survival and colorectal cancer-specific mortality in pa-
tients with CRC 26;28;34.  At the moment, three recently started trials, ASCOLT in Asian CRC 
patients, the Big A trial in lung cancer patients and the Add Aspirin trial in colorectal-, 
breast-, upper gastrointestinal- and prostate – cancer patients, investigate the role of 
aspirin as adjuvant treatment (http://clinicaltrials.gov).
The exact mechanism by which aspirin exerts its activity is not completely understood. 
Direct inhibition of the cyclooxygenase (COX) family of enzymes involved in prostaglan-
din synthesis has been attributed to the protective activity of aspirin. The COX-2 enzyme 
is strongly and rapidly induced in response to mediators of inflammation, growth 
factors, cytokines, and endotoxins; and its expression correlates with increased cell 
proliferation and tumor promotion 35. Aspirin can decrease the production of potentially 
neoplastic prostaglandins arising from COX-2 mediated catalysis of arachidonic acid 36. 
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Figure 2: Global overview of possible pathways responsible for the anti-cancer effects of aspirin.
Abbreviations; COX: cyclooxygenase,TXA2 thromboxane A2, NFκB nuclear factor-κB, IGF-1 insulin growth 
factor 1. Partly based on Langley et al, BJC 2011; 105,1107-1113.
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However, research has shown that aspirin has a much broader range of downstream 
effectors as well, such as NF-ĸB, insulin-like growth factor I (IGF-1), and the inhibition 
of Wnt-signaling and stem cell growth possibly as the result of enhanced beta-catenin 
phosphorylation 27;37-39 (Figure 2).
Studies trying to unravel the anti-cancer effects of aspirin thus far have been incon-
sistent. Possibly, more than one mechanism is responsible for the anti-cancer effects of 
aspirin. It is also plausible that different molecular mechanisms are responsible for the 
beneficial effects of aspirin on CRC incidence (prevention) than on already established 
CRC (therapy).
In the preventive setting of CRC COX-2 might play an influential role since regular aspi-
rin use has shown to be associated with a lower risk of CRCs that overexpress COX-2, but 
not CRCs without COX-2 overexpression 26. Also, inhibition of WNT/cadherin-associated 
protein b1 signaling (CTNNB1 or b-catenin), one of the most essential oncogenic path-
ways in CRC, has been described to reduce the risk for CRC. Aspirin inhibits this CTNNB1 
signaling pathway COX-dependently but also through COX-independent pathways by 
directly inducing phosphorylation and subsequent degradation of CTNNB1 40. More 
recently, a study showed that aspirin use stabilizes DNA methylation at promotors of 
genes controlling critical cancer pathways. Age dependent methylation was suppressed 
in aspirin users and long-term aspirin use was associated with a more than 50% sup-
pressed rate of methylation when compared with nonuse. Aberrant DNA methylation in 
gene promotors has been associated with aging and cancer 41.
In the first study investigating the molecular mechanisms responsible for the thera-
peutic effect of aspirin after a CRC diagnosis, COX-2 expression was mentioned to play 
a major role 26. The survival benefit with aspirin use after diagnosis in CRC was associ-
ated with COX-2 expression of the tumor. A much lower risk of CRC-specific and overall 
mortality with tumors that overexpress COX-2 was found.
Research from the same group has also shown that aspirin may suppress cancer-cell 
growth and induce apoptosis by blocking the phosphatidylinositol 3-kinase (PI3K) path-
way upstream of COX-2 42. This pathway plays an important role in carcinogenesis 43. Mu-
tations in PIK3CA (gene encoding for phosphatidylinositol-4,5-biphosphonate 3-kinase, 
catalytic subunit alpha polypeptide) are found in approximately 15 to 20% of colorectal 
cancers 44.
Furthermore, COX-1 might also be responsible for the improved survival of aspirin 
users in CRC, since aspirin influences platelet aggregation through COX-1 inhibition 45. 
Recent evidence suggest that platelets may play an important active role in promoting 
metastasis by active signalling to tumor cells through the TGF-b and NF-ĸB pathways 
resulting in a prometastatic phenotype that facilitates tumor cell extravasation and 
metastasis 46. Aspirin has shown to inhibit the activation of NF-ĸB 47.
14 Chapter 1
Finally, it has been shown that IL-4 expression is essential for the resistance to DNA 
damage-induced apoptosis of colon cancer stem cells (CSCs) 48. CSCs are also resistant 
to the cytotoxic effect of chemotherapy. It has been shown that IL-4 confers colon 
CSCs with resistance to apoptosis 48. Consistently, treatment with IL-4Ra antagonist or 
anti-IL-4 neutralizing antibody strongly enhances the antitumor efficacy of standard 
chemotherapeutic drugs through selective CSCs sensitization. Notably, aspirin inhibits 
IL-4 gene expression 49. Based on the above observations, it is plausible that aspirin may 
both act as a preventive agent in CRC onset by modulating the Wnt pathway in CSCs, but 
also as adjuvant treatment by increasing CSCs’ sensitivity to conventional chemotherapy 
regimens.
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN CRC
To date, tumor location and tumor stage have majorly influenced treatment decisions. 
However, new insights and advances in the molecular biology of CRC have started to 
influence prognostication and treatment decisions. Molecular mechanisms responsible 
for tumorigenesis are likely to influence clinical outcome 6. Also, research has shown that 
approximately 20-25% of patients with lymph-node negative stage II colon cancer, which 
were not recommended adjuvant treatment based on TNM stage, suffer from recurrent 
disease within 5-years of follow-up 50. The TNM stage is therefore not an optimal tool 
for prognostication and treatment allocation, especially in high-risk stage II patients, 
and needs to be supplemented with additional biomarkers that can improve the current 
staging and treatment allocation criteria substantially.
By investigating biomarkers that reflect tumor growth and metastatic potential, a 
more accurate prediction on prognosis and treatment benefit based on underlying 
biology can be made. Predicting the clinical behavior of a tumor through a combination 
of clinical, pathological and biological characteristics may lead to a well-targeted treat-
ment in the individual patient. Evading immune recognition, sustaining proliferative 
signaling and resisting cell death are important mechanisms that cancer cells acquire 
during further tumor development 7 and are therefore studied in the research described 
in this thesis.
OUTLINE OF THIS THESIS
The aim of this thesis was to define prognostic and predictive biomarkers in colorectal 
cancer for improved risk stratification and treatment benefit in the individual patient, 
with the introduction of precision medicine in the near future as the ultimate goal. By 
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definition, precision medicine is a multi-faceted approach to medicine that integrates 
molecular and clinical research with patient data and clinical outcome, and places the 
patient at the center of all elements. This thesis is divided in three parts. In Part one 
prognostic biomarkers in CRC are investigated, in Part two aspirin treatment and related 
predictive biomarkers for aspirin treatment benefit in colon cancer are investigated and 
finally, in Part three, the use of predictive and prognostic biomarkers in clinical practice, 
its utility and the road to precision medicine are discussed.
The last two decades, research has shown that the immune system has a substantial 
effect on tumor growth and metastasis 51. Tumors are thought to be ‘edited’ through a 
Darwinian selection process in poorly immunogenic tumor cell variants able to evade 
immune recognition and consequently growth progression 52-55. Several mechanisms in 
the tumor contribute to this process. First, downregulation of human leukocyte antigen 
(HLA) class I expression, which minimizes the level of tumor-associated antigen (TAA) 
expression by tumor cells, followed by less immune recognition and subsequently less 
destruction by cytotoxic T-cells (CTL) 56. Second, expression of non-classical HLA class I 
molecules (HLA-E and HLA-G) on the tumor cell surface. HLA-E is regularly expressed in 
various healthy tissues and correlates with HLA class I expression 57. In contrast, HLA-G 
is rarely expressed in healthy tissues but has been frequently observed in tumors 58. 
Both have been associated with inhibition of natural killer (NK) cell recognition resulting 
in further escape from immune recognition 58;59. Third, attraction of immunosuppres-
sive regulatory T cells (Tregs) into the tumor micro-environment, which suppress the 
activity of CTL 60;61. Conflicting results have been described for the association between 
expression of these markers and prognosis in CRC patients, possibly due to the use of 
different patient cohorts and the investigation of solely one marker. Research has shown 
a complex relationship between different immune markers, highlighting the need for 
combined marker analysis 62-64. Therefore, in Chapter 2 we evaluated the association 
of these immune markers, separately and combined, with prognosis in colon cancer 
patients.  We performed the same analysis in rectal cancer patients to investigate differ-
ences in immune escape mechanisms between colon- and rectal cancer in Chapter 3.
Deregulation of the proliferative signaling pathway and deregulation of the apoptotic 
pathway are also two important hallmarks of tumor development, which disturb tissue 
homeostasis and balance 6. Previous studies have shown contradicting results with re-
spect to the relation of apoptotic - or proliferation levels in tumor specimens and patient 
outcome in CRC 65-68. In Chapter 4 we therefore investigated if the combined analysis of 
these two processes would better reflect tumor aggressiveness.
Over the last decades the public health sector witnessed a vast and rapid develop-
ment of genomic profiling techniques, with the promise of precision medicine as a 
strong driving force.  Prediction of pathway deregulation coupled to molecular target 
identification using genome wide approaches may provide an opportunity to guide 
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treatment 69. Since various molecular pathways are involved in carcinogenesis, multigene 
assays might give a more reliable insight in tumour biology and risk of recurrence than 
single-gene analysis. One of those multi-gene assays is the Oncotype DX Colon Cancer 
Recurrence Score (RS) (Genomic Health, Redwood City, CA, USA), which measures the 
expression of 12 genes and was validated as a predictor of recurrence risk in stage II 
colon cancer patients 70;71. Validation of this multi-gene assay in rectal cancer has been 
performed and described in Chapter 5.
In Part two of this thesis, the benefit from aspirin treatment in colon cancer is 
described. In Chapter 6, this benefit was investigated in older colon cancer patients. 
Recent studies have shown that regular use of aspirin after diagnosis was associated 
with longer survival among patients with mutated- PIK3CA CRC, but not among wild-
type PIK3CA tumors 44, and among patients who express high tumor levels of COX-2 26. 
In Chapter 7 we showed that colon cancer patients only benefit from aspirin treatment 
when these patients expressed HLA class I on their tumor cell surface. The aspirin benefit 
on survival was not associated with PIK3CA or COX-2 expression in our cohort.
In Part three of this thesis the use and introduction of biomarkers in clinical practice 
influencing precision therapy (Chapter 8) and the impact of genomic profiling on sur-
gery (Chapter 9) are discussed.  Finally, an overall summary and discussion of the data 
presented in this thesis are provided in Chapter 10.
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ABSTRACT
Background
Evasion of immune surveillance and suppression of the immune system are important 
hallmarks of tumor development in colon cancer. The goal of this study was to establish 
a tumor profile based on biomarkers that reflect a tumors’ immune susceptibility status 
and to determine their relation to patient outcome.
Methods
The study population consisted of 285 Stage I-IV colon cancer patients of which a tissue 
micro array (TMA) was available. Sections were immuno-histochemically stained for 
presence of Foxp3+ cells and tumor expression of HLA Class I (HLA-A, -B, -C) and non-
classical HLA-E and HLA-G. All markers were combined for further analyses, resulting in 3 
tumor immune phenotypes: a, strong immune system  tumor recognition; b, intermedi-
ate immune system  tumor recognition; and c, poor immune system  tumor recognition.
Results
Loss of HLA class I expression was significantly related to a better OS (p-value 0.005) 
and DFS (p-value 0.008). Patients with tumors that showed neither HLA class I nor HLA-
E or -G expression (phenotype a) had a significant better OS and DFS (p-value <0.001 
and 0.001, respectively) compared to phenotype b (OS HR 4.7, 95% CI 1.2-19.0, p=0.001) 
or c (OS HR 8.2, 95% CI 2.0-34.2, p=0.0001). Furthermore, the tumor immune phenotype 
was an independent predictor for OS and DFS (p=0.009 and 0.013 respectively).
Conclusions
Tumors showing absence of HLA class I, HLA-E and HLA-G expression were related to 
a better OS and DFS. By combining the expression status of several immune-related 
biomarkers, three tumor immune phenotypes were created that related to patient 
outcome. These immune phenotypes represented significant, independent, clinical 
prognostic profiles in colon cancer.
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INTRODUCTION
Historically, the immune system has been attributed an important role in controlling 
tumor growth and metastasis 1-4. Evasion of immune surveillance and suppression of 
the immune system are two important traits cancer cells have to acquire during the 
process of tumorigenesis 5. Research of the last century has indicated that the influence 
of the immune system on tumor cells, both in the tumor micro-environment as well as 
during the process of tumor metastasis, also contributes to tumor progression 6. The 
cancer immune-editing hypothesis describes both the host-protective as well as the 
tumor-promoting actions the immune system might have on developing tumors, shap-
ing tumor immunogenicity 7-13. Tumors are thought to be ‘edited’ through a Darwinian 
selection process into poorly immunogenic tumor cell variants invisible to the immune 
system and able to grow progressively. Immune-editing might therefore have substan-
tial effects on patient’s prognosis.
Several mechanisms taking place at the tumor cell level contribute to this process. The 
first mechanism is downregulation of human leukocyte antigen (HLA) class I expression. 
Downregulation of HLA class I minimizes the level of tumor-associated antigen (TAA) 
expression by tumor cells and therefore their recognition and subsequently destruction 
by cytotoxic T-cells (CTL) 5;14-16. The second mechanism is the ability of tumor cells to 
regulate the expression of non-classical HLA class I molecules (HLA-E and HLA-G) on the 
cell surface. Expression of these markers has been found to inhibit Natural Killer (NK) 
cell recognition in the blood stream and therefore results in further tumor cell escape 
from immune surveillance 17-20. HLA-E is regularly expressed in various healthy tissues 
and correlated with HLA class I expression 21. In contrast, HLA-G is rarely found in healthy 
tissues, but is frequently observed in tumors 19. Thirdly, tumor cell immune reactivity can 
become suppressed by the attraction of immunosuppressive regulatory T cells (Tregs) 
into the tumor micro-environment 22;23. Tregs are able to modulate the anti-tumor im-
mune response as they suppress the activity of CTL through direct cell-to-cell contact 
or via the release of cytokines like transforming growth factor β 24-26. Tregs and CTLs 
therefore show opposing actions in tumor immunity 27.
Previously, both the downregulation of HLA class I, presence of Tregs and HLA-E and 
-G expression have been shown to be of clinical relevance in several types of cancers 28-31. 
In colorectal cancer (CRC), various studies have described the impact of the level of HLA 
class I tumor expression or the presence of Foxp3+ Tregs cells on patients with vary-
ing results 32-39. In general, loss of HLA class I tumor expression seemed to result in a 
better prognosis 39;40. The presence of high levels of Foxp3+ cells in CRC patients was 
related to a worse prognosis in some studies, although this relation could not always 
be established in CRC patients 33;34;37;38;41. Studies on the prognostic value of HLA-E and 
28 Chapter 2
HLA-G showed that expression of these molecules correlated with poor prognosis and 
tumor progression 42-45.
Previous studies have shown a complex interaction between different immune mark-
ers, highlighting the need for combined marker analysis 29;41;46. The purpose of this study 
was to investigate the prognostic value of the immune-related biomarkers HLA Class I, 
HLA-E and -G and Foxp3+, to establish distinct patterns that reflect a tumor’s immune-
escape mechanism by combining these markers, and to relate these patterns to clinical 
outcome.
MATERIALS AND METHODS
Study population
The patient population comprised a consecutive series of 470 colorectal cancer patients 
all treated with surgery for their primary tumor in the Leiden University Medical Center 
(LUMC) between 1991 and 2001. Of these patients tumor material, clinico-pathological 
data and information on the follow-up was collected in retrospect. This research was 
performed according to the code of conduct for responsible use. Mucinous differentia-
tion was defined as fully (>50%), partly (0-50%) or no mucinous differentiation. Tumor 
Node Metastasis (TNM) was defined by the Union for International Cancer Control 
(UICC) 47. Tumor differentiation was defined as good, moderate or poor, as described 
in the pathology report. Patients with rectal cancer, patients with a history of cancer 
other than basal cell carcinoma or cervical carcinoma in situ, patients with more than 
one colon tumor at the same time, and patients that received radio- or chemotherapy 
treatment prior to resection were excluded from the analysis (n=185 in total). The study 
cohort therefore consisted of 285 colon cancer patients.
Antibodies
The mouse monoclonal antibodies HCA2 and HC10 were used, which recognize the 
heavy chains of HLA Class I, and were kindly provided by Prof. Dr. J. Neefjes. The reactiv-
ity spectrum of HCA2 comprises all HLA-A chains (except HLA-A24), as well as some 
HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G chains. HC10 reacts with HLA-B and HLA-C 
heavy chains and some HLA-A (HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-
A32, HLA-A33) 46.  The mouse antibodies against human Foxp3 (ab20034 clone 236A/E7; 
Abcam) were used for Treg identification. The reactivity spectrum of Foxp3 is composed 
of regulatory T cells and may include small numbers of CD8+ cells but is generally con-
sidered to be the best single marker for Treg identification 48;49. For HLA-E and HLA-G 
identification mouse monoclonal antibodies against HLA-E (ab2216 clone MEM-E/02: 
AbCam, UK) and HLA-G (4H84: Exbio, Czech Republic) were used. MEM-E/02 recognizes 
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denatured HLA-E 50;51, while 4H84 recognizes denatured HLA-G molecules and also binds 
to free heavy chains of classical HLA class I molecules 51-53.
TMA production and immunohistochemistry
The histo-pathological characteristics of the tumor material from all patients included 
were determined by qualified pathologists according to current standards. Of the 
formalin-fixed paraffin-embedded (FFPE) tumor blocks of the primary tumors, sections 
were cut for haematoxylin and eosin staining. Based on microscopic inspection of the 
slides, histo-pathologically representative bulk tumor regions from each tumor block 
were identified and punched for preparation of tumor tissue microarray (TMA) blocks. 
From each donor block, three 0.6 mm diameter tissue cores were punched from the 
identified tumor areas and transferred into a receiver paraffin block using a custom-
made precision instrument. Immuno-histochemical staining (IHC) for Foxp3+ cells, non-
classical HLA-E and HLA-G, and classical HLA class I tumor expression was performed 
on 4 µm sections, which were cut from each receiver block and mounted on glass.
The sections were deparaffinized and rehydrated according to standard procedures. 
Endogenous peroxidase was blocked for 20 minutes in 0.3% hydrogen peroxide in PBS. 
For antigen retrieval, slides were boiled in 0.01 M EDTA buffer (pH 8) for 10 minutes 
at maximum power in a microwave oven. Sections were incubated overnight with 
anti-Foxp3+, -HLA-E or -HLA-G antibodies at pre-determined optimal dilution. After 30 
minutes of incubation with Envision anti-mouse (K4001; DAKO Cytomation, Glostrup, 
Denmark), sections were visualized using diaminobenzidine solution (DAB+). Tissue 
sections were counterstained with haematoxylin, dehydrated and finally mounted in 
pertex. The IHC for HCA2 and HC10 was performed using the Autostainer Link 48 (DAKO). 
For antigen retrieval Envision TM Target Retrieval Solution (DAKO), pH low, was used. 
The sections were incubated for 18 hours with either HCA2 or HC10 antibodies at pre-
determined optimal dilution, followed by incubation with Envision FLEX/HRP (DAKO). 
Sections were visualized using DAB+ liquid solution (DAKO). Finally these slides were 
counterstained with haematoxylin as well, dehydrated and finally mounted in pertex. 
All slides were stained simultaneously to avoid interassay variation. For each patient, 
normal epithelium, stromal cells, or lymphoid cells served as internal positive control 
for HLA class I antibody reactivity.   Placenta tissue slides served as positive control for 
HLA-E and HLA-G staining. Slides from human tonsil tissue served as positive control 
for Foxp3+ staining. Negative controls were tissue slides that did undergo the whole 
immunohistochemical staining without primary antibody.
Evaluation of immunohistochemistry
Microscopic analysis of HCA2, HC10, HLA-E and HLA-G expression and presence of Foxp3 
+ cells was performed by two independent observers in a blinded manner (M.S.R.: 100% 
30 Chapter 2
of the cohort, E.C.M.Z. 30% of the cohort). The Cohen’s Kappa was > 0.75 for all stainings 
indicating substantial agreement between the two observers. The scores of the three 0.6 
mm punches were averaged. For HCA2 and HC10 the percentage of tumor cells with 
membranous staining was assessed. HLA class I expression status was determined ac-
cording to the standard set by the International HLA and Immunogenetics Workshop 54. 
HCA2 and HC10 expression percentages were divided into two categories; 0-5% of the 
tumor cells show expression and 5-100% show expression. If <5% of the tumor cells 
showed expression for each of the two markers, this was determined to represent loss of 
HLA class I expression; if expression in <5% of the tumor cells of one of the two markers 
as HLA class 1 downregulation; and if expression in more than 5% of the tumor cells 
for each of the two markers this was denoted as HLA class I expression. For HLA-E and 
HLA-G, intensity of tumor staining (absent, weak, moderate or strong intensity) was 
determined. For HLA-E, absent and weak staining together versus moderate and strong 
staining together were used for the final analysis. For HLA-G, absent tumor staining was 
analyzed versus weak, moderate and strong tumor staining together, because HLA-G is 
normally not expressed on healthy tissues in comparison to HLA-E 19;21. Quantification of 
the number of Foxp3+ cells was microscopically assessed in the entire tumor punches of 
the TMA and the absolute number of positive cells was used for the analysis.
Determination of microsatellite stability status
DNA was extracted from 2mm tumor-cores. Paraffin was dissolved in xylene, tissue was 
rehydrated in ethanol (100%/70%) and dried for 10 minutes at 37°C. Nucleospin 96 Tis-
sue kit (Machery-Nagel, Düren, Germany) was used for DNA extraction according to the 
manufacturer’s protocol.
MSS-status was tested using the MSI Analysis System Version 1.2 (Promega, Mannheim, 
Germany) and interpreted by an experienced pathologist, as described previously 55.
Statistical Analysis
Statistical analyses were performed using the statistical package SPSS (version 17.0 for 
Windows; SPSS Inc.). The Student’s T-test and the Chi-squared test were used to evaluate 
associations between tumor expressions of HLA class I, and non-classical HLA-E and 
HLA-G and tumor infiltration of Foxp3+ cells and various clinico-pathological variables. 
Overall Survival (OS) was defined as time of surgery until death and Disease Free Sur-
vival (DFS) as time of surgery until death or relapse of disease, whichever came first. The 
Kaplan-Meier method was used for calculation of survival probabilities and the Log-rank 
test for comparison of survival curves between these three phenotypes. Cox regression 
was used for univariate and multivariable analysis for OS and DFS. Significant variables 
(p<0.05) in univariate analysis were included in multivariable analysis.
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RESULTS
HLA class I expression
Microscopic quantification of HLA class I expression was performed on 242 patients 
as, due to staining artifacts and loss of material during the staining procedure, the 
IHC results of 43 cases could not be analyzed.  Representative images of HLA class 1 
staining  and frequencies of HLA class I expression in the different groups are shown in 
Figure 1 and 2. Patient characteristics and data on HLA class I expression are shown in 
Figure 1: Representative images of HLA class 1, HLA-E, HLA-G and Foxp3+ staining 
  Representative images of 
immunohistochemical stainings 
for HLA Class I expression 
(HCA2 and HC10), HLA-E and 
HLA-G expression and presence 
of FOXP3+ on the left side with 
magnifications on the right side, 
performed according to standard 
protocols (details in Material and 
Methods).
(A) HCA2-positive tumor  (B) 
HC10-positive tumor (C) HC10- 
negative tumor with positive 
internal control (D) HLA-E-
positive tumor (E) HLA-G- 
positive tumor and (F) Presence 
of Foxp3+ cells as indicated by 
the arrows.  
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Figure 1: Representative images of HLA class 1, HLA-E, HLA-G and Foxp3+ staining.
Representative images of immunohistochemical stainings for HLA Class I expression (HCA2 and HC10), 
HLA-E and HLA-G expression and presence of FOXP3+ on the left side with magnifications on the right side, 
performed according to standard protocols (details in Material and Methods).
(A) HCA2-positive tumor  (B) HC10-positive tumor (C) HC10- negative tumor with positive internal control 
(D) HLA-E-positive tumor (E) HLA-G- positive tumor and (F) Presence of Foxp3+ cells as indicated by the 
arrows.
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Table I. Since HCA2 also reacts with some HLA-G chains 46, we examined the relationship 
between HCA-2 reactivity and HLA-G expression and found no correlation (p=0.348).
Patients whose tumors showed loss of HLA class I had a significantly better OS and 
DFS (logrank p-value 0.005 and 0.008) compared to patients with tumors with HLA class I 
downregulation or expression (Figure 3). The Hazard Ratios (HRs) for OS and DFS for HLA 
class I tumor expression are shown in Table IIa and IIb.
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.) 
322 (1.7) 
1322 (7.) 
02 (1.0) 
132 (.7) 
1112 (.3) 
12 (1.) 
2 (2.2) 
12 (7.) 
121 (20.3) 
32 (11.) 
20021 (7.7) 
A
C D
B
Figure 2: Frequencies of HLA class I tumor expression, Foxp3+ tumor infiltration and HLA-E and –G tumor 
expression.
Pie-charts indicating the frequencies of all stainings including missings due to staining artifacts and loss 
during the staining procedure. Details about group composition and scoring methods are written in Mate-
rial and Methods. (A) Frequency of HLA class I tumor expression; (B) Frequency of Foxp3+ tumor cell infiltra-
tion; (C) Frequencies of HLA-E tumor expression; (D) Frequency of HLA-G tumor expression.
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Foxp3+ cells
The number of Foxp3+ cells could be evaluated in 245 patients, because, due to stain-
ing artifacts and loss of material during the staining procedure, the IHC results of 40 
cases could not be analyzed. The mean number of positive cells per tumor punch was 19 
with a median of 12.0. In 4.1% (n=10) of the patients no Foxp3+ cells were present. 
Representative images of Foxp3+ staining are shown in Figure 1. Patients with expres-
sion of HLA class I showed borderline significantly higher levels of Foxp3+ cells in their 
tumor punches compared to HLA class I downregulation or loss: mean in expression 
A
0.
00
0.
25
0.
50
0.
75
1.
00
183 105 63 19
37 15 6 1
11 10 6 2
Number at risk
0 5 10 15 20
Years
Loss of HLA Class I Downregulation of HLA Class I
Expression of HLA Class I
P=0.005
B
0.
00
0.
25
0.
50
0.
75
1.
00
182 9 58 18
37 15 6 1
11 10 6 2
Number at risk
0 5 10 15 20
Years
Loss of HLA Class I Downregulation of HLA Class I
Expression of HLA Class I
P=0.00
Figure 3: Survival curves stratified for HLA class I tumor expression in colon cancer.
A ) Kaplan Meier curve for OS in the study population of 285 colon cancer patients stratified for HLA class I 
tumor expression status. B) Kaplan Meier curve for DFS in the study population of 285 colon cancer patients 
again stratified for HLA Class I tumor expression.
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group 21 vs. a mean of 12 and 14 positive cells in the downregulation group and loss 
of HLA class I group respectively; p-value 0.07. Patients with stage 1 tumors showed 
significantly higher levels of Foxp3+ cells compared to patients with stage 2, stage 3 and 
stage 4 tumors: mean level of Foxp3+ cells in stage 1 tumors was 38 compared to 13, 17 
and 20 for the stage 2, 3 and 4 tumors, p-value <0.001.  For further analysis Foxp3+ was 
categorized as below vs. above median based on the median due to the skewness in 
the spread of the data. Frequencies are shown in Figure 2. The presence of Foxp3+ cells 
in the tumor micro-environment was not related to OS (logrank p-value 0.114) or DFS 
(logrank p-value 0.155).
HLA-E and HLA-G
Representative images for HLA-E and HLA-G and frequencies in the different groups are 
shown in Figure 1 and 2. HLA-E and HLA-G were not related to OS and DFS (logrank 
p-values for OS 0.809 and 0.239 respectively, logrank p-values for DFS 0.876 and 0.117 
respectively). None of the clinico-pathological characteristics were significantly related 
to tumor expression of HLA-E or HLA-G (data not shown).
A combined variable of HLA-E and HLA-G scores was created (cEG). Expression was 
considered positive when both HLA-E and HLA-G were expressed (HLA-E+/-G+ further 
denoted as cEG+) and negative when either HLA-E or HLA-G was not expressed (HLA-
E+/-G- or HLA-E-/-G+ or HLA-E-/-G- further denoted as cEG-). Positive cEG was found 
in 14.7% (42 of 244) of tumors. Patient characteristics and data on the combined vari-
able HLA-E and -G expression can be found in Table I. None of the clinico-pathological 
variables shown in Table I were significantly related to tumor expression of cEG. cEG was 
not significantly related to OS (logrank p-value 0.245) and DFS (logrank p-value 0.100).
Multivariable analysis
Both for OS and DFS a univariate analysis was performed for the following parameters: 
sex, age, TNM stage, HLA class I expression status, mucinous differentiation, tumor 
grade, adjuvant therapy and microsatellite status. In the univariate analysis for OS, 
age (p-value <0.001), TNM status (p-value <0.001) and HLA class I expression status (p-
value 0.011) were significant predictors of survival. The same was true for the univariate 
analysis for DFS with a p-value of <0.001 for age and TNM status and a p-value of 0.02 for 
HLA class I expression. Therefore all three were included in the multivariable analysis. In 
this analysis age and TNM stage remained significant for both OS and DFS (OS and DFS 
p-values all <0.001): HLA class I was a borderline independent significant predictor for 
OS (p-value 0.08) (Table IIa and IIb).
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Table IIa: Univariate and multivariable analyses of Overall Survival (OS) in the different immune markers 
and in the tumor immune phenotypes
Univariate analysis Multivariable analysis*
HR 95% CI p-value HR 95% CI p-value
HLA class I 0.011 0.08
Loss 1.0  1.0  
Downregulation 7.3 1.7-30.8 4.3 1.0-18.5 
Expression 4.9 1.2-20.0 3.1 0.7-12.6 
Foxp3+ 0.116
Below median 1.0      
Above median 0.8 0.6-1.1     
HLA-E 0.810
Negative 1.0      
Positive 1.0 0.7-1.4     
HLA-G 0.242
Negative 1.0      
Positive 1.2 0.9-1.8     
HLA-EG 0.248
Negative 1.0      
Positive 1.3 0.8-1.9     
Immune phenotypes 0.001 0.009
Phenotype a 1.0   1.0   
Phenotype b 4.7 1.2-19.0  2.9 0.7-11.9  
Phenotype c 8.2 2.0-34.2  4.8 1.1-20.2  
*Corrected for sex, age, TNM stage, HLA class I expression status, mucinous differentiation, tumor grade, ad-
juvant therapy and microsatellite status. Only significant variables in univariate analysis are corrected in mul-
tivariable analysis. Note: HLA-EG is a combination of HLA-E and HLA-G (as explained in the results section).
Table IIb: Univariate and multivariable analyses of Disease Free Survival (DFS) in the different immune 
markers and in the tumor immune phenotypes.
Univariate analysis Multivariable analysis*
HR 95% CI p-value HR 95% CI p-value
HLA class I 0.021 0.104
 Loss 1.00  1.00  
 Downregulation 7.2 1.7-30.1 4.6 1.1-19.7 
 Expression 5.4 1.3-21.8 3.7 0.9-15.0
Foxp3+ 0.159
 Below median 1.00      
 Above median 0.8 0.6-1.1     
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Analysis of tumor immune phenotypes
Except for HLA class I, none of the tumor immune markers showed a significant correla-
tion with patients’ clinical outcome. The interaction between tumor cells and immune 
cells, however, is complex and multifaceted. Therefore, we hypothesized that analysis of 
combined tumor immune markers; describing a tumor’s immune phenotype may better 
reflect outcome of the interaction between tumor cells and the immune system. We 
combined all of the data into one combined variable. The Kaplan Meier curves performed 
with this combined variable indeed revealed 3 distinct patterns in relation to patient 
outcome (Figure 4 and 5). The entire population could be divided in 3 phenotypes:
a) Strong immune system tumor recognition: Patients with tumors that showed loss 
of HLA class I expression, presence of Foxp3+ cells in the tumor micro-environment, 
and negative cEG expression (n=11).
b) Intermediate  immune system tumor recognition: Patients with tumors that showed 
downregulation of HLA Class I expression and negative cEG expression, but were 
found to have Foxp3+ cells in the tumor micro-environment or patients with tumors 
that showed normal HLA class I expression irrespective of cEG expression and the 
presence of Foxp3+ cells (n=184).
Table IIb: Univariate and multivariable analyses of Disease Free Survival (DFS) in the different immune 
markers and in the tumor immune phenotypes. Continued
Univariate analysis Multivariable analysis*
HR 95% CI p-value HR 95% CI p-value
HLA-E 0.877
Negative 1.00      
Positive 0.97 0.7-1.4     
HLA-G 0.121
Negative 1.00      
Positive 1.3 0.9-1.9     
HLA-EG 0.104
Negative 1.00      
Positive 1.4 0.9-2.1     
Immune phenotypes 0.002 0.013
Phenotype a 1.00   1.00   
Phenotype b 5.1 1.3-20.7  3.5 0.8-14.2  
Phenotype c 8.4 2.0-34.9  5.4 1.3-22.7  
*Corrected for sex, age, TNM stage, HLA class I expression status, mucinous differentiation, tumor grade, adju-
vant therapy and microsatellite status. Only significant variables in univariate analysis are corrected in multivari-
able analysis. Note: HLA-EG is a combination of HLA-E and HLA-G (as explained in the results section).
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Figure 4: Survival curves stratified for combined tumor expression of HLA class I, HLA-E, HLA-G and Foxp3+ 
in colon cancer.
A) Kaplan Meier curve for OS in the study population of 285 colon cancer patients stratified for all the dif-
ferent combinations between tumor expression of HLA class I, combined expression of HLA-E and HLA-G 
(cEG) and the presence of Foxp3+ cells (Tregs) based on which 3 distinct patters could be distinguished, 
as shown in Figure 5. B) Kaplan Meier curve for DFS in the study population of 285 colon cancer patients 
stratified for all the different combinations between tumor expression of HLA class I, combined expression 
of HLA-E and HLA-G (cEG) and the presence of Foxp3+ cells (Tregs) based on which 3 distinct patterns could 
be distinguished, as shown in Figure 5.
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Figure 5: Survival curves stratified for immune phenotypes in colon cancer.
A) Kaplan Meier curve for OS in the study population of 285 colon cancer patients stratified for all the differ-
ent combinations between tumor expression of HLA class I, combined expression of HLA-E and HLA-G (cEG) 
and the presence of Foxp3+ cells (Tregs) based on which 3 immune phenotypes could be distinguished. 
See Results section for explanation of the phenotypes.  B) Kaplan Meier curve for DFS in the study popula-
tion of 285 colon cancer patients stratified for all the different combinations between tumor expression 
of HLA class I, combined expression of HLA-E and HLA-G (cEG) and the presence of Foxp3+ cells (Tregs) 
based on which 3 immune phenotypes could be distinguished. See Results section for explanation of the 
phenotypes.
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c) Poor immune system tumor recognition: Patients with tumors showing normal or 
downregulated HLA class I and no presence of Foxp3+ cells irrespective of their cEG 
expression (n=460).
These three phenotypes showed significant differences for OS (logrank p-value 
<0.001) and DFS (logrank p-value 0.001). The HRs of the three phenotypes for OS and 
DFS are shown in Table IIa and IIb.
Multivariable analysis
Again, both for OS and DFS a univariate analysis was performed for the following 
parameters: sex, age, TNM stage, tumor immune phenotype, mucinous differentiation, 
tumor grade, adjuvant therapy, and microsatellite status. In univariate analysis, next 
to age and TNM status,  the tumor immune phenotype was a significant predictor for 
OS (p-value 0.001) and DFS (p-value 0.002). Therefore all three these parameters were 
included in multivariable analysis. The tumor immune phenotype was an independent 
significant predictor for both OS (p-value 0.009) and DFS (p-value 0.013) and HRs are 
shown in table IIa and IIb.
DISCUSSION
Tumor-immune interactions may be important for the prognosis of cancer patients 17. 
In this study, we showed that by combining the immune-related markers HLA class I, 
HLA-E, HLA-G and Foxp3+, we were able to determine three distinct patterns in survival, 
which might represent how immune surveillance controls tumor growth and metastasis.
The first marker of tumor-immunogenicity used was the level of HLA class I expression 
of cancer cells. Our results are comparable with the results of other studies that were 
able to determine a prognostic effect of the HLA class I status in colon cancer 35;39. Wat-
son et al. showed that tumors with downregulation of HLA class I had a worse survival 
comparable with our results 39. In contrast, Menon et al. showed a survival benefit in 
patients with downregulated HLA-A tumors 35. However, when HLA-A and HLA-B/C were 
combined, statistical significance was lost. Furthermore, patients with expression of HLA 
class I were related to a better survival in the study by Watson et al., whereas our study 
showed an improved survival in patients with loss of HLA class I expression. Possible ex-
planations for these differences might be a different definition for HLA class I expression, 
differences in staining techniques and scoring or a different patient cohort, especially 
regarding the number of tumors showing microsatellite instability (MSI), which is associ-
ated with loss of HLA class I  and a better prognosis 56;57. In our study, 33% of the tumors 
with loss of HLA class I showed the MSI phenotype, in comparison to 14% and 13% for 
HLA class I downregulation and expression. Results from Menon et al. showed that 50% 
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of the tumors with loss of HLA class I had the MSI phenotype.  Unfortunately, Watson et 
al. did not mention microsatellite status of their study cohort.
As hypothesized, loss of HLA class I expression in tumor cells could also be related to 
a better patient survival because such cells, once they metastasize to the bloodstream, 
are eliminated by NK cell attacks 35;39;58. Tumors with loss of HLA class I have also shown 
to have significantly higher NK cell infiltration 15. More interestingly, the tumors showing 
loss of HLA class I in our cohort were also the ones that showed to be negative for HLA-E 
and -G expression (phenotype a). Absence of the HLA-E and -G expression makes them 
even more susceptible to NK cell elimination 17-20. Furthermore, this is also confirmed by 
CRC tumors with loss of HLA class I expression who do not metastasize to the liver 59.
The presence of the third marker Foxp3+ is thought to represent the inhibition of 
host-protective antitumor responses. When stimulated, they inhibit the function of 
CTL 6. Although the exact mechanism by which these cells are drawn into the tumor 
micro-environment remains unexplained, their immunosuppressive effect has been 
proven with a high density of tumor-infiltrating Foxp3+ cells found to be associated with 
an unfavorable prognosis in a wide range of human carcinomas, including breast and 
lung cancer 60;61. However, in colon cancer different results are reported as well 37;38. One 
possible explanation for these opposite results might be a different micro-environment 
of colon cancer, which is colonized with many gastro-intestinal bacteria, triggering the 
production of pro-inflammatory cytokines causing tumor-enhancing effects. Instead of 
the specificity of infiltrating T-cells for tumor-antigens, T-cells in colon cancer could be 
more specific for the microflora and suppress inflammation and immune responses from 
bacterial invasion, resulting in an anti-tumorigenic effect, which could explain the better 
prognosis of patients with tumors with a strong Foxp3+ infiltration 62. We were not able 
to demonstrate differences in disease outcome for Foxp3+ tumor infiltration supporting 
this latter hypothesis, but we did see differences in Foxp3+ infiltration if we combined 
them with HLA class I expression and with HLA-E and -G expression, especially in pa-
tients who have retained their HLA class I expression. Patients with normal HLA class I 
expression and absence of Foxp3+ cell infiltration showed a worse patient outcome. We 
hypothesize that the tumors of these patients have had a minimal CTL attack because 
the HLA class I expression is preserved, indicating no selective outgrowth of HLA class 
I-negative or downregulated tumors directed by CTL. Since CTL and Foxp3+ cells show 
opposing actions 27 and CTLs are supposed to be absent in these tumors, Foxp3+ cell 
infiltration might not be necessary. These tumors could therefore progress aggressively 
as immune surveillance is poor. In contrary, tumors with HLA class I expression, which 
were able to attract Foxp3+ cells, showed a slightly better prognosis. In this case, Foxp3+ 
cell infiltration might indicate CTL activity resulting in suppression of tumor growth.
Therefore, in our opinion, the clinical relevance of the studies by Watson et al. and 
several others does not provide an optimal perspective on prognosis 35;39, because ex-
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pression of a single immune marker is not sufficient for the selection of high-risk colon 
cancer patients or treatment allocation. As shown by our results and previous studies, 
immune markers are related to each other 29;46;63;64.
When all markers were combined, patients showing the worst prognosis were patients 
with HLA class I downregulation, negative or positive cEG expression and absence of 
Foxp3+ cells denoted as phenotype c.  We hypothesize that these poor immune system 
recognized tumors were able to elicit only a minimal CTL attack because they partly 
preserved HLA class I expression and subsequently attracted little to no Foxp3+ cells in 
their tumor micro-environment. Furthermore, these tumors showed a positive expres-
sion of HLA-E and -G, further escaping immune surveillance through inhibition of NK cell 
recognition 17-20. These tumor cells can therefore quickly progress to the bloodstream 
and might eventually metastasize.
It is important to realize that what we are evaluating is just a ‘snapshot’ of the ongoing 
process of cancer immuno-editing in the patient’s primary tumor at time of resection. 
Still, from a clinical point of view, at the patient’s bedside this is usually the only data 
available based on which clinical decision making has to take place and these data can 
actually be of clinical value to, for example, the allocation of adjuvant therapy as op-
posed by De Kruijf et al. in breast cancer and other studies 29;65;66.
Our study does have a few limitations. Not all combinations between HLA class I, 
HLA-E and -G and Foxp3+ were present in our cohort. There was no representation of 
tumors with loss of HLA class I, which were HLA-E and -G positive. Therefore we were not 
able to investigate the prognosis of these tumors, but we hypothesize that these tumors 
have a worse prognosis as these tumors might escape NK cell attack. Although there is a 
physiological correlation between HLA-E and HLA class I molecules, this has been found 
to be disturbed in tumors, suggesting further escape from immune recognition through 
upregulation of HLA-E 21;46. To truly investigate these tumors, our study has to be vali-
dated in a bigger cohort. Second, the antibodies we used for HLA class I detection only 
detected the heavy chain, but not the trimeric complex consisting of β2-microglobuline 
heavy chain and antigen 67. Therefore we should be careful using the term total loss 
of HLA class I. Third, we did not investigated the role of NK cells in patients with loss 
or downregulation of HLA class I, possibly explaining the positive prognostic effect of 
patients with loss of HLA class I expression. However, NK cell infiltration at the tumor site 
is scarce, indicating that tumor staining for NK cells might be minimally informative 40.
In conclusion we were able to identify local immune escape mechanisms of colon 
cancer, where the presence of Foxp3+ cell infiltration favors a better prognosis, indicat-
ing CTL activity. HLA-E and -G expression might play a pivotal role in distant immune 
escape mechanisms, where in case of loss or downregulation of HLA class I, HLA-E and 
-G expression determines distant metastases and prognosis of colon cancer patients. 
Furthermore we were able to determine three distinct survival patterns in colon cancer 
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patients based on immune surveillance. In the future these findings might contribute to 
better treatment allocation and maybe even the development of new cancer immuno-
therapies.    
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ABSTRACT
Background
Evasion of immune surveillance and suppression of the immune system are important 
hallmarks of tumorigenesis. The goal of this study was to establish distinct patterns that 
reflect a rectal tumors’ immune-phenotype and to determine their relation to patient 
outcome.
Methods
The study population consisted of 495 Stage I-IV non-preoperatively treated rectal can-
cer patients of which a tissue micro array (TMA) was available. Sections of this TMA were 
immunohistochemically stained and quantified for presence of Foxp3+ cells (Tregs) and 
tumor expression of HLA Class I and non-classical HLA-E and HLA-G. All markers were, 
separate and combined, analyzed for clinical prognostic value.
Results
Expression of HLA class I (DFS HR 0.637 (0.458-0.886), p=0.013), Foxp3+ infiltration 
above median (OS HR 0.637 (0.500-0.813), p<0.001 and DFS HR 0.624 (0.491-0.793), 
p<0.001) and expression of HLA-G (DFS HR 0.753 (0.574-0.989), p=0.042) were related 
to a better clinical prognosis. When these markers were combined, patients with 2 or 3 
markers associated with poor prognosis (loss of HLA Class I, Foxp3+ below median, and 
weak HLA-G expression), showed a significantly worse survival (OS and DFS p<0.001). 
This immune-phenotype was an independent predictor for DFS (HR 1.56 (1.14-2.14), 
p=0.019).
Conclusions
In conclusion, rectal tumors showing loss of HLA class I expression, Foxp3+ infiltra-
tion below median and weak HLA-G expression were related to a worse OS and DFS. 
Combining these immune markers lead to the creation of tumor immune-phenotypes , 
which related to patient outcome and were significant independent clinical prognostic 
markers in rectal cancer.
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BACKGROUND
The immune system has proven to play an important role in tumorigenesis and gained 
a lot of attention in cancer research 1-4. Consequently, evasion of immune surveillance 
has become one of the important hallmarks of cancer 5. Tumors are thought to be ‘ed-
ited’ through a Darwinian selection process into poorly immunogenic tumor variants, 
invisible to the immune system and able to grow progressively. Immuno-editing might 
influence patient’s prognosis substantially 6.
We have  described a few mechanisms responsible for evasion of immune surveillance 
below.
First, cytotoxic T-cells (CTL) are capable of destroying tumor cells by recognizing 
tumor-associated antigens (TAA) on the tumor cell surface presented by classical human 
leukocyte antigen (HLA) class I. Tumor cells can escape this CTL recognition through 
downregulation or complete loss of HLA class I, resulting in minimization of TAA expres-
sion and absence of CTL destruction 7-9. Second, non-classical HLA-E and HLA-G also 
play an important role in immune surveillance. Presence of HLA-E and HLA-G causes 
an inhibitory signal to natural killer (NK) cells, resulting in further immune escape 7;10-14. 
HLA-E is regularly expressed in various healthy tissues and correlates with HLA class 
I expression 15. HLA-G is rarely found in healthy tissues, but is frequently observed in 
tumors 16. Third, immune reactivity can become suppressed by the attraction of immu-
nosuppressive regulatory T cells (Tregs) into the tumor microenvironment 17;18.
In colorectal cancer (CRC), the presence of Tregs in the tumor micro-environment has 
been related to a worse prognosis in some studies, although other studies showed an 
inverse association 19-22. Loss of HLA Class I tumor expression was related to a better 
prognosis in CRC in most studies 14;23 and HLA-E and HLA-G tumor expression has been 
correlated with a poor prognosis and tumor progression 24;25.
In rectal cancer specifically, only a few studies reported on the role of the immune sys-
tem, in which expression of HLA Class I was related to a better prognosis 26;27. Recently, 
more studies showed differences in biology between colon- and rectal cancer 28-30. 
Unfortunately, most studies so far have focused on CRC and did not perform separate 
analyses. Furthermore, often only one immune marker was investigated in CRC, while 
recent studies showed the complex interaction between the different mechanisms of 
immune-escape 6;31;32.
In this study we therefore aimed to investigate the immune-related biomarkers HLA 
Class I, HLA-E and -G and Tregs, determined with immunohistochemistry, in rectal cancer 
specifically, and to establish distinct patterns that reflect immune-escape mechanisms of 
rectal cancer by combining these markers and relate these patterns to clinical outcome.
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METHODS
Study population
The study cohort consisted of patients obtained from the non-preoperative treated 
arm of the Dutch TME trial (January 12th, 1996, DUT-KWF-CKVO-9504, EORTC-40971, EU-
96020), a multicenter trial that evaluated total mesorectal excision (TME) surgery with or 
without preoperative radiotherapy (5 × 5 Gray) from 1996-1999 33. Radiotherapeutical, 
surgical and pathological procedures were standardized and quality-controlled 34. Before 
the start of the TME trial the Medical Ethical Committee of the Leiden University Medical 
Center approved the trial and retrospective use of samples. Written informed consent for 
participation and retrospective use of samples was obtained from all patients enrolled 
in the TME trial. Previously, a tissue microarray (TMA) including 1208 patients (irradiated 
and non-irradiated) of the Dutch TME trial was available. Because of insufficient tissue 
on this TMA a new TMA was constructed for this study. Sufficient formalin-fixed paraffin-
embedded tumor material was available for 495 non-preoperative radiotherapy-treated 
stage I-IV Dutch patients, resulting in a total study cohort of 495 rectal cancer patients 
who only had surgery.
Antibodies
The mouse monoclonal antibodies HCA2 and HC10 were used, which recognize the 
heavy chains of HLA Class I, these were kindly provided by Prof. Dr. J. Neefjes (NKI, Am-
sterdam, The Netherlands). The reactivity spectrum of HCA2 comprises all HLA-A chains 
(except HLA-A24), as well as some HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G chains. HC10 
reacts with HLA-B and HLA-C heavy chains and some HLA-A chains (HLA-A10, HLA-A28, 
HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33) 31. The mouse antibody against human 
Foxp3 (ab20034 clone 236A/E7; Abcam) was used for Treg identification. The reactivity 
spectrum of Foxp3 is composed of regulatory T cells and may include small numbers 
of CD8+ cells but is generally considered to be the best single marker for Treg identifi-
cation 35;36. For HLA-E and HLA-G identification mouse monoclonal antibodies against 
HLA-E (ab2216 clone MEM-E/02: AbCam) and HLA-G (4H84: Exbio, Czech Republic) were 
used 32. MEM-E/02 recognizes denatured HLA-E 37;38, while 4H84 recognizes denatured 
HLA-G molecules and also binds to free heavy chains of classical HLA class I molecules 38-40.
TMA production and immunohistochemistry
Histo-pathological characteristics of tumor material from all patients were standardized 
and quality-controlled 33;34. Sections from formalin-fixed paraffin-embedded (FFPE) 
tumor blocks of the primary tumors were cut for haematoxylin and eosin staining. Based 
on these slides, histopathologically representative tumor regions were identified and 
punched for preparation of tumor tissue microarray (TMA) blocks. From each donor 
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block, three 1.0 mm diameter tissue cores were punched from three different identified 
tumor areas to account for tumor heterogeneity and transferred into a receiver paraffin 
block using the TMA master (3DHISTECH, Budapest, Hungary). Immunohistochemical 
staining (IHC) for Foxp3+ cells, non-classical HLA-E and HLA-G, and classical HLA class I 
tumor expression was performed on 4 µm sections, which were cut from each receiver 
block and mounted on glass. For each type of primary antibodies, all slides were stained 
simultaneously to avoid inter-assay variation.
The sections were deparaffinized and rehydrated in accordance with standard proto-
col. Endogenous peroxidase was blocked for 20 minutes in 0.3% hydrogen peroxide in 
PBS. For antigen retrieval, slides for staining with HLA-E, HLA-G or Foxp3+ were boiled 
in a 0.01 M EDTA buffer (pH 8) for 10 minutes at maximum power in a microwave oven. 
Slides for staining with HCA2 and HC10 were boiled in a 0.1 M citrate buffer (pH 6). 
Sections were incubated overnight with Foxp3, HLA-E, or HLA-G antibodies at pre-
determined optimal dilution. The next day, after 30 minutes of incubation with Envision 
anti-mouse (K4001; DAKO Cytomation, Glostrup, Denmark), sections were visualized 
using diaminobenzidine solution (DAB). Tissue sections were counterstained with hae-
matoxylin, dehydrated and finally mounted in pertex.
For the HCA2 and HC10 stainings a double staining was performed to better dis-
criminate between stroma (using a mixture of anti-extracellular matrix antibodies that 
resulted in brown staining of tumor stroma) and tumor tissue (using a blue staining for 
the HLA expression to be determined) in the tissue sections. Sections were incubated 
overnight at room temperature with all primary antibodies simultaneously (anti-collagen 
I, anti- collagen VI, anti-elastin (all polyclonal rabbit antibodies obtained from AbCam) 
and HCA2 and HC10). Afterwards, sections were washed three times for 5 minutes in PBS 
and incubated for 30 minutes with Envision+ System HRP anti Rabbit (DAKO, Glostrup, 
Denmark). After washing the sections three times with PBS, sections were developed 
using Liquid DAB+ Substrate Chromogen System (DAKO, Glostrup, Denmark) follow-
ing manufacturer’s instructions for visualization of stromal tissue. Then, sections were 
washed again three times for 5 minutes in PBS followed by 30 minutes incubation with 
rabbit-anti-mouse antibodies (DAKO, Glostrup, Denmark). Afterwards , the sections 
were incubated with APAAP (DAKO, Glostrup, Denmark) diluted in PBS/BSA 1% for 30 
minutes. And finally, sections were washed three times for 5 minutes in PBS followed 
by 20 minutes incubation with Vector-Blue following manufacturer’s instructions for 
visualization of the HCA2 and HC10 antibodies, and mounted in Aquamount (Merck, 
Darmstadt, Germany).
For each patient, normal epithelium, stromal cells, or lymphoid cells served as internal 
positive control for HLA class I and HLA-E antibody reactivity 24. Tonsil tissue served as 
external positive control for the HCA2 and HC10 stainings and placenta tissue slides for 
the HLA-E and HLA-G stainings. Slides from human tonsil tissue served as positive control 
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for Foxp3 staining. Tissue slides that underwent the whole immuno-histochemical stain-
ing without primary antibodies served as negative controls (Supplemental Figure 1).
Evaluation of immunohistochemistry
Microscopic analysis of HCA2, HC10, HLA-E and HLA-G expression and presence of 
Foxp3+ cells was performed by two independent observers in a blinded manner 
(M.S.R.: 100% of the cohort, C.C.E. 30% of the cohort). The kappa values for inter-observer 
agreement were all between 0.5 and 0.7, indicating substantial agreement between the 
two observers 41. The scores of the three 1.0 mm punches were averaged. For HCA2 and 
HC10 the percentage of tumor cells with membranous staining was assessed. HLA class 
I expression status was determined according to the International HLA and Immuno-
genetics Workshop 42, with tumor cell HLA class I expression status defined as follows: 
loss of HLA class I expression: less than 5% of tumor cells expressing both HCA2 and 
HC10, downregulation of HLA class I; less than 5% of tumor cells expressing either of the 
markers, and expression of HLA class I: 5% or more expressing both markers. For HLA-E 
and HLA-G, intensity of tumor staining (absent (undetectable or faint in <20% of the 
cells), weak (faint to weak in 20% but ≤70% of the cells), moderate (weak to moderate in 
>70% of the cells) or strong intensity (intense in 20-70% of the cells)) was determined, 
based on previous studies 43;44. The scores of the three 1.0 mm punches were averaged 
as well. For analysis these scores were further categorized as weak (absent and weak 
intensity together) versus strong (moderate and strong intensity together) tumor stain-
ing. Quantification of the number of Foxp3+ cells was microscopically assessed in the 
entire tumor punches of the TMA and the absolute number of positive cells was used for 
analysis, with the use of the median as cut-off value for categorization in two categories: 
Foxp3+ below median and Foxp3+ above median.
Statistical Analysis
Statistical analyses were performed using the statistical package SPSS (version 17.0 
for Windows; SPSS Inc.). The Student’s T-test and the Chi-squared test were used to 
evaluate associations between tumor expression of classical HLA Class I, non-classical 
HLA-E and HLA-G and tumor infiltration of Foxp3+ cells and various clinico-pathological 
variables. Overall Survival (OS) was defined as time of surgery until death; Disease Free 
Survival (DFS) as time of surgery until death or relapse of disease, whichever came first. 
The Kaplan-Meier method was used for calculation of survival probabilities and the 
Log-rank test for comparison of survival curves between expression levels of markers. 
Cox regression was used for univariate and multivariable analysis for OS and DFS. To 
preserve statistical power in subgroup analyses, patients with stage IV disease (n=32) 
and positive resection margin (n=98) were included in the final analyses. In multivari-
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able analyses corrections were made for TNM stage, circumferential margin, age, tumor 
grade and adjuvant therapy.
RESULTS
HLA class I tumor expression
The analysis of HLA class I expression was performed on 468 stage I-IV rectal cancer 
patients as, due to staining artifacts and loss of material during the staining procedure, 
the IHC results of 27 cases could not be analyzed. Representative images of HLA Class I 
expression are shown in Figure 1. Loss of HLA Class I expression was seen in 70 patients 
out of  468 patients (15%), down regulation in 105 patients (22 %) and expression was 
present in the majority of the cases: 293 patients (63%). Patient characteristics and data 
on HLA class I expression are shown in Table I. Patients with loss of HLA class I tumor ex-
pression were diagnosed significantly more often with stage IV tumors (p=0.001) and T3 
or T4 tumors (p=0.016). Also, loss of HLA class I was related to more nodal involvement 
(p=0.003), tumors with poor differentiation (p=0.033) and more adjuvant treatment 
(p=0.001).
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Figure 1: Representative images of HCA2, HC10, HLA-E and –G and Foxp3+ staining in rectal cancer.
Representative images of immunohistochemical stainings for HLA Class I expression (HCA2 and HC10), 
HLA-E and HLA-G expression and presence of Foxp3+ cells, performed according to standard protocols 
(details in Material and Methods). (A) HCA2-positive tumor (note: positive tumor cells in blue, stromal cells 
are stained brown);(B) HC10-positive tumor (note: positive tumor cells in blue, stromal cells are stained 
brown);(C) HLA-E positive tumor (note: positive tumor cells in brown);(D) HLA-G positive tumor (note: posi-
tive tumor cells in brown);(E) Presence of Foxp3+ cells (two representative examples of Foxp3+ cells are 
indicated by arrows) with a magnification in (F).
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HLA class I expression was borderline significantly related to a better OS (logrank p-
value 0.073), but also significantly related to a better DFS (logrank p-value 0.012) with a 
HR of 0.637 (95% CI 0.458-0.886, p=0.013) for expression of HLA class I compared to loss 
of HLA class I expression (Figure 2).
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Figure 2: Survival curves stratified for HLA class I tumor expression in rectal cancer.
A) Kaplan Meier curve for Overall Survival in 495 rectal cancer patients stratified for HLA class I tumor ex-
pression status. B) Kaplan Meier curve for Disease Free Survival in 495 rectal cancer patients stratified for 
HLA Class I tumor expression. HLA class I was immunohistochemically determined as described in the Ma-
terial and Methods section.
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Tumor infiltrating Foxp3+ cells
The number of Foxp3+ cells was evaluated in 478 patients, as, due to staining artifacts 
and loss of material during the staining procedure, the IHC results of 17 cases could not 
be analyzed. Representative images of Foxp3 staining are shown in Figure 1 and patient 
characteristics and data on Foxp3+ tumor infiltration are shown in Table I. The mean 
number Foxp3+ cells per tumor punch was 39 with a median of 27.0. For further analysis 
Foxp3+ was categorized as below vs. above median due to skewness in the spread of 
the data. This resulted in 240 patients with presence of Foxp3+ cells below median 
and 238 patients with presence of Foxp3+ cells above median. Tumors with Foxp3+ cells 
above median were significantly more often stage I tumors (p<0.001), T1 or T2 tumors 
(p<0.001) and showed less nodal involvement (p<0.001). Poorly differentiated tumors 
were associated with tumors with presence of Foxp3+ cells below median (p=0.022). 
Furthermore, tumors with expression of HLA class I showed significantly more Foxp3+ 
cells above median compared to tumors with loss of HLA class I expression (p<0.001).
The presence of Foxp3+ cells above median in the tumor microenvironment was 
significantly related to a better OS (logrank p-value <0.001) and DFS (logrank p-value 
<0.001) with HR’s of 0.637 (95% CI 0.500-0.813, p<0.001) and 0.624 (95% CI 0.491-0.793, 
p<0.001) respectively in case of presence of Foxp3+ cells above median compared to 
Foxp3+ cells below median (Figure 3).
HLA-E and HLA-G tumor expression
The analysis of HLA-E and HLA-G was performed on 486 and 484 patients respectively, 
as, due to staining artifacts and loss of material during the staining procedure, the IHC 
results of 9 and 11 cases respectively, could not be analyzed. Representative images of 
non-classical HLA-E and HLA-G immunohistochemical staining results are shown in Fig-
ure 1. For HLA-E, 8 patients (1.6%) showed absence of tumor staining, 73 patients (15.0%) 
showed weak tumor staining, 298 patients (61.3%) showed moderate tumor staining 
and 107 patients (22.0%) showed strong tumor staining in their punches. For HLA-G, 31 
patients (6.4%) had absence of tumor staining, 319 patients (65.9%) had a weak tumor 
staining, 103 patients (21.3%) had a moderate tumor staining and 31 patients (6.4%) 
had a strong tumor staining. For analysis the scores were further categorized as weak 
(absent and weak intensity together) versus strong (moderate and strong intensity 
together) tumor staining. Strong expression was found in 83.3% (405 out of 486) of the 
tumors for HLA-E and in 27.7% (134 out of 484) of the tumors for HLA-G expression. 
Weak expression of HLA-E was significantly related to T4 tumors (p=0.020) and more 
nodal involvement (p=0.050). Weak expression of HLA-G was also significantly related 
to higher tumor stage (p=0.008) and more  nodal involvement (p=0.006). Furthermore, 
strong expression of HLA-G was significantly associated with presence of Foxp3+ cells 
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Figure 3: Survival curves stratified for Foxp3+ tumor infiltration in rectal cancer.
A) Kaplan Meier curve for Overall Survival in 495 rectal cancer patients stratified for Foxp3+ tumor infiltra-
tion based on the median of the total Foxp3+ infiltration in this cohort. B) Kaplan Meier curve for Disease 
Free Survival in 495 rectal cancer patients stratified for Foxp3+ tumor infiltration. Foxp3+ tumor infiltration 
was immunohistochemically determined as described in the Material and Methods section.
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above median (p=0.001) and with HLA class I expression (p<0.001). Strong HLA-E was 
also significantly related to HLA class I expression (p=0.028).
HLA-E expression was not related to OS (p=0.823) or DFS (p=0.784). Strong expres-
sion of HLA-G was borderline significantly related to a better OS (logrank p-value 0.056) 
and significantly related to a better DFS (logrank p-value 0.040) with a HR of 0.753 (95% 
CI 0.574-0.989, p=0.042) in case of strong expression of HLA-G compared to weak ex-
pression of HLA-G.
Multivariable analysis
A multivariable analysis was performed for OS and DFS using the following parameters: 
age, TNM stage, tumor grade, adjuvant therapy, circumferential margin, HLA class I 
expression status, HLA-G expression status and Foxp3+ tumor infiltration. Foxp3+ was 
an independent significant predictor of OS (p=0.018) and DFS (p=0.012). HLA Class I and 
HLA-G were not significantly related to OS and DFS in multivariable analysis. In Table II 
all univariate and multivariable analyses are summarized.
Because the type of antibody we used to detect HLA-G expression is known to bind 
to free heavy chains of classical HLA class I molecules as well 38-40, interaction between 
these two markers was analysed for survival. In multivariable analysis for OS there was 
no interaction between HLA-G expression and HLA class I expression (p=0.174). Also, 
there was no interaction between HLA-G expression and the two types of antibodies 
used for detection of HLA class I separately; HCA2 expression (p=0.183) and HC10 
expression (p=0.461) respectively. For DFS, there was  no interaction between HLA-G 
expression and HLA class I expression as well (p=0.301), neither for HCA2 (p=0.516) nor 
HC10  (p=0.329).
Analysis of tumor immune-phenotypes
The interaction between tumor cells and immune cells is complex, multifaceted and 
different interactions are closely linked to each other. In breast- and colon cancer 
patients, immune subtyping has already shown a promising value in the prediction of 
prognosis 44;45.  Therefore, we hypothesized that combined analysis of immune mark-
ers may better reflect patients’ outcome as a result of interaction between tumor cells 
and the immune system in rectal cancer as well. We have shown above that patients 
with tumors showing expression of HLA class I, expression of HLA-G and presence of 
Foxp3+ cell infiltration above median showed better survival outcomes when analyzed 
separately. HLA-E tumor expression was not related to survival. Based on the prognostic 
value of the individual markers, a score was created for the combination of HLA class I, 
HLA-G and Foxp3+. HLA class I was divided into 3 scores, which ranged from 0 for loss 
of expression to 2 for high expression. HLA-G and Foxp3+ were divided into 2 scores; 0 
for weak HLA-G expression or Foxp3+ below median  and 1 for strong HLA-G expression 
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or Foxp3+ above median. Combining the scores of the individual markers resulted in 
a scoring range from 0 to 4. The entire population was divided into 3 tumor immune-
phenotypes: patients with scores 3 and 4 (phenotype 1, n=210), patients with score 2 
(phenotype 2, n=139) and patients with scores 0 and 1 (phenotype 3, n=112).
In survival analyses, these phenotypes showed significant differences in patient out-
come. Survival outcome increased with an increasing number of positive prognostic im-
mune markers expressed in the tumor. Patients with phenotype 3 showed a significantly 
worse OS (logrank p<0.001) and DFS (logrank p<0.001) with HR’s of 1.88 (95% CI 1.40-
2.53, p<0.001) for OS and 2.06 (95% CI 1.54-2.75, p<0.001) for DFS, when compared to 
phenotype 1 (Figure 4).
Multivariable analysis of the tumor immune-phenotypes
For the tumor immune-phenotype, univariate analysis and multivariable analysis was 
also performed  to determine OS and DFS as written above. In univariate analysis the 
immune-phenotype was a significant predictor of OS (p<0.001) and DFS (p<0.001) (Table 
II). In multivariable analysis the immune-phenotype was an independent predictor of 
DFS (p=0.019). It was not an independent predictor of OS (p=0.122). When compared 
to the multivariable analyses of the individual immune markers as shown in table II, 
the combination between immune markers, the tumor immune-phenotype, showed 
a stronger and additive prognostic potential, indicating a complex and multifaceted 
interaction between tumor cells and immune cells.
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Figure 4: Survival curves stratified for immune-phenotypes in rectal cancer.
A) Kaplan Meier curve for Overall Survival in 495 rectal cancer patients stratified for all the different combi-
nations between tumor expression of HLA class I, HLA-G and the presence of Foxp3+ cells based on which 
3 immune-phenotypes could be distinguished. See results section for explanation of the phenotypes. B) 
Kaplan Meier curve for Disease Free Survival in 495 rectal cancer patients stratified for all the different com-
binations between tumor expression of HLA class I, HLA-G and the presence of Foxp3+ cells based on which 
3 immune phenotypes could be distinguished. See results section for explanation of the phenotypes.
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DISCUSSION
In this study, by combining the immune-related tumor markers HLA class I, HLA-G and 
Foxp3+, we reported an independent association between tumor immune-phenotype 
and patient outcome. These phenotypes might represent how the immune system 
controls tumor growth and metastases in rectal cancer.
Previous studies on HLA class I expression, which focused on a mixed population of co-
lon- and rectal cancer together, have shown inconsistent findings 13;14. Our study showed 
a survival benefit for patients with tumors expressing HLA class I. These results are partly 
comparable with results from Watson et al., who showed that low expression of HLA class 
I was related to a poor prognosis in a large group of colorectal cancer patients, whereas 
tumors with loss or expression of HLA class I were associated with a survival benefit 14. 
A substantial part of Watson’s cohort showed HLA class I negative tumors (24.6%). In 
our cohort, consisting solely of rectal cancer patients, only 15.0% of the patients had 
tumors with loss of HLA class I expression, which might indicate that colon cancers lose 
their HLA class I expression more often. Previously, Speetjens et al. investigated the 
prognostic value of HLA class I expression in rectal cancer patients from the Dutch TME 
Trial as well 27. In this study, as described in the methods sections, a new TMA was used 
without complete overlap and thus different patients. Both studies showed a survival 
benefit for patients with tumors showing expression of HLA class I. Because we have 
changed the scoring criteria based on recommendation by the International HLA and 
Immunogenetics Workshop [42] differences have to be acknowledged. Speetjens et al. 
reported that 16% of non-irradiated patients had tumors with loss and downregulation 
of HLA Class I, whereas our study showed 37% (15% loss and 22% downregulation). Thus, 
besides a different patient cohort, other possible explanations for inconsistent findings 
between studies are the use of different definitions of HLA class I expression and differ-
ences in staining techniques. Furthermore, tumor microsatellite status might also play 
an important role. Approximately 50% of all proximal colon tumors show microsatellite 
instability (MSI), whereas almost all distal colon and rectal cancers are microsatellite 
stable (MSS) tumors 46;47. Loss of HLA class I has been described more significantly in MSI 
colorectal tumors compared to MSS right-sided colon tumors 48;49. HLA class I negative 
tumors are therefore more likely to be MSI tumors with a different clinical behavior than 
MSS colorectal tumors 27. Since MSI tumors have a better prognosis, MSI might influ-
ence prognostic results when considering HLA class I expression in colorectal tumors 46. 
In this rectal cancer cohort determination of the microsatellite status would not have 
been useful. Research has shown that in only 2% of rectal cancers MSI can be found 50, 
resulting in insufficient statistical power for separate analyses Finally, colon and rectum 
are biologically different tissues; the colon epithelium consists of simple columnar epi-
thelium, whereas the rectum is a transition from single columnar epithelium to stratified 
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squamous epithelium, which might result in different outcomes. The Cancer Genome 
Atlas Network attempted to find biological differences between colon and rectal cancer. 
However, only differences in anatomical tumor site with more hypermethylation in right-
sided tumors were found, which might be explained by different embryonic origins of 
the right-and left-sided tumors 28.
Results in our study regarding non-classical HLA-G are remarkable. HLA-G expression 
can inhibit NK-cells from lysing tumor cells that have lost or downregulated classical 
HLA class I expression as a secondary immune escape 51;52. However, in this study, posi-
tive HLA-G expression was correlated with a longer disease free survival.
The antibody used to stain HLA-G can also bind to free heavy chains of classical 
HLA class I molecules as well, possibly explaining the remarkable results. We therefore 
performed an interaction analysis between these antibodies. However, no interaction 
between HLA-G and HLA class I expression was found. Furthermore, HLA-G is found to 
be highly immunosuppressive by directly inhibiting NK cells, but also by recruitment 
of Tregs and induction of Treg differentiation 53. Our study showed that strong HLA-G 
expression was significantly related to presence of more Foxp3+ cells, possibly explain-
ing the favourable prognosis of tumors with strong HLA-G expression, since tumors that 
attracted more Foxp3+ cells had a better outcome in our cohort. Immune regulation in 
cancer still remains complex and multifaceted, and not all immune related mechanisms 
are completely clear. To our knowledge, no other studies on HLA-E and HLA-G are per-
formed on rectal cancer specifically and therefore no other comparisons could be made.
The presence of Foxp3+ cells in the tumor microenvironment is thought to inhibit 
host-protective antitumor responses and especially CTL activity 6. A high density of 
tumor infiltrating Foxp3+ cells has shown to be associated with an unfavorable progno-
sis in a wide range of human carcinomas 54;55. However, in accordance with our results, 
opposite results are described in CRC 20;21. A possible explanation could be a significant 
association between HLA class I tumor expression and Foxp3+ tumor infiltration in our 
cohort. Foxp3+ infiltrating cells might be necessary to counteract CTL activity in tumors 
expressing HLA class I to prevent an auto-immune response on other bodily cells as 
well. Another explanation might be a different micro-environment of rectal cancer, 
which is colonized with many gastro-intestinal bacteria, triggering the production of 
pro-inflammatory cytokines causing tumor-enhancing effects. Instead of the specificity 
of infiltrating T-cells for tumor-antigens, T-cells in rectal cancer could be more specific 
for the microflora and suppress inflammation and immune responses from bacterial 
invasion, resulting in an anti-tumorigenic effect 56.
As shown in our results and results from our previous studies in breast cancer, immune 
markers are related to each other 31;32. Studying solely one marker might not be enough 
to truly understand cancer immune surveillance. When we combined our markers, 
patients showing the worst prognosis were patients with tumors bearing 2 or 3 nega-
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tive prognostic markers; patients with loss of HLA class I tumor expression, weak HLA-G 
tumor expression and low tumor infiltration with Foxp3+ cells. These patients therefore 
qualify as very low immune susceptible. They probably were able to elicit only a minimal 
CTL attack and subsequently attracted little to no Foxp3+ cells in their tumor micro-
environment, possibly explaining their worse prognosis. Furthermore, patients with 
tumors showing loss of HLA class I expression, low Foxp3+ cell infiltration and strong 
HLA-G expression showed the worst outcome perspectives. These patients probably 
had tumors which were highly ‘edited’ as well, causing a minimal CTL attack and subse-
quently attracted little to no Foxp3+ cells, and because of strong HLA-G expression were 
able to escape further immune recognition through inhibition of NK cell recognition 
and subsequently no elimination 51;52.
CONCLUSIONS
In conclusion, we were able to identify local immune escape mechanisms of rectal 
cancer, where the presence of Foxp3+ infiltration greatly influences a better prognosis. 
Loss of HLA class I expression, weak non-classical HLA-G expression and the presence 
of Foxp3+ below median were related to a worse outcome. Combining these immune-
related markers identified 3 groups, which were highly selective and discriminative 
regarding patient outcome. Prognosis increased with a decrease in negative prognostic 
markers. In the future these findings might contribute to better treatment allocation.
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Supplemental Figure 1: Representative images of HCA2, HC10, HLA-E, HLA-G and Foxp3+ staining in rectal 
cancer.
Representative images of immunohistochemical stainings with positive and negative controls for HLA 
Class I expression (HCA2 and HC10), HLA-E and HLA-G expression and presence of Foxp3+ cells, performed 
according to standard protocols (details in Material and Methods section). (A) HCA2 expression, positive 
tumor (note: positive tumor cells in blue, stromal cells are stained brown) (A1), negative tumor (A2), tonsil 
which served as positive control (A3), tonsil which underwent the whole immuno-histochemical staining 
without primary antibody served as negative control (A4); (B) HC10 expression, positive tumor (note: posi-
tive tumor cells in blue, stromal cells are stained brown) (B1), negative tumor (B2), tonsil which served as 
positive control (B3), tonsil which underwent the whole immuno-histochemical staining without primary 
antibody served as negative control (B4); (C) HLA-E  expression, positive tumor (note: positive tumor cells 
are stained brown) (C1), negative tumor (C2), placenta which served as positive control (C3), placenta which 
underwent the whole immuno-histochemical staining without primary antibody served as negative con-
trol (C4); (D) HLA-G expression, positive tumor (note: positive tumor cells are stained brown) (D1), negative 
tumor (D2), placenta which served as positive control (D3), placenta which underwent the whole immuno-
histochemical staining without primary antibody served as negative control (D4); (E) Presence of Foxp3+ 
cells, tumor with presence of Foxp3+ cells (indicated by arrows) (E1), tumor with absence of Foxp3+ cells 
(E2), tonsil which served as positive control for Foxp3+ cells (indicated by arrows) (E3), tonsil which under-
went the whole immuno-histochemical staining without primary antibody served as negative control (E4).
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ABSTRACT
Background
Disturbance of the balance between proliferation and apoptosis is an important hallmark 
of tumor development. The goal of this study was to develop a descriptive parameter 
that represents this imbalance and relate this parameter to clinical outcome in all four 
stages of colon cancer.
Methods
The study population consisted of 285 stage I-IV colon cancer patients of which a tumor 
tissue micro array (TMA) was available. TMA sections were immunohistochemically 
stained and quantified for presence of Ki67 and cleaved caspase-3 tumor expression. 
These results were used to develop the combined apoptosis proliferation (CAP) param-
eter and correlated to patient outcome.
Results
The CAP parameter was significantly related to clinical outcome; patients with CAP ++ 
(high level of both apoptosis and proliferation) showed the best outcome perspectives 
(Overall Survival (OS), p=0.004 and Disease Free Survival (DFS), p=0.009). The effect of 
the CAP parameter was related to tumor microsatellite status, and indirectly to tumor 
location, where left-sided tumors with CAP + - (high level of proliferation, low level of 
apoptosis) showed a worse prognosis (DFS p-value 0.02) and right-sided tumors with 
CAP + - had a better prognosis (DFS p-value 0.032). With stratified analyses, the CAP 
parameter remained significant in stage II tumors only.
Conclusions
The CAP parameter, representing outcome of the balance between the level of apop-
tosis and proliferation, can be used as a prognostic marker in colon cancer patients for 
both DFS and OS, particularly in left sided, microsatellite stable tumors when TNM stage 
is taken into account.
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INTRODUCTION
A key factor in tissue homeostasis, especially of the intestinal mucosa, is the balance that 
exists between the level of cell death and the level of cell proliferation 1-3. Two important 
hallmarks of the process of tumorigenesis are responsible for disturbance of this balance 
and therefore contribute to the initiation and maintenance of tumor growth and devel-
opment 4;5. These hallmarks are: deregulation of the proliferative signaling pathway and 
deregulation of the pathway of apoptosis 4. Both result in either non- or malfunction 
of important enzymes or unrestricted release of growth-promoting signals that under 
normal circumstances are necessary to maintain tissue homeostasis 5-12. The level of cell 
proliferation and apoptosis can be studied with immunohistochemistry (IHC) taking 
advantage of all of the benefits of this technique, such as speed, routine availability, low 
costs, and high level of automation. The level of apoptosis can be evaluated through 
staining specifically the activated, cleaved form of the pro-apoptotic enzyme caspase-3 
in the tumor cell cytoplasm. Caspase-3 is the final enzyme to become activated in the 
caspase cascade, which is the common pathway in the execution of apoptosis after the 
intrinsic and extrinsic apoptosis induction pathways converge. Therefore, the expres-
sion level of activated or cleaved caspase-3 should give a reliable measure of the level of 
apoptosis 13. The proliferation activity of a tumor can be estimated by determining the 
expression levels of specific cell cycle-related proteins also by using IHC. A widely used 
marker is the Ki67 antigen, which is expressed in nuclei during all cell cycle phases except 
during the G0 phase 14. Previous studies showed contradicting results with respect to 
the relation of the level of apoptosis or proliferation in tumor resection specimens and 
patient outcome in colon cancer 15-22. We hypothesize that, because tissue homeostasis 
depends on the balance between cell death and proliferation levels, the level of disbal-
ance between these processes indicate tumor aggressiveness. Therefore, combined and 
not separate analysis of these parameters might be of prognostic relevance in colon 
cancer patients.
In this study we determined both the level of tumor cell apoptosis and proliferation in 
resection specimens of a large cohort of colon cancer patients. We combined the results 
into one parameter and related this parameter to patient outcome data.
MATERIALS AND METHODS
Patients and tumors
The patient cohort consisted of 470 colorectal cancer patients treated with surgery for 
their primary tumor in the LUMC between 1991 and 2001. Clinico-pathological and 
follow-up data were collected retrospectively from hospital records and the hospital’s 
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oncology database. This research was performed according to the code of conduct for 
responsible use.
Patient records information was anonymized and de-identified prior to analysis ac-
cording to national ethical guidelines (“Code for Proper Secondary Use of Human Tissue”, 
Dutch Federation of Medical Scientific Societies). Patients with a history of cancer other 
than basal cell carcinoma or cervical carcinoma in situ, patients that received radio- and/
or chemotherapy treatment prior to resection, patients with multiple synchronous colon 
tumors, and patients with rectal cancers were excluded from the analysis (n=185). The 
entire study cohort consisted of 285 patients. Right-sided tumors were defined as those 
originating proximal to the splenic flexure and left-sided as those originating distal to 
the splenic flexure.
Primary Antibodies
The following antibodies were used in the immunohistochemical stainings: Mouse 
monoclonal antibody anti-Ki67 (DAKO Glostrup Denmark Art.M7240 clone MIB-1) to de-
termine the level of tumor cell proliferation and rabbit polyclonal antibody anti-ASP-175 
(Cell signaling Danvers, USA, Art.9661) was used for cleaved caspase-3 identification to 
determine the level of apoptosis.
Immunohistochemistry
Qualified pathologist evaluated the tumor material from all patients included for histo-
pathological characteristics according to current standards during the routine hospital 
diagnostic process. Formalin-fixed paraffin-embedded tumor blocks of the primary tu-
mor were collected from the pathology department. Sections were cut for haematoxylin 
and eosin staining, and representative tumor regions based on histological assessment 
were used for preparation of tumor tissue microarray (TMA) blocks. From each donor 
block, three 0.6 mm tissue cores were punched from tumor areas and transferred into a 
recipient paraffin block using a custom-made precision instrument.
Immunohistochemistry (IHC) staining was performed on 4 µm sections that were cut 
from each receiver block and mounted on glass. For each primary antibody, all slides 
were stained simultaneously to avoid inter-assay variation. Tissue sections were deparaf-
finized and rehydrated. For antigen retrieval, 0.01 M EDTA buffer (pH 8) was used for 10 
minutes at maximum power in a microwave oven for anti-Ki67. Citrate buffer 0.1M (pH 6) 
was used for anti-ASP-175. Endogenous peroxidase was blocked for 20 minutes in 0.3% 
hydrogen peroxide in methanol. Sections were incubated overnight with either anti-
Ki67 or anti-ASP-175 at predetermined optimal dilutions. After 30 minutes of incubation 
with Envision anti-mouse (K4001; DAKO Cytomation, Glostrup, Denmark) or Envision 
anti-rabbit (K4003); DAKO Cytomation, Glostrup, Denmark), sections were visualized us-
ing diaminobenzidine solution. Tissue sections were counterstained with haematoxylin, 
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dehydrated and finally mounted in malinol. Sections with phosphate buffer saline (PBS) 
instead of primary antibody, which underwent the complete staining protocol served as 
negative controls.
Evaluation of immunohistochemistry
Microscopic analyses of Ki67 and cleaved caspase-3 expression was performed by two 
independent observers (M.S.R: 100% and T.C.A.: 30%) in a blinded manner. For Ki67, the 
percentage of tumor cells that showed nuclear staining was assessed. For determination 
of tumor cell apoptosis, the absolute number of caspase-3 expressing tumor cells in 
each tumor punch that showed cytoplasmatic and perinuclear staining was counted. 
The Cohen’s Kappa for inter observer variability was 0.73 and 0.6 for Ki67 and cleaved 
caspase-3 respectively. Therefore, there was substantial agreement between the two 
observers and all scores were averaged. For analysis a cut-off at the median was chosen, 
dividing the samples in low (<27% positive tumor cells) or high nuclear Ki67 expression 
(≥27%). The use of this percentage of positive cells as a cut-off point is supported by 
Fluge et al. [18]. Cleaved caspase-3 was quantified into two categories of IHC cytoplas-
matic tumor staining levels. Negative staining; implied no positive tumor cells in either 
of the three cores, in all other cases the staining was denoted as positive. Representative 
images of the Ki67 and caspase-3 staining are shown in Figure 1.
Figure 1: Representative images of Ki67 and cleaved caspase-3 immunohistochemical 
staining in colon cancer tissues 
 
 
 
A) Ki67 tumor staining with low expression B) Ki67tumor staining with high expression C) Tumor 
showing absence of cleaved Caspase-3 tumorcell expression and D) Tumor showing presence of 
cleaved caspase-3 tumorcell expression, as indicated by the arrows. All magnifications x200.  
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Figure 1: Representative images of Ki67 and cleaved caspase-3 immunohistochemical staining in colon 
cancer tissues.
A) Ki67 tumor staining with low expression; B) Ki67tumor stai i g with high expression; C) Tumor showing 
absence of cleaved Caspase-3 tumor cell expression and; D) Tumor showing presence of cleaved caspase-3 
tumor cell expression, as indicated by the arrows. All magnifications x200.
76 Chapter 4
Determination of microsatellite stability status
DNA was extracted from 2mm tumor-cores. Paraffin was dissolved in xylene, tissue was 
rehydrated in ethanol (100%/70%) and dried for 10 minutes at 37°C. Nucleospin 96 Tis-
sue kit (Machery-Nagel, Düren, Germany) was used for DNA extraction according to the 
manufacturer’s protocol.
Microsatellite stability status was tested using the MSI Analysis System Version 1.2 
(Promega, Mannheim, Germany) and interpreted by an experienced pathologist, as 
described previously 23.
Statistical Analysis
Statistical analyses were performed using the statistical package SPSS (version 17.0 for 
Windows; SPSS, inc). The Student’s T-test and the Chi-squared test were used to evaluate 
associations between Ki67 or cleaved caspase-3 and various clinico-pathological param-
eters. The Overall Survival (OS) was defined as time between primary tumor resection and 
time of death and Disease Free Survival (DFS) as time between primary tumor resection 
and time of death or relapse of disease, whichever came first. The Kaplan-Meier method 
was used for calculation of survival probabilities and the Log-rank test for comparison 
of survival curves. Cox regression was used for univariate and multivariable analysis for 
OS and DFS. Significant variables (in univariate analysis) were included in multivariable 
analysis. For all tests, a p-value <0.05 was considered to be statistical significant.
RESULTS
Patient characteristics, and cleaved caspase-3 and Ki67 expression levels
The study cohort consisted of 285 patients. In 41 cases for Ki67, and 38 for cleaved 
caspase-3 the results of the IHC could not be analyzed due to loss of the tumor material 
during IHC or due to staining artifacts. Representative images of the biomarkers and 
their staining categories are shown in Figure 1. The mean percentage of tumor cells 
expressing Ki67 in the tumor tissue cores was 29.2% with a median of 27.5%. For analysis 
we used the median as cutoff based on skewness of the data distribution. This resulted 
in 121 patients (49.6%) with tumors showing low expression level (below median) of 
Ki67 and (‘low’ tumor cell proliferation level) and 123 patients (50.4%) with high expres-
sion level (above median) of Ki67 (‘high’ tumor cell proliferation level). In 85 (34.4%) 
patients the tumor tissue cores showed no staining of cleaved caspase-3 and therefore 
no apoptotic activity of tumor cells. The remaining 65.6% of the samples showed posi-
tive staining and thus ongoing tumor cell apoptosis.
The clinico-pathological characteristics of the patient cohort and their relation to 
expression levels of the biomarkers are listed in Table I. Interestingly, tumor location 
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Table I: Patient Characteristics of the Total Colon Cancer Cohort and Stratified for Ki67 and cCaspase-3 
expression
Total
Population
(N=285)
Ki67
Absence
N=121
Ki67
Presence
N=123
cCaspase-3
Absence
N=85
cCaspase-3
Presence
N=162
Gender
Male 137 (48.1%) 55 (45.5%) 65 (52.8%) 42 (49.4%) 80 (49.4%) 
Female 148 (51.9%) 66 (54.5%) 58 (47.2%) 43(50.6%) 82 (50.6%) 
Age (average) 65.7
(±13.3 SD)
67.3
(±11.6 SD)
64.2
(±13.6 SD)
66.5
(±12.6 SD)
65.6
(±12.9 SD)
TNM stage
I 44 (15.4%) 14 (11.6%) 20 (16.3%) 16(18.8%) 18 (11.1%) 
II 114 (40.0%) 43 (35.5%) 53 (43.1%) 31 (36.5%) 68 (42.0%) 
III 74 (26.0%) 36 (29.8%) 30 (24.4%) 19 (22.4%) 47 (29.0%) 
IV 48 (16.8%) 27 (22.3%) 19 (15.4%) 17 (20.0%) 29 (17.9%) 
Unknown 5 (1.8%) 1 (0.8%) 1 (0.8%) 2 (2.4%) 0 (0.0%) 
Grade p=0.004 p=0.017
Moderate 145 (50.9%) 61 (50.4%) 63 (51.2%) 35(41.2%) 89 (54.9%) 
Poor 23 (8.1%) 5 (4.1%) 16 (13.0%) 4 (4.7%) 18(11.1%) 
Good 58 (20.4%) 32 (26.4%) 16 (13.0%) 22(25.9%) 26 (16.0%) 
Unknown 59 (20.7%) 23 (19.0%) 28 (22.8%) 24 (28.2%) 29(17.9%) 
MS Status     p=0.004 
MSS 168 (58.9%) 77 (63.6%) 87 (70.7%) 61 (71.8%) 103 (63.6%) 
MSI 30 (10.5%) 12 (9.9%) 14 (11.4%) 2 (2.4%) 27 (16.7%) 
Unknown 87 (30.5%) 32 (26.4%) 22 (17.9%) 22 (25.9) 32 (19.8%)
Location p=0.023 p=0.011
Right 110 (38.6%) 37 (30.6%) 53 (43.1%) 27 (31.8%) 64(39.5%) 
Left 153 (53.7%) 78 (64.5%) 60 (48.8%) 57 (67.1%) 83(51,2%) 
Unknown 22 (7.7%) 6 (5.0%) 10 (8.1%) 1 (1.2%) 15 (9.3%) 
This table describes the baseline characteristics of the entire cohort of 285 patients in the first column. The Ki67 
immunohistochemistry results could be analyzed in 244 cases and Ki67 expression (above the median of 27.5% 
expression level) was found to be present in 123 and absent in 121 patients. The second and third columns de-
scribe the relation of either Ki67 absence or presence in the tumor resection specimens to clinico-pathological 
parameters. The cleaved caspase 3 results were available for analysis in 247 patients. In this population 85 tumor 
samples showed no presence of cleaved caspase 3, expression was present in 162 tumor samples of patients. 
The fourth and fifth column describe the relation of either cleaved caspase 3 absence or presence to clinico-
pathological parameters. Only significant (p<0.05) differences between marker expression as proven by χ2 tests 
are displayed. Abbreviations: MS Status; Microsatellite Status, cCaspase3; cleaved caspase 3.
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was significantly related to both cleaved caspase-3 expression level and Ki67 expres-
sion level. Microsatellite instability also showed statistical significance, but was only 
significantly related to cleaved caspase-3 expression and not to Ki67 expression. In 
the tumor samples without cleaved caspase-3 expression, 2.4% of the cases showed 
microsatellite instability vs. 16.7% in the tumors with expression of cleaved caspase-3 
(p-value 0.004). Additional analysis showed in our patient cohort a strong, significant 
correlation between tumor location and microsatellite stability status with significantly 
more microsatellite instable tumors (MSI) located on the right side of the colon and the 
majority of the microsatellite stable (MSS) tumors located on the left side of the colon 
(70%), whereas this was only 8% in microsatellite instable tumors (MSI) (p=<0.001).
Relation of single marker expression with patient outcome
The level of tumor cell proliferation based on Ki67 expression level was significantly 
related to OS and DFS: high tumor expression level correlated significantly to a better 
patient OS and DFS (OS, Logrank p-value 0.002; DFS, Logrank p-value 0.003) (Figure 2). 
Tumor cell apoptotic level, as represented by cleaved caspase-3 expression, was not 
related to either OS or DFS (OS, Logrank p-value 0.83; DFS, Logrank p-value 0.73).
Combined analysis of tumor cell apoptosis and proliferation in relation to 
patient outcome
To analyze the effect of the balance between apoptosis and proliferation levels in the 
tumor resection specimens on patient outcome, the results of the Ki67 expression 
analysis were combined with those of the cleaved caspase-3 expression analysis in a 
combined apoptosis-proliferation (CAP) parameter (Table II). The CAP parameter was 
not significantly related to TNM stage (p-value 0.211), but was significantly related to 
the tumor microsatellite status (p-value 0.008). Tumors of both the CAP -+ (Ki67 below 
median, presence of cleaved caspase-3) and ++ (Ki67 above median, presence of 
cleaved caspase-3) patients showed significantly more often microsatellite stability 
compared to the CAP +- (Ki67 above median, absence of cleaved caspase-3) and CAP 
— (Ki67 below median, absence of cleaved caspase-3) patients (p-value 0.03). Patients 
with a CAP ++ tumor showed the best survival outcomes with respect to OS and DFS 
(Figure 3). In the entire cohort patients with a CAP -+ tumor had the worst outcome 
perspectives. Because tumor microsatellite status was significantly related to the pres-
ence of cleaved caspase-3, the next step would be to perform the survival analysis with 
the CAP parameters stratified for tumor microsatellite status. Unfortunately the number 
of MSI tumors that was successfully determined was too small to perform this analysis 
specifically for MSI within this population. We therefore used tumor location, which we 
previously showed to be highly correlated to tumor microsatellite status, as a surrogate 
marker in this analysis (Figure 4). These Kaplan Meier curves showed in left-sided tumors 
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Figure 2: Survival curves stratified for Ki67 and cleaved caspase-3 tumor expression in colon cancer.
A) Kaplan Meier curves for OS and DFS in the study population of 285 colon cancer patients stratified for 
Ki67 tumor expression. B) Kaplan Meier curve OS and DFS in the study population of 285 colon cancer pa-
tients stratified for cleaved caspase-3 expression in their tumor sections.  Abbreviations: cCaspase3; cleaved 
caspase-3.
Table II: Description of  the CAP (Combined Apoptosis and Proliferation) parameter.
CAP ++ Ki67 expression above the median and presence of cleaved caspase-3 IHC
CAP +- Ki67 expression above the median and no presence of cleaved caspase-3 IHC
CAP -+ Ki67 expression below the median and presence of cleaved caspase-3 IHC
CAP — Ki67 expression below the median and no presence of cleaved caspase-3 IHC
This table provides the definitions of the CAP parameter. This parameter resulted from data combination on the 
tumor cell apoptotic level based on the cleaved caspase-3 immunohistochemistry results with the data on the 
tumor cell proliferation level based on the Ki67 expression levels as determined with IHC. Abbreviations: IHC; 
immunohistochemistry.
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Figure 3: Survival curves stratified for combined tumor apoptosis-proliferation (CAP) expression in colon 
cancer.
Kaplan Meier curves for OS and DFS in the study population of 285 colon cancer patients stratified for 
combined tumor apoptosis-proliferation (CAP) expression. This parameter is described in detail in Table II 
and in the Results section.
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comparable curves to those presented in Figure 3 of the total cohort, but the course 
of the curves changed in right-sided tumors. The CAP ++ and the CAP - - population 
within the cohort of left-sided tumors had the best outcome perspectives as opposed 
to the CAP -+ and +- population that had similar but worse outcome perspectives. The 
CAP + - actually had, within this left-sided cohort, the worst outcome perspectives (DFS 
p-value 0.02). In right-sided tumors, the CAP ++ and CAP +- population had the best 
outcome perspectives as opposed to the CAP — and CAP -+ population that had worse 
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Figure 4: Survival curves stratified for combined tumor apoptosis-proliferation expression and for location 
of the colon tumor.
A) Kaplan Meier curves for OS and DFS stratified for the CAP parameter in patients with left sided colon 
tumors (originating distal to the splenic flexure). B) Kaplan Meier curves for OS and DFS in patients with 
right-sided tumors (originating proximal to the splenic flexure). The CAP parameter is described in detail in 
Table II and in the Results section.
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outcome perspectives. We conclude based on these results that combined analysis of 
apoptosis and proliferation as described with the CAP parameter is related to survival 
in stage I-IV colon cancer patients. The impact of this parameter on patient outcome, 
however, varies with tumor location and therefore highly likely with tumor microsatel-
lite status.
Univariate and multivariable analysis
Both for OS and DFS a multivariable analysis was performed including the variables; 
sex, age at time of operation, TNM stage, tumor grade, administration of adjuvant 
therapy, microsatellite status, tumor location and the CAP parameter. Age and TNM 
stage were found to be independent predictors of OS and DFS (Table III & IV). To test 
whether the effect of the CAP parameter on outcome differed between patients with 
left- and right-sided tumors, an interaction term was implemented that was borderline 
significant (p-value 0.06). Although the CAP parameter was not significantly related to 
TNM stage, stratified analyses for TNM stage showed that the effect of CAP on outcome 
only remained significant in the stage II patient population. Therefore analysis was again 
performed with an interaction term, and again this term was borderline significant (p-
value 0.05).
Table III: Univariate and multivariable analyses of Overall Survival (OS)
Univariate analysis Multivariable analysis
HR 95% CI p-value HR 95% CI p-value
TNM <0.001 <0.001
1 1  1  
2 1.57 0.9-2.6 2.01 1.1-3.7 
3 2.17 1.3-3.6 2.61 1.4-4.8 
4 6.27 3.6-10.7 7.67 4.1-14.3 
Age 1.04 1.026-1.053 <0.0001 1.054 1.037-1.071 <0.001
CAP 0.006 0.28
— 1.00  1  
-+ 1.42 0.9-2.4 1.10 0.6-1.9 
+- 0.71 0.5-1.0 1.27 0.8-2.0 
++ 0.52 0.3-0.9 0.85 0.5-1.4 
This table provides the data for the univariate en multivariable analysis of OS. The univariate analysis included 
sex, age, tumor grade, adjuvant therapy administration, microsatellite status, TNM stage, the CAP parameter, 
microsatellite status and tumor location. The CAP parameter, age and TNM stage were all significant predictors 
of OS in univariate analysis. In multivariable analysis only TNM stage and the patient age at time of surgery re-
tained significance. The CAP parameter is therefore not an independent predictor of overall survival in stage I-IV 
in this cohort of colon cancer patients.
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Based on these results we conclude that although the CAP parameter is not a statisti-
cally independent prognostic indicator of survival in the total patient cohort, the CAP 
parameter, which is influenced by location, microsatellite stability status and TNM stage, 
does behold prognostic significance in certain subsets of patients populations such as 
in stage II, MSS patients.
DISCUSSION
Our study shows that a combined parameter, CAP, describing the level of tumor cell pro-
liferation and apoptosis is significantly related to patient outcome in a stage I-IV colon 
cancer patient cohort with respect to DFS and OS. Although counterintuitively, patients 
with CAP ++ tumor, showing high levels of both proliferation and apoptosis, showed 
the best clinical outcome perspectives. The effect of the CAP parameter, however, varied 
with TNM stage and tumor location and was significantly related to tumor location and 
tumor microsatellite status. These results confirm our hypothesis that clinical outcome 
is dependent on both tumor cell proliferation and apoptosis.
The processes of both tumor cell proliferation and apoptosis both have been exten-
sively studied with varying results in many types of cancer. In general, high tumor cell 
Table IV: Univariate and multivariable analyses of Disease Free Survival (DFS)
Univariate analysis Multivariable analysis
HR 95% CI p-value HR 95% CI p-value
TNM <0.001 <0.001
1 1  1  
2 1.56 0.9-2.5 1.94 1.1-3.5 
3 2.25 1.4-3.7 2.52 1.4-4.6 
4 6.14 3.6-10.4 7.17 3.9-13.1 
Age 1.032 1.019-1.045 <0.001 1.043 1.028-1.059 <0.001
CAP 0.02 0.235
— 1  1  
+- 1.04 0.6-1.8 1.08 0.6-1.8 
-+ 1.60 1.0-2.5 1.37 0.9-2.1 
++ 0.75 0.5-1.2 0,91 0.6-1.5 
This table provides the data for the univariate en multivariable analysis of DFS The univariate analysis included 
sex, age, tumor grade, adjuvant therapy administration, microsatellite status, TNM stage, the CAP parameter, 
microsatellite status and tumor location. The CAP parameter, age and TNM stage were all significant predictors 
of DFS in univariate analysis. In multivariable analysis only TNM stage and the patient age at time of surgery 
retained significance. The CAP parameter is therefore not an independent predictor of disease free survival in this 
cohort of stage I-IV colon cancer patients.
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proliferation levels were associated with aggressive tumor development and progres-
sion 20;24. However, other studies reported on an inverse association between tumor cell 
proliferation level and clinical outcome 8;17;22;25. These latter results are in line with what 
we have found: a better outcome perspective in colon cancer patients with high levels 
of tumor cell proliferation. In this study we were not able to establish a relationship 
between the level of apoptosis as a single marker and patient outcome in colon cancer 
patients. Although there are studies that describe a link between tumor cell apoptosis 
and clinical outcome, for example Jonges et al. who described cleaved caspase-3 expres-
sion as a prognostic marker in colon cancer patients 19, the majority of the studies have 
presented us with more ambiguous results 1;15;16;26;27.
The contradicting results derived from studies reporting on either proliferation or 
apoptosis in colon cancer strengthened our hypothesis that a balance between both 
these processes determines patient’s clinical outcome. Michael-Robinson et al. previ-
ously reported on a cohort of 100 colorectal cancer patients in which they determined 
an Apoptotic Index: Proliferation Index (AI:PI) ratio 25. This AI:PI ratio was based on M30 
IHC for the apoptosis level and Ki67 IHC for the proliferation level. They were able to 
determine a relationship between the proliferation index and outcome comparable 
to our results: they also related their AI:PI index significantly to patient outcome. In 
previous studies the use of the apoptotic index has been criticized as researches found 
the use of the parameter to be accompanied with high amounts of interobserver vari-
ability 28. Therefore we didn’t use a continuous variable based on counted percentages, 
but developed a more descriptive parameter, the CAP, to determine the combined 
effect of apoptosis and proliferation within our patients tumor samples. The differ-
ences in outcome parameters and also patient selection make it difficult to perform a 
one-to-one correlation of the results of Michael-Robinson et al. and our results. Their 
conclusions though do affirm our hypothesis. Interestingly, the survival difference they 
found between a high and low AI:PI index was similar in both MSS and MSI patients. Our 
results showed that the effect of the CAP parameter differed between tumors emerging 
from colon proximal and colon distal to the splenic flexure. In the left-sided cohort the 
patients with CAP — and ++ tumors performed better with respect to outcome. In the 
right-sided cohort the CAP +- performed significantly better than the CAP — cohort. 
This is comparable to what we have previously found and described by Jonges et al. 19. 
The effect of apoptosis on patient outcome is related to tumor location. Based on our 
results we hypothesize that it is either tumor microsatellite status as suggested by both 
Jonges and Michael-Robison, or tumor location which might influence the balance 
between tumor cell proliferation and apoptosis and therefore patient outcome 19;25. The 
concept of the effect of tumor location is in accordance with what has recently been 
described by The Cancer Genome Atlas Network in their publication in Nature in 2012, 
who tested the hypothesis that differences between tumors originating from the left 
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or the right side of the colon is not based on their microsatellite status but it might be 
caused by the different embryonic origins of the right- and left-sided colon 29.
It is not unlikely that the tumor microsatellite status influences the balance between 
tumor cell proliferation and apoptosis. Microsatellite instable tumors are known to have 
high levels of proliferation and tend to accumulate gene mutations leading to increased 
production of abnormal peptides 30;31. This phenotype has been hypothesized to cause 
an immune reaction resulting in higher levels of apoptosis, eventually resulting in better 
patient outcome 32.
In conclusion, the CAP variable described in this study reflects the balance between 
the apoptosis and proliferation in colon cancer tissue and showed to be related to 
patient outcome. These results confirm our hypothesis that apoptosis and proliferation 
together determine patient outcome in colon cancer and this relation is influenced by 
tumor location and/ or by tumor microsatellite instability. This was shown by the differ-
ent effects of the CAP parameter on patient outcome in the left and right-sided colon 
cancer patients cohorts and the statically significant relation of the level of apoptosis 
with tumor microsatellite status, also described in previous studies 19;25 . Important 
steps have been taken towards the implementation of a CAP like parameter into clinical 
practice, such as the development of the CDK1 SA (Cyclin Dependent Kinase 1 Specific 
Activity Assay), a biochemical assay that can replace the Ki67 IHC, and the improvement 
of the existing biochemical assays to measure cleaved caspase-3 activity for easy clini-
cal use 23. Further studies should focus on the design of clinical tests combining both 
proliferation-based markers and apoptosis-based markers into one analysis to assure 
clinical applicability.
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ABSTRACT
Background
The 12-gene Recurrence Score assay is a validated predictor of recurrence risk in stage II 
and III colon cancer patients. We conducted a prospectively designed study to validate 
this assay for prediction of recurrence risk in stage II and III rectal cancer patients from 
the Dutch Total Mesorectal Excision (TME) trial.
Methods
RNA was extracted from fixed paraffin-embedded primary rectal tumor tissue from stage 
II and III patients randomized to TME surgery alone, without (neo)adjuvant treatment. 
Recurrence Score was assessed by quantitative RT-PCR using previously validated colon 
cancer genes and algorithm. Data were analysed by Cox proportional hazards regression 
adjusting for stage and resection margin status.
Results
Recurrence Score predicted risk of recurrence (p=0.011), risk of distant recurrence 
(p=0.030), and rectal cancer-specific survival (p=0.007). The effect of Recurrence Score 
was most prominent in stage II patients and attenuated with more advanced stage 
(interaction p≤0.007 for each endpoint). In stage II, 5-year cumulative incidence of re-
currence ranged from 11% in the pre-defined low Recurrence Score group (48% of pts) 
to 43% in the high Recurrence Score group (23% of pts).
Conclusions
The 12-gene Recurrence Score is a predictor of recurrence risk and cancer specific sur-
vival in rectal cancer patients treated with surgery alone, suggesting a similar underlying 
biology in colon and rectal cancers.
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INTRODUCTION
Before the introduction of the total mesorectal excision (TME) technique, which re-
sulted in a substantial decrease in local recurrences and improved survival, the 5-year 
local recurrence rate of rectal cancer with conventional surgery was over 20% 1. Be-
tween 1996-1999, the Dutch TME trial investigated the effect of short-term preoperative 
radiotherapy in combination with TME surgery compared to TME surgery alone in 1861 
rectal cancer patients 2. Five and ten year results of this trial showed improved local re-
currence rates in patients treated with preoperative radiotherapy and TME 3-5. However, 
no significant effect was seen on distant recurrence and overall survival (OS) 5.
While TME surgery and preoperative therapy have reduced local recurrence, the role 
of adjuvant chemotherapy in rectal cancer in reducing distant recurrence rates and 
improving OS remains controversial. In a systematic review and meta-analysis of 21 
randomized clinical trials, the use of 5-fluorouracil (5-FU) based adjuvant chemotherapy 
for rectal cancer patients who received no preoperative therapy was found to improve 
both OS and disease-free survival (DFS) 6. However, for rectal cancer patients receiv-
ing preoperative chemo- or radiotherapy, most trials did not show a survival benefit 
for adjuvant chemotherapy 7-10. Current clinical and pathologic features in rectal cancer 
are not able to adequately characterize recurrence risk. As such, aggressive approaches 
combining preoperative chemoradiation, TME surgery, and in some countries, postop-
erative adjuvant chemotherapy continue to be used in stage III and many stage II rectal 
cancers, with attendant clinical toxicity, patient burden, and financial cost. There is thus 
a strong need for new clinical tools which more accurately identify patients with low and 
high-risk of recurrence; especially for stage II patients, a more individualized approach 
to balancing risk of recurrence, modest treatment benefit, and therapy-related toxicities 
should improve treatment decision-making.
The 12-gene Recurrence Score assay (Genomic Health, Redwood City, CA, USA) was 
developed by using tumor gene expression data from 1851 patients with resected colon 
cancer from four independent clinical trials 11. This 12-gene assay, measuring expression 
of 12 genes (seven recurrence and five reference genes) in fixed, paraffin-embedded 
(FPE) primary colon tumor tissue, was validated as a predictor of recurrence risk in stage II 
and III colon cancer patients from QUASAR, Cancer and Leukemia Group B (CALGB) 9581, 
and National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trials 12-14, provid-
ing risk discrimination beyond conventional clinical and pathologic factors.
The purpose of this prospectively-designed study was to validate the 12- gene Recur-
rence Score assay in stage II and III rectal cancer for recurrence risk prediction in patients 
from the TME alone arm of the Dutch TME trial who received no pre- and postoperative 
therapy.
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METHODS
Patients and Tissue Specimens
Stage II and III rectal cancer patients enrolled in the Dutch TME trial, randomized to sur-
gery alone, underwent radical resection (i.e. R0-R1), were treated per TME trial protocol 
and had FPE tumor tissue were eligible for the study 3. Informed consent was obtained 
from all patients enrolled in the TME trial. The study was approved by the Medical Ethi-
cal Committee of the Leiden University Medical Center. Per TME protocol, patients with 
tumor spillage during operation or tumor-positive resection margin were allowed to 
receive radiotherapy. Follow-up assessments involved clinical evaluation every three 
months during the first year after surgery and yearly for at least two more years, includ-
ing liver imaging and endoscopy. Additionally, chest X-ray/CT, CEA determination and 
endo-ultrasound were performed on indication.
Pathology and Gene expression
Pathologic T-stage, number of nodes examined and involved by carcinoma, resection 
margin status, distance from anal verge, and local grade assessments were obtained 
from the TME clinical database. Positive resection margin (RM) was defined as positive 
circumferential, distal, proximal, or nodal margin, or presence of the tumor ≤ 1mm from 
any of these margins.  In addition, tumor type and grade were centrally assessed 15 
according to WHO guidelines 16 by an academic surgical pathologist specialized in gas-
trointestinal pathology.
RNA was extracted from six 5-µm sections, quantified by RiboGreen (Invitrogen, Carls-
bad, CA) and analysed by reverse transcriptase quantitative polymerase chain reaction 
using a standardized, analytically validated process 17. The 12-gene Recurrence Score 
results were calculated using prespecified genes and algorithm, as previously validated 
in QUASAR, CALGB 9581, and NSABP C-07 12-14. Prespecified cut points were used to 
define low, intermediate, and high Recurrence Score groups (i.e., RS<30, 30 to 40, and 
≥ 41 respectively) 12.
All centrally-performed pathology and laboratory procedures were prespecified and 
conducted without knowledge of patient clinical characteristics or outcomes.
Statistical Methods
The prespecified primary study endpoint was recurrence-free interval (RFI), defined 
as time from surgery to first rectal cancer recurrence (local or distant) or death with a 
documented recurrence at time of death. Local recurrence was defined as tumor within 
the lesser pelvis or perineal wound and distant recurrence as tumor in any other area 
including at the colostomy site or in the inguinal region 3. Deaths without evidence 
of recurrence and losses to follow-up were censored. Second primary cancers were 
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ignored. RFI was chosen as primary endpoint, as opposed to time to local recurrence in 
the parent TME trial, because gene expression was expected to be associated with any 
recurrence of the primary tumor and most recurrences in rectal cancer are distant.
Secondary endpoints included distant RFI (DRFI), where local recurrences were neither 
censored nor considered as events, rectal cancer-specific survival (RCSS), where  death 
is either preceded by rectal cancer recurrence or occurs with documented recurrence, 
DFS, and OS.
The primary analysis model used Cox proportional hazards (PH) regression to evaluate 
the association between continuous Recurrence Score results and outcome, adjusted for 
stage (II, IIIA/B, IIIC corresponding to 0, 1-3 and 4+ positive nodes, respectively) and RM 
status (RM-negative, RM-positive treated with surgery alone, and RM-positive treated 
with surgery followed by radiotherapy). A two-sided p-value < 0.05, based on a likeli-
hood ratio test, was considered significant.  The hazard ratio for Recurrence Score was re-
ported for an increase of 25 units, consistent with previous studies. Proportional hazards 
were assessed by examining the relationship between scaled Schoenfeld residuals and 
time. Non-linearity was assessed by a likelihood ratio test for squared and cubic terms 
for Recurrence Score results. Stage-specific additive splines that were constrained to be 
linear in the tails 18 were used to model non-linear effects of the continuous Recurrence 
Score. Contribution of Recurrence Score beyond prespecified pathologic covariates 
was evaluated using multivariable Cox PH models. The relationship between Recur-
rence Score groups and RFI, DRFI and RCCS was characterized by cumulative incidence 
estimates and Aalen’s estimates of variance accounting for death without evidence of 
recurrence and death due to cancers other than rectal cancer as competing risks 19. Ad-
ditionally, Kaplan-Meier methods were used. Relative utility curves and a test tradeoff 
were computed 20;21. Analyses used IBM SPSS Statistics 20, R version 2.14.0 (cmprsk and 
mstate packages) and SAS version 9.2.   
RESULTS
Patient characteristics
Tumor tissue was available for 308 (59%) of 518 eligible stage II and III patients in the 
TME trial who were randomized to surgery alone.  Following prespecified procedures 
for pathology and laboratory processing, 11 (3.6%) patients were excluded, primarily for 
insufficient tumor tissue (Figure 1). The final evaluable data set contained 297 patients 
with 128 (43%) recurrences, including 50 (17%) local and 112 (38%) distant recurrences 
(34 patients had both local and distant recurrence).  Recurrences were observed in 34 
(26%) of 130 stage II patients, 57 (52%) of 110 stage IIIA/B patients and 37 (65%) of 57 
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stage IIIC patients. A total of 182 patients died, including 120 (66%) patients who died 
after recurrence of rectal cancer.
Patient characteristics were representative of a contemporary rectal cancer popula-
tion, with median age of 66 (range 23-92), the majority being male (63%), and receiving 
a low anterior resection (LAR) (64%) (Table I).  Most patients had T3-T4 tumors (90%) 
and 30% of the tumors were high grade. The median number of nodes examined was 9 
(range 1-52) and 36% of the patients had ≥12 nodes examined (Table I). Importantly, a 
quarter of patients had positive resection margins, with the proportion of RM-positive 
patients increasing from 16% in stage II to 53% in stage IIIC (Table I).
The demographic and pathologic characteristics of patients evaluated in this study 
were similar to those of eligible stage II and III patients in the parent trial without FPE 
tissue (Supplemental Table I). RFI was comparable as well (logrank p-value 0.507).
Dutch	  TME	  trial	  
	  (n=1861)	  
Stage	  II/III	  pa;ents	  	  
randomized	  to	  TME	  surgery	  alone	  
(n=583)	  
Final	  evaluable	  popula;on	  
(n=297)	  
Recurrences	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=128	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Local	  recurrences	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=50	  	  	  	  	  	  	  
Distant	  recurrences	  	  	  	  	  	  	  	  	  	  	  	  	  n=112	  
Local	  and	  distant	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=34	  
Death	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=182	  
Excluded	  (n=11,	  4%)	  
Insuﬃcient	  ;ssue	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=5	  	  	  	  	  	  	  	  	  
Ineligible	  histology	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=3	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RNA	  quality/quan;ty	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=3	  
Ineligible	  for	  the	  study	  (n=65,11%):	  
	  
R2	  resec;on	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=	  4	  
Chemotherapy	  use	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  n=61	  
Eligible	  stage	  II/III	  pa;ents	  	  with	  
tumor	  blocks	  	  
(n=308)	  
No	  tumor	  blocks	  	  
(n=210,	  41%)	  
Eligible	  stage	  II/III	  pa;ents	  
(n=518)	  
Excluded:	  arm	  with	  pre-­‐opera;ve	  
radiotherapy	  followed	  by	  TME	  
surgery	  (n=924)	  and	  stage	  0,	  I	  &	  IV	  
pa;ents	  (n=354)	  
Figure 1: Study flow diagram.
TME, Total Mesorectal Excision
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Association of Recurrence Score Result with Outcomes
Recurrence Score values ranged from 0 to 72 with a median score of 32 (interquartile 
range, 24 to 42) and a mean ± SD of 33.3 ± 12.7. In the primary analysis, the continuous 
Recurrence Score result was significantly associated with recurrence risk, when control-
ling for stage and RM status, with a hazard ratio (HR) of 1.57 for a 25-unit increase in the 
score (95% CI 1.11-2.21, p=0.011). The proportional hazards assumption held (p=0.52). 
An interaction between Recurrence Score result and stage was observed (p=0.002), with 
evidence of nonlinearity in the relationship between the continuous score and the log 
hazard of recurrence (p<0.001). Adjusting for stage and RM status and accounting for 
interaction with stage and non-linearity, the Recurrence Score result was associated 
Table I: Baseline Clinical and Pathologic Characteristics for the total cohort and stratified for stage.
Characteristic Values All N(%)
297 pts
Stage II (N%)
130 pts
Stage III A/B 
(N%)
110 pts
Stage III C 
(N%)
57 pts
Year of surgery <1998
≥1998
157 (52.9)
140 (47.10
69 (53.1)
61 (46.9)
56 (50.9)
54 (49.1)
32 (56.1)
25 (43.9)
Age <60
60 to <70
70+
102 (34.3)
89 (30.0)
106 (35.7)
50 (38.5)
33 (25.4)
47 (36.2)
35 (31.8)
41 (37.3)
34 (30.9)
17 (29.8)
15 (26.30
25 (43.9)
Gender Female
Male
111 (37.4)
186 (62.6)
56 (43.1)
74 (56.9)
34 (30.9)
76 (69.1)
21 (36.8)
36 (63.2)
Resection type LAR
APR
191 (64.3)
106 (35.7)
80 (61.5)
50 (38.5)
77 (70.0)
33 (30.0)
34 (59.6)
23 (40.4)
Resection margin 
status
R0
R1 no RT
R1+RT
223 (75.1)
37 (12.5)
37 (12.5)
109 (83.8)
15 (11.5)
6 (4.6)
87 (79.1)
9 (8.2)
14 (12.7)
27 (47.4)
13 (22.8)
17 (29.8)
Distance from anal 
verge*
<5 cm
5-9.9 cm
10+ cm
103 (34.7)
110 (37.0)
84 (28.3)
49 (37.7)
42 (32.3)
39 (30.0)
36 (32.7)
49 (44.5)
25 (22.7)
18 (31.6)
19 (33.3)
20 (35.1)
T-Stage T1
T2
T3
T4
1 (0.3)
29 (9.8)
248 (83.5)
19 (6.4)
123 (94.6)
7 (5.4)
1 (0.9)
22 (20.0)
82 (74.5)
5 (4.5)
0 (0.0)
7 (12.3)
43 (75.4)
7 (12.3)
Number  of lymph 
nodes examined
<12
12+
190 (64.0)
107 (36.0)
95 (73.1)
35 (26.9)
74 (67.3)
36 (32.7)
21 (36.8)
36 (63.2)
Grade ** High
Low
88 (29.6)
209 (70.4)
22 (16.9)
108 (83.1)
38 (34.5)
72 (65.5)
28 (49.1)
29 (50.9)
Tumour type Mucinous
Adenocarcinoma
16 (5.4)
281 (94.6)
4 (3.1)
126 (96.9)
8 (7.3)
102 (92.7)
4 (7.0)
53 (93.0)
Obstruction or 
perforation
Present
Absent
21 (7.1)
276 (92.9)
7 (5.4)
123 (94.6)
6 (5.5)
104 (94.5)
8 (14.0)
49 (86.0)
Abbreviations: RT=Radiotherapy, R0= Radical resection, R1: residual disease after resection
* To inferior margin of tumor
** Centrally assessed by a pathologist at Genomic Health
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with risk of recurrence in stage II (HR defined as ratio of the hazards at the 75th and 25th 
percentile of RS, 3.27, 95% CI 1.52-7.01, p<0.001) and stage IIIA/B (HR,  1.87, 95% CI 1.18-
2.95, p=0.007) (Figure 2). The Recurrence Score result was not associated with recurrence 
risk in stage IIIC (HR, 0.75, 95% CI 0.46-1.21, p=0.243). The pre-defined high Recurrence 
Score group had higher recurrence risk than the low group in stage II (HR, 5.81, 95% 
CI 2.33-14.50, p<0.001) but not in stage IIIA/B (HR, 1.62, 95% CI 0.82-3.19, p=0.169) or 
stage IIIC (HR, 0.64, 95% CI 0.29-1.41, p=0.272): the effect of the Recurrence Score was 
most prominent in stage II and attenuated in more advanced stage (Figure 3). In the 
stage II patients, cumulative incidence estimates of 5-year recurrence risk for the low- (63 
patients, 48%), intermediate- (37 patients, 28%), and high (30 patients, 23%) Recurrence 
Score groups were 11% (95% CI 6-22%), 27% (95% CI 16-46%) and 43% (95% CI 29-65%), 
respectively (Table II). Recurrence risk estimates by Kaplan-Meier methods were similar 
for low group and higher for the high score group (Supplemental Table II and Figure 1).
Figure 2 
 
A) Stage II 
 
 
B) Stage III A/B 
 
 
Figure 2: Relationship between risk of recur-
rence and continuous Recurrence Score in pa-
tients with negative resection margins.
Relationship between risk of recurrence and 
continuous Recurrence Score in 297 rectal 
cancer patients with negative resection mar-
gins. A) stage II, B) stage IIIA/B (1-3 positive 
lymph nodes). The solid line represents risk 
of recurrence; the dotted lines represent 95% 
confidence intervals.  A rug plot depicting the 
distribution of Recurrence Score values is in-
cluded at the bottom of each figure.
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Figure 3: Cumulative incidence for recur-
rence by stage and Recurrence Score group
Cumulative incidence curves for recurrence 
in 297 rectal cancer patients by Recurrence 
Score group based on prespecified cut-
points and separated by stage. A) stage II, 
B) stage IIIA/B (1-3 positive lymph nodes), 
C) stage IIIC (4 or more positive lymph 
nodes).
Solid black line represents low Recurrence 
Score group, solid grey line – intermediate 
Recurrence Score group and dashed black 
line - high Recurrence Score group.
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Similar results were observed for DRFI and RCSS: in the pre-specified main-effects 
models, the Recurrence Score result was significantly associated with DRFI (HR for 25 
unit increase in the score of 1.50, 95% CI 1.04-2.17, p=0.030) and RCSS (HR of 1.64 (95% 
CI 1.15-2.34, p=0.007). Significant interaction between Recurrence Score result and 
stage and non-linearity were also observed for these endpoints. In stage II patients, 
cumulative incidence estimates of 5-year recurrence ranged from 8% (95% CI 3-18%) 
to 33% (95% CI 20-55%) for DRFI and from 5% (95% CI 2-14%) to 30% (95% CI 17-52%) 
for RCSS for low vs. high score groups, respectively (Table II).
The Recurrence Score result was not significantly associated with DFS (p=0.118) and 
OS (p=0.111) in the pre-specified analyses, similar to one of the colon cancer validation 
studies 13 where most deaths were not cancer-related.  Notably, in this study, 52% of 
deaths in stage II patients were not due to rectal cancer.
Recurrence Score in the Context of Conventional Clinical and Pathologic Factors
When clinical and pathologic factors were examined (Supplemental Table III), higher age 
(p=0.041) and higher T-stage (T4N0, T3-4N1 vs. T3N0, T1-2N1, p=0.016) were associated 
with recurrence in analyses adjusted for stage and resection margin. Type of surgical 
resection and distance from anal verge showed an interaction with stage (p=0.026 and 
p=0.049, respectively), with LAR and greater distance from the anal verge associated 
with lower risk of recurrence in stage IIIC (both p<0.005) but not in stage II or stage 
IIIA/B.  While resection margin status was significantly associated with outcome in the 
univariate analysis (p=0.015), its effect was attenuated after adjustment for stage in the 
multivariable analyses, paralleling what was observed for resection margin status in all 
eligible stage II-III surgery alone patients in the TME trial.
In pre-specified multivariable analysis adjusted for stage, RM status, T-stage, grade 
and number of nodes examined, the Recurrence Score result was a significant predic-
tor of recurrence risk in stage II (p<0.001) and stage IIIA/B (p=0.019), but not Stage IIIC 
(p=0.122) (Table III). Similar results were observed when age, the only other covariate 
associated with RFI, was added to the model, and when the analysis was adjusted 
for circumferential (radial) margin status only. The model with Recurrence Score and 
Table II: Five-year Estimates of Cumulative Incidence in Stage II Rectal Cancer Patients (n=130)
Recurrence 
Score group
N (%) pts Cumulative Incidence 
for Recurrence  
(95% CI)
Cumulative 
Incidence for Distant 
Recurrence  (95% CI)
Cumulative Incidence 
for Rectal Cancer 
Specific Mortality 
(95% CI)
Low 63 (48.5%) 11.1% (5.5%, 22.3%) 7.9% (3.4%, 18.4%) 4.8% (1.6%, 14.4%)
Intermediate 37 (28.5%) 27.0% (15.9%, 45.8%) 24.3% (13.8%, 42.9%) 18.9% (9.7%, 36.9%)
High 30 (23.1%) 43.3% (28.8%, 65.2%) 33.3% (20.1%, 55.2%) 30.0% (17.4%, 51.8%)
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conventional measures identified 25% of stage II patients with 5-year recurrence risk 
below 15% and 39% of patients with risks above 30% while the model based on the 
conventional measures alone assessed the risk for 95% of stage II patients to be in 
the 15%-30% range and 5% of patients with risk above 30%.  Addition of the Recur-
rence Score assay to conventional measures resulted in higher relative utility (Figure 4). 
A test tradeoff calculation 21 illustrates the value of the assay for different treatment 
paradigms. If default strategy is treating everyone, testing 14 to 18 patients is required 
for every correct prediction of recurrence to increase the net benefit of risk prediction 
compared to conventional measures alone (risk thresholds 25-30%). If therapy is not 
routinely recommended, testing 37 to 45 patients is required (risk thresholds 45-50%).
The Recurrence Score result predicted DRFI (stage II p=0.009, stage IIIA/B p=0.020) and 
RCSS (stage II p<0.001 and stage IIIA/B p=0.034) after adjustment for these additional 
covariates.
Table III: Multivariable Analysis: Contribution of Recurrence Score to Prediction of Recurrence Risk beyond 
Clinical and Pathologic Covariates
Variable HR HR (95% CI) p-value
Stage
IIIA/B vs. II
IIIC  vs. II
1.36
2.48
(0.71-2.95)
(1.22-5.02)
0.36
0.01
Resection margin status
R1 no RT vs. R0
R1 + RT vs.R0
1.02
1.01
(0.59-1.75)
(0.62-1.67)
0.95
0.96
T-Stage
T4N0, T3-4N1 vs. T3N0, T1-2N1 2.03 (1.14-3.60) 0.01
Grade *
High vs. low 0.99 (0.67-1.45) 0.95
Number of nodes examined
12+ vs. <12 1.10 (0.75-1.62) 0.63
RS contribution**
RS in stage II
RS in stage IIIA/B
RS in stage IIIC
3.40
1.75
0.69
(1.58-7.30)
(1.11-2.77)
(0.42-1.12)
<0.001
0.02
0.12
* Centrally assessed by a pathologist at Genomic Health
** Includes stage specific linear and spline terms (2 d.f.) to account for non-linearity. Hazard Ratio for Recurrence 
Score is the ratio of the hazards at the 75th and 25th percentiles of Recurrence Score
100 Chapter 5
DISCUSSION
In this prospectively-designed study, the 12-gene Recurrence Score was validated as a 
predictor of recurrence in stage II and III rectal cancer patients treated with TME surgery 
alone, providing information beyond conventional clinical and pathologic factors 12-14. 
There was a significant interaction between Recurrence Score and stage, with the Recur-
rence Score providing the greatest discrimination of recurrence risk in stage II disease 
and little discrimination in stage IIIC.
Consistency of these rectal cancer results with 3 large validation studies of the Recur-
rence Score assay in colon cancer supports the association of this score with metastatic 
potential of large bowel cancers, and demonstrates the presence of common biological 
determinants of recurrence across tumors arising from the colon as well as the rectum.
Improved risk discrimination with the Recurrence Score result in stage II and IIIA/B 
rectal cancer should have clinical relevance for patients and physicians considering 
individualized approaches to pre-operative and post-operative treatment. In the 
United States the standard recommendation for treatment of stage II and III rectal 
Figure 4: Relative utility curves for recurrence risk prediction using the models with and without Recur-
rence Score in all patients.
Relative utility curves for recurrence risk prediction in 297 rectal cancer patients. Relative utility is the maxi-
mum net benefit of prediction divided by the net benefit of perfect prediction. Risk threshold is the recur-
rence risk at which a patient is indifferent to the use of a treatment (e.g. post-operative chemotherapy).
Solid black line represents Cox regression model with Recurrence score, N and T stage, resection margin 
status, number of nodes examined and grade. Dashed black line represents Cox regression model with N 
and T stage, resection margin status, number of nodes examined and grade.
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cancer patients includes neoadjuvant chemoradiation followed by TME surgery and 
postoperative adjuvant chemotherapy, based on extrapolation from trials in colon can-
cer 22;23. By contrast, in most countries in Europe, adjuvant chemotherapy is not routinely 
recommended in rectal cancer. The benefit of adjuvant chemotherapy in patients with 
combined chemoradiation before surgery is controversial 7-10. Across these treatment 
paradigms, the ability of Recurrence Score to identify patients with widely different 
risks of recurrence may enable tailored approaches, directing use of pre-operative and 
post-operative chemotherapy and radiation to patients at high risk of tumor recurrence 
and less aggressive treatment for low risk patients. In this regard, the low recurrence risk 
observed in our study for the large sub-group of stage II rectal cancer patients with low 
Recurrence Score results may be particularly impactful, as these patients demonstrated 
excellent outcomes without any pre- or post-operative chemotherapy or radiation. In 
moderate risk patients, the decision for more aggressive treatment should be discussed 
by patient and physician taking into account potential recurrence risk, morbidity associ-
ated with treatment, comorbidities and patient preferences. It is important to note that 
the ability of the Recurrence Score to predict neoadjuvant or adjuvant chemotherapy 
benefit in rectal cancer has not been studied. This study focused on patients who did not 
receive pre-operative chemotherapy or radiation, and the assay’s ability to differentiate 
risk for patients with neoadjuvant therapies should be addressed in future studies.
The results of this validation study are consistent with recent analyses by the Cancer 
Genome Atlas Network 24, demonstrating similarity of colon and rectal cancers at the 
genomic level.  A number of recent studies have suggested the existence of different 
subtypes of colorectal cancer 25-29. All support the notion that colorectal tumors with 
a stromal response signature (EMT/TGFbeta signalling) have the worst outcome. Our 
results reaffirm the clinical relevance of two key biological pathways measured by the 
Recurrence Score assay - stromal response and cell cycle control, which is consistently 
reflected across multiple subtyping and genomic profiling efforts in the literature.
This prospectively-designed validation study demonstrates that the 12-gene colon 
cancer assay, can assess risk of recurrence in rectal cancer patients. The low exclusion 
rate observed during sample processing was consistent with QUASAR (3.6%), CALGB 
(3.1%) and C-07 (3.1%), indicating a precise and robust analytical process 12-14. Limita-
tions should also be acknowledged. First, blocks for only 59% of eligible patients were 
collected, although the demographics for those with blocks and without blocks were 
similar. Second, risk discrimination by Recurrence Score was attenuated in stage IIIA/B 
and IIIC, and Recurrence Score was not an independent recurrence risk predictor in 
stage IIIC. The reason for this attenuation is unclear, but may relate to challenges with 
achieving a complete resection of tumor at higher stage, which may affect recurrence 
rates beyond the biology of the tumor itself.  Furthermore, the total study size is modest 
in absolute numbers and some subgroup analyses may be underpowered, but this is 
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one of the largest cohorts of well-characterized rectal cancer patients to be studied with 
a gene expression assay.
The use of adjuvant chemotherapy in rectal cancer is still under debate, and efforts 
are underway to study reduced-intensity approaches, including those that spare radia-
tion and even surgery. Incorporation of the Recurrence Score assay into clinical trials, 
along the lines of the TAILORx and RxPonder trials in breast cancer30;31, may enable these 
efforts through improved patient stratification for risk-adapted treatment strategies. 
Our results highlight the importance of understanding the underlying biology of rectal 
tumors for individual patients in assessing risk and potentially guiding treatment deci-
sions in this disease.
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SUPPLEMENTAL MATERIAL
Supplemental Table I: Comparison of patient characteristics for eligible patients with and without blocks 
from the TME trial
Characteristic Values Evaluable patients in 
this study (N=297)
Eligible TME trial 
patients without 
blocks (N=210)
p-value*
Age <60 102 (34.3) 58 (27.6) 0.07
  60 to <70 89 (30.0) 63 (30.0)
  70+ 106 (35.7) 89 (42.4)
Gender Female 111 (37.4) 83 (39.5) 0.62
Number of Nodes       
Examined
<12 190 (64.0) 133 (63.9)  0.99
Number of 0 (Stage II) 130 (43.8) 111 (53.4) 0.17
Nodes Involved 1-3 (Stage IIIA/B) 110 (37.0) 57 (27.4)
  4+ (Stage IIIC) 57 (19.2) 40 (19.2)
T-Stage T1-T2 30 (10.1)  14 (6.7)  0.85
  T3 248 (83.5)  190 (90.9)
  T4 19 (6.4)  5 (2.4)
Obstruction or     
Perforation
Present 21 (7.1)  9 (4.3)  0.19
Grade** High 73 (24.6)  35 (28.2)  0.43
Resection margin R1 74 (24.9) 38 (18.3) 0.08
* p-values are from the chi-square and Cochran-Mantel-Haenszel chi-square tests for nominal categorical and 
ordered categorical variables, respectively
**  Locally assessed during TME trial; available for 124 patients without blocks.
Supplemental Table II: Five-year Estimates of Risk based on Kaplan Meier analysis in Stage II Rectal Cancer 
Patients (n=130)
Recurrence 
Score group
N (%) pts Recurrence Risk  
(95% CI)
Distant Recurrence 
Risk (95% CI)
Rectal Cancer Specific 
Mortality (95% CI)
Low 63 (48.5%) 12.4% (6.1%, 24.3%) 9.1% (3.9%, 20.4%) 5.3% (1.8%, 15.7%)
Intermediate 37 (28.5%) 28.7% (16.6%, 46.8%) 25.8% (14.4%, 43.8%) 20.3% (10.2%, 37.9%)
High 30 (23.1%) 52.7% (34.7%, 73.2%) 45.9% (27.6%, 68.8%) 37.0% (21.2%, 59.1%)
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Supplemental Table III: Association of conventional clinical and pathologic factors with risk of recurrence.
Characteristic Values HR HR
95% CI
p-value* p-value for 
interaction 
with stage***
Age
Continuous, per 1 
year increase
1.02 (1.00,1.03) 0.04 0.92
Grade, central High vs low 1.01 (0.68,1.49) 0.96 0.61
Grade, local High vs low 1.06 (0.71,1.57) 0.78 0.74
Nodes examined <12 vs. 12+ 1.18 (0.80,1.74) 0.40 0.67
Gender Male vs. Female 1.09 (0.75,1.58) 0.64 0.58
T Stage
T4N0, T3-4N1 vs. 
T3N0, T1-2N1
1.89 (1.10,3.25) 0.02 0.28
Surgery APR vs. LAR 1.44 (1.00,2.06) 0.05 0.03
Distance from anal verge 5-9.9 vs. <5 0.93 (0.62,1.39) 0.72 0.05
10+ vs. <5 0.62 (0.39,0.99) 0.04
Residual disease** R1 vs. R0 1.28 (0.86,1.92) 0.23 0.30
Resection margin status** R1 no RT vs. R0 1.18 (0.69,2.04) 0.55 0.52
R1 + RT vs. R0 1.37 (0.85,2.22) 0.21
CRM margin (<1 mm)** Positive vs Negative 1.34 (0.89,2.00) 0.17 0.27
CRM margin (<2 mm)** Positive vs Negative 1.28 (0.87,1.87) 0.21 0.21
*Based on Cox PH models including a given covariate, stage and RM status.
**Based on Cox PH models including a given covariate and stage.
***Based on Cox PH models including a given covariate, stage and interaction of covariate and stage.
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Supplemental Figure 1: Kaplan Meier analysis for recurrence-free interval by stage and 
Recurrence Score group 
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C) stage IIIC
Supplemental Figure 1: Kaplan Meier analysis for recurrence-free interval by stage and Recurrence Score 
group.
Kaplan Meier curves for Recurrence Free Interval (RFI) in 297 rectal cancer patients stratified for Recurrence 
Score group based on prespecified cut-points and separated by stage. A) stage II, B) stage IIIA/B (1-3 posi-
tive lymph nodes), C) stage IIIC (4 or more positive lymph nodes).
Solid black line represents low Recurrence Score group, dashed black/grey line-intermediate Recurrence 
Score group and dotted black line-high Recurrence Score group.
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ABSTRACT
Background
Preclinical studies have shown aspirin might prolong survival due to inhibition of tumor 
growth and metastases in colon cancer patients. To date, however, it is unclear whether 
aspirin, prescribed as an adjuvant therapy, can influence the prognosis of colon cancer 
patients. An effective and well-tolerated adjuvant therapy would be a major clinical 
advancement, particularly in older cancer patients. The aim of this study was to assess 
survival in relation to aspirin use after diagnosis in older colon cancer patients.
Methods
Subgroup analysis of a previously published cohort and retrospective study of 536 
patients aged 70 years and older diagnosed with colon cancer registered in the Eind-
hoven Cancer Registry (ECR) between 1998 and 2007, linked to prescriptions of low dose 
aspirin (80 mg) registered in the community pharmacy database of the PHARMO record 
linkage system.
Survival was analyzed with user status as a time-dependent covariate. Multivariable 
Poisson regression survival models were used to study the effect of aspirin on Overall 
Survival (OS).
Results
Overall, 107 patients (20.0%) started aspirin after being diagnosed with colon can-
cer; 429 patients (80.0%) were not prescribed aspirin. In total 339 patients (63.2%) died 
at the end of follow up. Aspirin use after diagnosis was associated with a better OS with 
a Rate Ratio (RR) of 0.51 (95% CI 0.38-0.70 p<0.001). Multivariable proportional hazards 
regression analysis revealed aspirin use was associated with overall survival (adjusted 
RR 0.59 (95% CI 0.44-0.81, p=0.001)).
Conclusions
Aspirin use after the diagnosis of colon cancer in older patients was associated with 
better survival. These results suggest that low dose aspirin could be used as an effective 
adjuvant therapy in older colon cancer patients.
Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study 113
INTRODUCTION
Nearly half of all patients with colon cancer are above 70 years of age and this age group 
is expanding as a result of increasing life expectancy 2. Approximately fifty percent of all 
patients undergoing colorectal cancer surgery are known to develop a relapse and die 
of metastatic disease 1;3;4. The introduction of adjuvant chemotherapy has significantly 
improved the prognosis of colon cancer patients. However, the effect of adjuvant che-
motherapy on older patients is less clear. Some studies have suggested lack of survival 
benefit with adjuvant chemotherapy in patients older than 65 years 5. Other studies, 
however, have suggested that older patients do benefit similar from chemotherapy, but 
that they are less frequently treated 4;6.  Undertreatment with adjuvant chemotherapy of 
older patients often occurs because of co-morbidities and patient preferences 7.  Due to 
underrepresentation in clinical trials there is no treatment consensus for elderly patients 
with colon cancer.
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in 
preventing colorectal cancer 8-10.  Aspirin inhibits cyclooxygenase-2 (COX-2), which is 
expressed in 70% of the colorectal tumors and increases with disease stage 11;12.  COX-2 
plays an important role in colorectal carcinogenesis, invasion, angiogenesis and metas-
tasis. Several studies have shown that this COX-2 effect can be reversed by selective 
COX-2 inhibitors 13. It is not clear whether aspirin can influence the prognosis of patients 
with colorectal cancer, but in animal models aspirin and NSAIDs with activity against 
the COX-2 isoenzyme have shown to inhibit tumor progression and increase survival 14. 
Besides, clinical studies have shown an association between aspirin and prognosis as 
well. A recent study in patients with stage I-III colorectal cancer selected from two na-
tionwide health professional cohorts in the U.S. showed that regular aspirin use after 
the diagnosis of colorectal cancer compared with non-users was associated with a lower 
risk of colorectal cancer-specific and overall mortality, especially among individuals with 
tumors that overexpress COX-2 11.
The number of colon cancer patients is increasing and there is a strong need for thera-
peutic improvement, especially in elderly patients, who are less frequently treated with 
standard chemotherapy. The aim of this study was to assess the association of aspirin 
use after the diagnosis of colon cancer on survival in patients aged 70 years and older.
METHODS
Patients
The central patient database of PHARMO, which links to more than 10 databases using 
different medical record linkage algorithms, was recently combined with data from the 
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Eindhoven Cancer Registry (ECR) 15. From the PHARMO database, prescriptions of low 
dose aspirin (80 mg) were selected and linked to patients diagnosed with colorectal 
cancer, registered in the ECR between 1998 and 2007.  In total, 4481 colorectal can-
cer patients were included in this database. We performed a subgroup analysis on 
this previously published cohort, comprising specifically patients 70 years and older, 
diagnosed with colon cancer, who used aspirin only after diagnosis or who never used 
aspirin (n=536).1 The date of prescription and date of diagnosis were compared to assess 
whether the aspirin was prescribed only after the diagnosis. Nonusers were defined as 
patients who were never used prescribed aspirin. Patients who were prescribed aspirin 
after diagnosis were defined as users.
Statistics
Vital status of patients was established either directly from the patient’s medical record or 
through linkage of cancer registry data with the municipal population registries, which 
record information on the vital status of their inhabitants. Follow-up started at 30 days 
from diagnosis of colorectal cancer (T0), as information concerning the prescriptions in 
hospital was unknown. Follow-up was until the last contact date or date of death. Users 
were defined as patients who had at least 1 prescription for aspirin for at least 14 days; 
patients who were prescribed aspirin for less than 14 days were defined as nonusers. 
Time-dependent survival analyses were used to assess survival. Patients were defined as 
nonusers from T0 to first use and user from first use to the end of the follow-up. Poisson 
regression survival models were used to study the effect of aspirin on overall survival. In 
multivariable proportional hazards regression analysis adjustments were made for sex, 
age (continuous), stage (pathological stage and clinical stage if pathological stage was 
unknown), adjuvant chemotherapy (yes/no), co-morbidity (yes/no), surgery (yes/no), 
grade, localization of the tumor, and year of diagnosis. Finally, stratified analyses were 
performed for type of co-morbidity, chemotherapy, grade, stage, surgery and localiza-
tion of the tumor.
RESULTS
Overall, 536 patients aged 70 years and older diagnosed with colon cancer between 1998 
and 2007 were included in the analyses. There were 107 patients (20%) who started low-
dose aspirin (80 mg) after diagnosis and 429 patients (80%) who did not use prescribed 
aspirin before or after diagnosis. Table I shows the patient baseline characteristics; Medi-
an age was 77.6 (SD 5.3) years. Patients who used aspirin were significantly younger than 
patients without aspirin use. Non-users were more likely to be diagnosed with stage IV 
colon cancers compared to aspirin users. Also, aspirin users were more often diagnosed 
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Table I: Baseline Characteristics of Study Population
Overall
N=536
% Aspirin +
N=107
% Aspirin –
N=429
% P-value
Age,Mean (SDa) 77.6 (5.3) 76.6 (4.9) 77.8 (5.4) 0.04
Sex 0.57
Female
Male
258
278
48.1
51.9
48
59
44.9
55.1
210
219
49.0
51.0
Grade 0.87
I
II
III
Unknown
69
311
84
72
12.9
58.0
15.7
13.4
13
64
18
12
12.1
59.8
16.8
11.2
56
247
66
60
13.1
57.6
15.4
14.0
Stage <0.01
I
II
III
IV
Unknown
89
212
115
85
35
16.6
39.6
21.5
15.9
6.5
25
53
24
2
3
23.4
49.5
22.4
1.9
2.8
64
159
91
83
32
14.9
37.1
21.2
19.3
7.5
Chemotherapy 0.25
Yes
No
68
468
12.7
87.3
10
97
9.3
90.7
58
371
13.5
86.5
Radiotherapy 0.86
Yes
No
9
527
1.7
98.3
2
105
1.9
98.1
7
422
1.6
98.4
Surgery <0.01
Yes
No
463
73
86.4
13.6
105
2
98.1
1.9
358
71
83.4
16.6
Pulmonary 0.15
Yes
No
67
469
12.5
87.5
9
98
8.4
91.6
58
371
13.5
86.5
Cardiovascular 0.35
Yes
No
244
292
45.5
54.5
53
54
49.5
50.5
191
238
44.5
55.5
Diabetes 0.64
Yes
No
62
474
11.6
88.4
11
96
10.3
89.7
51
378
11.9
88.1
Comorbidity 0.86
0-1
2+
439
97
81.9
18.1
87
20
81.3
18.7
352
77
82.1
17.9
a SD=Standard Deviation
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with stage I colon cancer. Most of the patients did not receive chemotherapy (87%) 
or radiotherapy (98%). This was similar in both groups. Aspirin users more frequently 
underwent surgery compared to non-users. There were no differences in co-morbidities 
between the two groups.
Survival with time-varying covariate
Between 1998 and 2007, 339 patients (63.2%) died during follow-up, and 197 patients 
were still alive in 2007. For all patients with colon cancer, aspirin use after the diagnosis 
was associated with a significant reduction in overall mortality (Rate Ratio (RR) 0.51 (95% 
CI 0.38-0.70 p<0.001)). Multivariable analysis revealed that aspirin use was also associ-
ated with better survival when adjusted for sex, stage, age, adjuvant chemotherapy, 
co-morbidity, incidence year, surgery and grade (adjusted RR 0.59 (95% CI 0.44-0.81, 
p=0.001)). Figure 1 shows the OS curve for aspirin users and non-users. Stratification 
for various factors, as shown in Figure 2, revealed survival gain was present in all strata. 
The greatest association between aspirin use and survival was in patients with higher 
disease stage and grade, and in patients who did not receive chemotherapy (adjusted 
RR for no chemotherapy: 0.71, 95% CI 0.64-0.79, p<0.001). Because older patients are 
frequently known to have co-morbidities we also stratified for this possible confounder. 
Again, the association between aspirin use and survival persisted in patients with 
diabetes (adjusted RR 0.53, 95% CI 0.32-0.86, p=0.01), cardiovascular disease (adjusted 
RR 0.69, 95% CI 0.59-0.79, p<0.001), no cardiovascular disease (adjusted RR 0.77, 95% 
CI 0.66-0.89, p=0.001) and absence of pulmonary disease (adjusted RR 0.72, 95% CI 0.64-
0.80, p<0.001).
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Figure 1: Survival Curve for Overall Survival in Older Colon Cancer Patients According to Use of Aspirin.
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DISCUSSION
Here we report an independent strong association of improved survival in older patients 
who used aspirin after colon cancer diagnosis. This effect also persisted after adjusting 
for several confounders and was present in most strata of colon cancer.
Since 1968, it has been suggested that aspirin could be a possible preventive agent 
for colorectal cancer 16. Only recently, aspirin has been mentioned as a possible adjuvant 
agent for colorectal cancer 11. Our study implicates that aspirin could be an effective 
adjuvant agent in the treatment of colorectal cancer, especially in older, chemo-naive 
colon cancer patients, as aspirin use was associated with a clinically and statistically sig-
nificant increase in overall survival. To our knowledge, this is the first report that focuses 
on older colon cancer patients specifically.
Our results are consistent with results by Chan et al., who found an improved OS 
of 0.79 (95% CI 0.65-0.97) for regular aspirin users compared to non-users in a cohort 
study of 1279 patients diagnosed with stage I-III colorectal cancer 11. In our study as-
Surgery yes
Surgery no
Stage IV
Stage III
Stage II
Stage I
Grade III
Grade II
Grade I
Chemotherapy yes
Chemotherapy no
CVD yes
CVD no
DM yes
DM no
Pulmonary yes
Pulmonary no
Adjusted OS
 Figure 2: Adjusted  Rate Ratio (RR) with 95% Confidence Interval (CI) for Aspirin Use for Older Colon Cancer 
Patients Stratified for Sex, Stage, Age, Adjuvant chemotherapy, Co-morbidity, Incidence year, Surgery and 
Grade.
CVD, Cardiovascular disease; DM, diabetes mellitus
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pirin users had a RR of 0.51 (95% CI 0.38-0.70, p<0.001) for OS. A major strength of this 
investigation is the use of a time-dependent covariate in the survival analyses and the 
large number of patients enrolled in the PHARMO database, which gave us the unique 
opportunity to assess older colon cancer patients specifically. By using two validated 
databases we have avoided the possibility of recall bias, which will be more likely with 
the use of questionnaires to assess aspirin use.
Our results underscore the findings found in cardiovascular prevention trials, where 
long-term aspirin use was associated with fewer deaths due to cancer. Hazard ratios in 
these studies ranged from 0.63-0.85, which correspond with our findings, in favor of 
aspirin use to reduce cancer death. Benefit increased with treatment duration and was 
consistent across the various populations included in these studies 9;10. Nevertheless, we 
assessed aspirin as adjuvant treatment, starting after diagnosis of colon cancer, whereas 
these studies investigated aspirin use in the preventive setting, including aspirin use 
before diagnosis. Our results suggest that aspirin use after cancer diagnosis is associ-
ated with a survival advantage, when compared to aspirin use before diagnosis. Also, 
the slightly greater survival advantage for older aspirin users in our cohort might be 
explained by the undertreatment of these elderly patients with adjuvant chemotherapy, 
while younger patients receive chemotherapy more often, with good results. Therefore, 
the absolute effect of aspirin could be higher in older colon cancer patients who, 
without chemotherapy, have a higher a-priori chance of developing metastases. This 
is also reflected in the larger effect of aspirin on survival in older colon cancer patients 
without chemotherapy (HR 0.71) and the previously published data where the largest 
survival gain of aspirin use after diagnosis was found in older colon cancer patients, 
when compared to other age categories 1.  Furthermore, the expression of COX-2 may 
increase with older age and this could be the reason for the larger effect of aspirin on 
survival in older colon cancer patients 17.
In recent studies, in which prediagnosis NSAID use and survival following colorectal 
cancer diagnosis was evaluated, a higher reduction in colorectal cancer mortality risk 
after diagnosis by aspirin use was found compared to overall NSAID use 1;18;19. These 
results, along with results of our study, suggest that aspirin and not overall NSAID use, 
which was mostly used in all previous studies12;18, may be an important agent in improv-
ing survival in colon cancer patients.
Most studies evaluated the use of aspirin or other non-steroidal anti-inflammatory 
agents before diagnosis. Our study established a longer survival in aspirin users, when 
started after cancer diagnosis and surgery. Also, due to the large number of patients in 
the total cohort (4481 colorectal cancer patients) we were able to perform an analysis on 
older chemo-naive colon cancer patients. Although currently only hypothesis generat-
ing, our results suggest that aspirin use as an adjuvant therapy for colon cancer treat-
ment is a clinically relevant option, especially in older adults.
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Our study has limitations inherent to observational studies. First, aspirin use was not 
randomized, so it is possible that patients took aspirin for cancer prevention purposes. 
However, in the Netherlands, low dose aspirin (80 mg) is exclusively prescribed for 
cardiovascular risk management, and cannot be purchased ‘over the counter.’ Second, 
our data is limited to prescribed drugs. Therefore it is not possible to obtain information 
regarding to aspirin use or other NSAIDs at home. Third, the improved prognosis could 
also be explained by the reduced number of cardiac events. However, a meta-analysis 
for aspirin in the primary and secondary prevention of vascular disease showed a sur-
vival gain around 5% for aspirin users 20. This minimal gain in survival cannot explain the 
larger survival gain associated with aspirin use in our study. Finally, there were differ-
ences in baseline characteristics of patients included in our investigation. Aspirin users 
more frequently underwent surgery compared to non-users, had lower stage disease 
and were slightly younger. However, even after adjustment for these confounders and 
after stratification, the effect of aspirin persisted (Figure 2). More importantly, this longer 
survival in aspirin users in our study and in other observational studies was consistent 
with the findings in randomized trials.21 Nevertheless, residual confounding may still 
be present. This could only be resolved in a randomized clinical trial, one of which has 
already been started in Asia (ASCOLT NCT 00565708) and two trials are in preparation 
in Europe 22.
The exact mechanism by which aspirin exerts its activity is not completely understood. 
It is likely that the anti-inflammatory and chemopreventive effects of aspirin are medi-
ated through direct inhibition of COX-1 and COX-2 13;23;24.  Approximately 70% of colorec-
tal tumors express COX-2 12. COX-2 plays an important role in colorectal carcinogenesis, 
invasion, angiogenesis and metastasis. Several studies have shown that this COX-2 effect 
can be reversed by selective COX-2 inhibitors 13. Chan et al. found a much lower risk of 
colorectal cancer-specific and overall mortality with tumors that over express COX-2 11. 
Elevated COX-2 expression was found to be associated with tumor metastases, and 
multiple studies demonstrated COX-2 overexpression as a negative prognostic factor 
in colorectal cancer 25-27. Also, studies have linked the COX enzyme-mediated mecha-
nisms to the ability of tumors to initiate vascularization 28 and angiogenesis 29, probably 
through the production of prostaglandin by COX-2 30. This prostaglandin pathway may 
also be responsible for the regulation of apoptosis 31, and evading apoptosis is one of 
the key hallmarks of cancer 32. By using aspirin, a COX-2 inhibitor, the effects of COX-2 on 
tumor progression can ultimately be altered in a positive way.
This is the first study focusing specifically on older colon cancer patients. Elderly 
patients are a frequently overlooked, understudied and often undertreated group of 
patients. Our findings may have important clinical implications in older adults with 
colorectal cancer. Demonstration of a significant therapeutic effect of a well-tolerated, 
inexpensive drug would be a major clinical advancement. In this study, aspirin is impli-
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cated as an effective adjuvant agent, increasing overall survival in older colon cancer 
patients. However, a randomized trial in this age group is necessary to confirm the 
therapeutic role of aspirin, and is currently being developed in the Netherlands.
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ABSTRACT
Background
Use of aspirin (which inhibits platelet function) after a colon cancer diagnosis is asso-
ciated with improved overall survival. Identifying predictive biomarkers of this effect 
could individualize therapy and decrease toxicity. Platelets are thought to protect cir-
culating tumor cells from natural killer cells which preferentially eliminate targets with 
low or absent human leukocyte antigen (HLA) class I expression. We hypothesized that 
the survival benefit associated with low dose aspirin use after a diagnosis of colorectal 
cancer might depend upon HLA class I expression.
Methods
A cohort study with tumor blocks from 999 colon cancer patients ( surgically resected 
between 2002 and 2008), analyzed for HLA class I and PTGS2 expression using a Tissue 
Micro Array (TMA). PIK3CA mutation analysis was also performed. Aspirin use post-
diagnosis was obtained from a prescription database. Parametric survival models with 
exponential (Poisson) distribution were used to model overall survival.
Results
The overall survival benefit associated with aspirin use after a diagnosis of colon cancer 
had an adjusted Rate Ratio (RR) of 0.53 (95% CI 0.38-0.74, p<0.001) when tumors ex-
pressed HLA class I compared to a RR of 1.03 (95% CI 0.66-1.61 p=0.9) when HLA expres-
sion was lost. The benefit of aspirin was similar for tumors with strong PTGS2 expression 
(RR 0.68 95% CI 0.48-0.97, p=0.03), weak expression (RR 0.59 95% CI 0.38-0.97, p=0.02), 
and wild-type PIK3CA tumors (RR 0.55, 95% CI 0.40-0.75, p<0.001). With mutated PIK3CA 
tumors a non-significant trend was observed (RR 0.73 (95% CI 0.33-1.63, p=0.4).
Conclusions
Aspirin use after colon cancer diagnosis was associated with improved survival if tumors 
expressed HLA class I contrary to the original hypothesis. Increased PTGS2 expression or 
the presence of mutated PIK3CA did not predict benefit from aspirin. HLA class I might 
serve as a predictive biomarker for adjuvant aspirin therapy in colon cancer.
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INTRODUCTION
There is a significant body of preclinical, epidemiological and randomized data demon-
strating that aspirin has anti-cancer effects 1-7. Several studies have shown that aspirin 
use after a diagnosis of colorectal cancer improves colorectal cancer specific and overall 
survival 2;4;8-10. Randomized trials designed to assess the cardiovascular benefits of aspi-
rin demonstrate that allocation to aspirin reduces the risk of distant metastasis when 
cancer is diagnosed (hazard ratio (HR) 0.69 (95% CI 0.5–0.95) p=0.02) and on subsequent 
follow-up in patients without metastasis at diagnosis (HR 0.45 (95% CI 0.28–0.72) 
p=0.0009), with the largest effects seen for colorectal cancer (HR at diagnosis 0.36 (95% 
CI 0.18–0.74) p=0.005 and at follow-up HR 0.26 (95% CI 0.11–0.57) p=0.0008) 7. Although 
questions remain about the optimal dose and duration of aspirin use, its efficacy in pre-
diagnostic users and the localization of tumors most likely to benefit, the data suggest 
that aspirin is a potential adjuvant therapy to prevent distant metastasis in colorectal 
cancer, and possibly other tumors.
The precise biological mechanisms underlying the anti-cancer effects are unknown. 
PTGS2 (prostaglandin-endoperoxide synthase 2, also known as cyclo-oxygenase -2) 
overexpression has been associated with a poor prognosis in colorectal cancer 11;12. 
Aspirin inhibits PTGS, at low doses (75-300 mg once daily), given the short half-life of 
around 30 minutes, this effect is manifest as a permanent inhibition of PTGS1 in the 
anucleate platelet, which is unable to resynthesize the enzyme. Higher and more fre-
quent dosing for example 600 mg qds would be required to constantly inhibit PTGS2 
in systemic tissues 13-16. Despite this, data from two observational cohorts (the Nurses’ 
Health Study (NHS) and Health Professionals Follow-Up Study (HPFS)), have indicated 
that the survival benefits of regular low-dose aspirin use after a diagnosis of colorectal 
cancer are associated with the molecular characteristics of the tumor particularly muta-
tions in the gene PIK3CA (a component of the PTGS2 pathway) with a multivariable HR 
for aspirin users compared to non-users in tumors with mutated PIK3CA of 0.18 (95% 
CI 0.06–0.61; P <0.001) for cancer death and 0.54 (95% CI 0.31–0.94; p = 0.01) for death 
from any cause 17.
The metastatic potential of cancer cells that are shed into the bloodstream can be 
modified by environmental conditions, including platelets and bone marrow-derived 
cells in the vasculature 18. Platelets are thought to protect disseminating tumor cells 
from natural killer (NK) cells which preferentially recognize and eliminate cells with low 
or absent expression of HLA class I 19. We hypothesized that the survival benefit associ-
ated with low dose aspirin use after a cancer diagnosis would be associated with tumors 
that have low or absent HLA class I expression. We analyzed tumors from a cohort where 
we had previously shown an association between overall survival (OS) and low-dose 
aspirin use after diagnosis (adjusted HR 0.65 (95% CI 0.50-0.84; p=0.001) with an even 
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larger effect in older colon cancer patients ((>70 years) adjusted HR 0.59 (95% CI = 0.44-
0.81, p = 0.001))8;10 for HLA class I and PTGS2 expression, and PIK3CA mutations.
METHODS
Study cohort
The Eindhoven Cancer Registry was initially used to identify patients diagnosed with 
colorectal cancer and linked to data on aspirin use from the PHARMO database network 
(PHARMO, Netherlands). As previously reported, compared with non-users, aspirin initi-
ated or continued after diagnosis was associated with improved survival for colon cancer 
patients but not rectal cancer patients 8. Paraffin-embedded tissue blocks were retrieved 
from 1026 colon cancer patients who had a surgical resection between 2002 and 2008. 
For this study, 27 patients with more than one colon tumor at the time of diagnosis 
were excluded thus n=999. There were no significant demographic differences between 
the patients included in this study and the whole colon cancer cohort in the registry 
(n= 3586) (Supplementary Table I).
TMA production and immuno-histochemistry
Three 1.0 mm diameter cores were obtained from formalin-fixed paraffin-embedded 
(FFPE) tumor blocks using haematoxylin and eosin stained sections for tumor identi-
fication (with a qualified pathologist confirming the identification of the tumor) and 
transferred into a receiver paraffin block using the TMA Master (3D Histech, Budapest, 
Hungary). Immuno-histochemical staining was performed on 4 µm sections, cut from 
each receiver block and mounted on glass. For each primary antibody, all slides were 
stained simultaneously to avoid inter-assay variation.
Immuno-histochemical analyses to detect HLA class I expression with mouse mono-
clonal antibodies HCA2 and HC10 using diaminobenzidine solution (DAB+) (DAKO, 
Glostrup, Denmark) for visualization of the antibodies, were performed by two inde-
pendent observers, M.R and R.V, as previously described 20, with good inter-observer 
agreement (kappa value of 0.5-0.7). The mouse monoclonal antibodies HCA2 and HC10 
used recognize the heavy chains of HLA Class I. Their reactivity spectrum has been de-
scribed in detail before 18. HLA class I expression status was determined according to the 
International HLA and Immunogenetics Workshop 21, with tumor cell HLA class I status 
defined as follows: loss <5% expressing both HCA2 or HC10 or <5% expressing either of 
the markers and expression as > 5% expressing either marker. Normal epithelial, stromal 
or lymphoid cells served as positive internal controls. PTGS2 expression was analyzed 
automatically with a double staining to separately visualize stromal cells (using DAB+ for 
visualization of anti-collagen I, anti-collagen VI and elastin (all polyclonal rabbit antibod-
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ies obtained from AbCam)) and positive tumor cells (with the monoclonal mouse anti-
body anti-PTGS2 (Cayman Chemical Co., Ann Arbor, MI, USA)),  using Vector Blue ((Vector 
Laboratories, Burlingame, USA) for visualization of the PTGS2 antibody. Slides were 
scanned with the Panoramic Midi scanner (3D-Histech, Hungary) and PTGS2 expression 
was assessed using the criteria proposed by Buskens et al. 22 using AxioVision 4.6 (Zeiss, 
Jena, Germany), and comparable to the scoring method used by Chan et al. 2.
Microsatellite stability status was determined by immuno-histochemical analyses 
as previously described 23.  In short, four antibodies directed against MutL homolog21 
(MLH1, clone ES05, DAKO Cytomation, Glostrup, Denmark), MutS homolog 2 (MSH2, 
clone g219-1129, BD Biosciences, Franklin Lakes, USA), MutS homolog 6 (MSH6, clone 
EPR3945, Epitomics, Burlingame, USA) and postmeiotic segregation of Saccharomyces 
cerevisia 2 (PMS2, clone A16-4, BD Biosciences, Franklin Lakes, USA ) were used. The 
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Figure 1: Representative images of HCA2, HC10 and PTGS2 staining in colon cancer.
Representative images of immunohistochemical stainings for HLA Class I expression (HCA2 and HC10) and 
PTGS2 performed according to standard protocols (details in Material and Methods).(A) HC10-negative tumor 
(B) HC10-positive tumor (C) HCA2- negative tumor (D) HCA2- positive tumor (E) Tumor with weak PTGS2 expres-
sion (F) Tumor with strong PTGS2 expression, with a magnification in (G).
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criteria used to confirm microsatellite instability (MSI) in the tissues are described else-
where 23;24.
All slides were stained simultaneously to avoid interassay variation. Slides that did 
undergo the whole immunohistochemical staining procedure but without primary 
antibodies served as negative controls. The quality of the staining, the scoring method 
and discrepancies between the two observers were checked by a pathologist (H.M).
Representative images of the immuno-histochemical stainings are shown in Figure 1.
PIK3CA mutation analysis
DNA was extracted from 1 to 2, 2.0 mm diameter and variable length cores taken from 663 
of the 999 blocks randomly chosen, with a ratio 1:2 for aspirin user: non-user, using a 
fully automated system (Tissue Preparation System with VERSANT Tissue Preparation Re-
agents, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) as described previously 25.
Hydrolysis probes assays were performed for the major known mutations (hotspots) 
in exon 9, c.1624G>A; p.E542K, c.1633G>A; p.E545K and in exon 20 the c.3140A>G; 
p.H1047R as described before 26. Hydolysis probe assays were analyzed using qPCR 
analysis software (CFX manager version 3/0, Bio-Rad). To identify additional non-
hotspot mutations, Sanger sequencing was performed on exon 9 and exon 20 of all 
samples. Mutation detection was performed by two observers independently (M.R and 
R.E) using DNA variant analysis software (Mutation Surveyor version 4.0.9, Softgenet-
ics, State College, PA, USA). All primers and probes used for the assays can be found in 
Supplementary Table II.
Statistics
The vital status of patients (alive/dead) was established from medical records or through 
linkage of cancer registry data with the municipal population registries. Follow-up 
started 30 days from diagnosis of colorectal cancer (T0), as information on hospital pre-
scriptions was not available, and was continued until last contact date (January 2012) 
or date of death. Patients who died within 30 days were excluded from the survival 
analyses (2.4% for colon cancer). Non-users were classified as those who never had a 
prescription for aspirin or had a prescription for less than 14 days after diagnosis of 
colon cancer. Users were defined as those who had been given a prescription for aspirin 
for 14 days or more after a colon cancer diagnosis. The median duration of prescriptions 
was 30 days and the mean number of prescriptions was 12 (range 1- 220). Non-users 
were defined from T0 to first use and users from first use to the end of the follow-up in 
the time-dependent exposure survival analysis.
As the data was split in  two episodes  for users (multiple  ID  rows  for one patient), 
we were not able to model a Cox proportional hazard model and used a parametric 
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survival model with an exponential (Poisson) distribution after the data was declared 
as survival-time data (stset) and split at the time to first prescription.
Adjustments for potential confounders were made for sex, age (continuous), stage 
(pathological stage and clinical stage if pathological stage was unknown), adjuvant che-
motherapy (yes/no), co-morbidity (yes/no), tumor grade and year of diagnosis. Stratified 
analyses were performed for HLA class I expression, weak or strong PTGS2 expression 
and for wild-type PIK3CA / PIK3CA mutation.
RESULTS
Aspirin use, survival and tumor HLA class I expression
Of the 999,18.2% (182/999) were defined as aspirin users and there had been 465 deaths 
recorded until January 2012. There were 396 deaths in 817 nonusers (48.5%) and 69 
deaths in 182 aspirin users (37.9%) after diagnosis. In this cohort, aspirin use after diag-
nosis was associated with an improved OS (RR 0.64, 95% CI 0.49-0.83, p=0.001), when 
compared to nonusers.
36/999 tumors could not be analyzed for HLA class I expression due to staining arte-
facts or loss of material. Table I summarizes the clinical characteristics of the patients 
presented by HLA class I expression and according to aspirin use/non-use after diagno-
sis. Loss of HLA class I expression was found in 33.2% (320/963) and expression in 66.8% 
(643/963), in accord with results from previous studies 27;28.  Aspirin use was similar in 
both groups, loss of HLA 18% (57/320) and expression of HLA class I 19% (122/643), 
Table I: Baseline Characteristics of the Colon Cancer Patients according to Tumor HLA Class I Expression and 
Use of Aspirin after Diagnosis
All patients
(N=999)
HLA Loss
(N=320)
HLA Expression
(N=643)
No aspirin Aspirin p-value No aspirin Aspirin p-value
Sex
Male
Female
505 (50.6)
494 (49.4)
121 (46.0)
142 (54.0)
35 (61.4)
22 (38.6)
0.04 260 (49.9)
261 (50.1)
78 (63.9)
44 (36.1)
0.005
Age
<65
66-74
75 and 
older
342 (34.2)
304 (30.4)
353 (35.4)
110 (41.8)
66 (25.1)
87 (33.1)
8 (14.0)
26 (45.6)
23 (40.4)
<0.001 188 (36.1)
155 (29.7)
178 (34.2)
23 (18.8)
45 (36.9)
54 (44.3)
0.001
Year of diagnosis
2002-2004
2005-2007
451 (45.2)
548 (54.8)
102 (38.8)
161 (61.2)
27 (47.4)
30 (52.6)
0.2 232 (44.5)
289 (55.5)
65 (53.3)
57 (46.7)
0.08
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Table II: Rate Ratio for Death (Time-Dependent Analysis Overall Survival), According to Tumor HLA Class 
I Expression, PTGS2 Expression and PIK3CA Mutation Status and Use or Nonuse of Aspirin after Diagnosis
Patients Deaths Univariate
RR (95%CI)
p-value Adjusted
RR* (95%CI)
p-value p-value 
(interaction)**
HLA Class I 0.007
Loss
No aspirin use
Aspirin use
263
57
123
26
1.00 (reference)
1.08 (0.70-1.64)
0.7 1.00 (reference)
1.03 (0.66-1.61)
0.9
Expression
No aspirin use
Aspirin use
521
122
257
42
1.00 (reference)
0.61 (0.44-0.85)
0.003 1.00 (reference)
0.53 (0.38-0.74)
<0.001
PTGS2 0.12
Low
No aspirin use
Aspirin use
360
66
190
25
1.00 (reference)
0.66 (0.44-1.01)
0.05 1.00 (reference)
0.59 (0.38-0.91)
0.02
High
No aspirin use
Aspirin use
434
114
192
42
1.00 (reference)
0.80 (0.57-1.12)
0.2 1.00 (reference)
0.68 (0.48-0.97)
0.03
PIK3CA 0.004
Wild-type
No aspirin use
Aspirin use
384
147
200
55
1.00 (reference)
0.66 (0.49-0.89)
0.007 1.00 (reference)
0.55 (0.40-0.75)
<0.001
Mutation
No aspirin use
Aspirin use
73
27
34
9
1.00 (reference)
0.70 (0.34-1.46)
0.3 1.00 (reference)
0.73 (0.33-1.63)
0.4
Aspirin use = use of aspirin after diagnosis.  *Adjusted for sex, age, comorbidity, year of incidence, histological 
grade, stage and chemotherapy. ** Interaction between the markers and aspirin use status (user/nonuser).
Table I: Baseline Characteristics of the Colon Cancer Patients according to Tumor HLA Class I Expression 
and Use of Aspirin after Diagnosis (Continued)
All patients
(N=999)
HLA Loss
(N=320)
HLA Expression
(N=643)
No aspirin Aspirin p-value No aspirin Aspirin p-value
Disease stage
I
II
III
IV
Unknown
138 (13.8)
402 (40.2)
287 (28.7)
169 (16.9)
3 (0.3)
24 (9.1)
108 (41.1)
77 (29.3)
54 (20.5)
5 (8.8)
30 (52.6)
17 (29.8)
5 (8.8)
0.2 71 (13.6)
210 (40.3)
142 (27.3)
95 (18.2)
3 (0.6)
33 (27.0)
39 (32.0)
40 (32.8)
10 (8.2)
<0.001
Comorbidity
No
Yes
443 (44.3)
556 (55.7)
138 (52.5)
125 (47.5)
14 (24.6)
43 (75.4)
<0.001 253 (48.6)
268 (51.4)
25 (20.5)
97 (79.5)
<0.001
Microsatellite status
MSI
MSS
Unknown
90 (9.0)
870 (87.1)
39 (3.9)
28 (10.7)
227 (86.3)
8 (3.0)
11 (19.3)
45 (78.9)
1 (1.8)
0.2 38 (7.3)
472 (90.6)
11 (2.1)
8 (6.6)
112 (91.8)
2 (1.6)
0.9
Overall aspirin use: 182 patients (18.2%).
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though aspirin users were older and more likely to have co-morbidity. In the HLA class I 
expression group, there were more lower stage tumors in the aspirin users compared to 
non-users (p<0.001).
The effect of HLA class I expression status on the survival benefit associated with post-
diagnosis aspirin use was examined (Table II and Figure 2). For patients whose tumors 
expressed HLA class I, aspirin use after diagnosis was associated with a significantly 
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Figure 2: Overall Survival Curves Aspirin Use versus No Aspirin Use Stratified by HLA Class I.
Survival curves for overall survival in colon cancer patients, according to aspirin use after diagnosis or 
nonuse of aspirin after diagnosis and HLA Class I expression. Above: Overall survival among colon cancer 
patients with loss of HLA class I in their tumor sections. Below: Survival among colon cancer patients with 
expression of HLA Class I in their tumor sections.
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longer OS, RR 0.61 (95% CI 0.44-0.85, p=0.003), and when adjusted for potential con-
founders, this effect remained with an adjusted RR of 0.53 (95% CI 0.38-0.74, p<0.001). In 
contrast, for patients whose tumors had loss of HLA class I expression, aspirin use after 
diagnosis was not associated with a survival benefit (Adjusted RR 1.03 (95% CI 0.66-1.61, 
p=0.9).
Aspirin use, survival and tumor PTGS2 expression and PIK3CA mutations
25/999 samples could not be analyzed for PTGS2 expression due to staining artefacts 
or loss of material. Weak expression of PTGS2 was seen in 43.7% (426/974) of samples, 
and strong PTGS2 expression in 56.3% (548/974) in accord with the literature 2;29. Use of 
aspirin after diagnosis was significantly associated with a survival benefit, both when 
tumors showed weak PTGS2 expression (Adjusted RR 0.59, 95% CI 0.38-0.91, p=0.02) 
and with strong PTGS2 expression (Adjusted RR 0.68, 95% CI 0.48-0.97, p=0.03) (Table II).
DNA was extracted from 663 tumor blocks and PIK3CA mutation status (wild-type/mu-
tation) was established in 95% (631/663) of the samples. Baseline characteristics among 
participants with colon cancer whom we analyzed for PIK3CA were largely similar as the 
baseline characteristics of the PTGS2/HLA class I cohort (mean age at inclusion, 70.38 
vs. 69.01 years; male, 54% vs. 51%; stage I, 15% vs. 14%; stage II, 40% vs. 40%; stage 
III, 29% vs. 29%; stage IV 15% vs. 17%; presence of comorbidity, 60% vs. 56%; adjuvant 
chemotherapy, 28% vs. 31%; histological grade I, 11% vs. 11%; grade II, 70% vs. 68%; 
grade III 19% vs. 21%; p>0.091 for all comparisons). A PIK3CA mutation was found 
in 15.8% (100/663), also in accord with what has been found previously 30. Aspirin use 
was 27% (27/100) among patients with a mutated PIK3CA tumor and 28% (147/531) in 
patients with a PIK3CA wild-type tumor. Aspirin use after a colon cancer diagnosis was 
significantly associated with a better OS among patients with a wild-type PIK3CA tumor 
(Adjusted RR 0.55, 95% CI 0.40-0.75, p<0.001). In patients with a PIK3CA mutation, post-
diagnosis aspirin use showed the same trend (though non-significant) with an adjusted 
RR of 0.73 (95% CI 0.33-1.63, p=0.4). The small number of deaths (9) among patients with 
mutated PIK3CA tumors precludes robust statistical assessment (Table II).
DISCUSSION
We found that the survival benefit associated with low-dose aspirin use after a diagnosis 
of colon cancer was significantly associated with HLA class I positive tumors. In contrast, 
in patients whose tumors had lost their HLA expression, aspirin use did not change 
outcome. PTGS2 expression and PIK3CA mutation analysis could not identify patients 
with a high likelihood of benefit from aspirin in contrast to previous studies 2;17;31.
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Currently, the molecular mechanism(s) underlying the anti-cancer effects of aspirin 
are incompletely understood. Given that the majority of our cohort (> 80%) were diag-
nosed as stage III or less at the time of diagnosis the predominant effect of aspirin on 
cancer outcomes is likely to result from an effect on circulating tumor cells and their 
ability to develop into metastatic deposits. Natural killer (NK) cells play an important 
role in tumor immune-surveillance, preferentially eliminating targets with low or absent 
expression of HLA class I 19. Adhesion of HLA expressing platelets to tumor cells with 
absent or low HLA class I expression is thought to result in a “pseudonormal phenotype” 
and reduced NK mediated lysis 19. We originally hypothesized that aspirin might inhibit 
platelet adhesion to tumor cells leaving those with absent or low HLA Class I expression 
susceptible to immune clearance, however we unexpectedly found that the effect of 
aspirin is dependent on intact HLA class I expression within the original primary tumor, 
and assuming that circulating tumor cells retain the same HLA phenotype as the original 
tumor does not support the hypothesis that the attenuation of metastases by aspirin 
and possibly other anticoagulants is a result of enhanced NK activity 19.
A possible explanation for this intriguing observation is that HLA expression might 
be necessary for platelet mediated NF-ĸB signaling in circulating tumor cells resulting 
in an epithelial-mesenchymal-like phenotype with enhanced metastatic potential 18. In 
this model direct contact of platelets and tumor cells results in secretion of TGF-β and 
activation of the NF-ĸB pathway, which, in synergistic action, prime circulating tumor 
cells for subsequent metastases. In a breast cancer model acquisition of an epithelial-
mesenchymal phenotype markedly reduced susceptibility of cancer cells to T-cell medi-
ated immune surveillance in-vitro 32. Our data would be compatible with the hypothesis 
that aspirin inhibits platelet-tumor cell signaling (which is dependent upon intact HLA 
expression) and prevents epithelial-mesenchymal transition in circulating tumor cells, 
thereby reducing the metastatic potential.
Our data has not confirmed previous reports that the benefits of aspirin after a colorec-
tal cancer diagnosis are associated with strong PTGS2 expression in the original tumor 
and the presence of mutations in PIK3CA, with no benefit for patients whose tumors 
had wild-type PIK3CA 2;17. Liao et al. postulated that by blocking the PIK3CA pathway 
PTGS2 activity decreases, which leads to apoptosis of colon cancer cells and which was 
in accord with their previous work demonstrating a clinical benefit of aspirin in patients 
with PTGS2 positive tumors 2. In a separate study, benefits of aspirin in PIK3CA mutated 
tumors were seen but the correlation with strong expression of PTGS2 expression was 
not confirmed 31.
Pharmacological data on aspirin indicate that systemic concentrations of aspirin, 
reached with low-doses, (75-325 mg once daily) are inadequate to permanently acety-
late PTGS2, but are optimal for platelet inhibition 13. It is possible that there may be more 
than one mechanism of action that accounts for the anti-cancer effects of aspirin. A 
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direct anti-platelet effect due to PTGS1 inhibition that is responsible for the reduction 
in metastases and only requires a dose of aspirin that inhibits platelets, and a second 
mechanism, possibly mediated through platelets again, or perhaps activated with 
higher or more frequent dosing that inhibits the PTGS2 pathway in systemic tissues and 
may partly explain the differences between the results of our study and that of Liao et 
al. In breast cancer it has also been reported that PTGS2 expression could not identify 
a subgroup of patients where aspirin decreased recurrence 33. Furthermore, in breast 
cancer low dose aspirin did not influence local recurrence, but was significantly associ-
ated with a decrease in metastatic disease 34.
Aspirin use has also been associated with a decreased risk of developing a colorectal 
tumor with an intact BRAF gene but no association between post-diagnosis aspirin use, 
BRAF mutation status and clinical outcome has been found 35. BRAF is a member of RAF-
MAPK signaling pathway and involved in the up-regulation of PTGS2 again suggesting 
aspirin may have differential effects on carcinogenesis and prevention of metastatic 
spread 35.
Strengths of our study include a more precise definition of regular aspirin use and 
dose as this information was derived from prescriptions (rather than patient recall), 
noting also that low-dose aspirin is not available as an over-the-counter medication 
in the Netherlands, thereby minimizing non-differential misclassification of exposure. 
Higher dose over-the-counter aspirin use is unknown, which could have biased our re-
sults towards the null hypothesis. However, it has been shown that, pharmacy data can 
give valid associations even though a high proportion (25%) of the drugs are available 
over-the-counter 36.  Other limitations of our study include the inherent issue that this 
is non-randomized data, compliance is unknown, and some subgroups contained small 
numbers of events, although our series is the largest study thus far that has reported on 
aspirin use in colon cancer patients.
The molecular profiling of tumors for example KRAS testing in colorectal cancer and 
HER-2 testing in breast cancer has become standard clinical practice and the basis of 
therapeutic decisions. If the association of HLA expression and benefit from aspirin is 
confirmed in other datasets it could be used in clinical practice, where, our data may have 
important clinical implications for both the dose and timing of aspirin as an anti-cancer 
agent. First, low dose daily aspirin may suffice as an anti-metastatic therapy in early 
stage cancer patients. Second, as circulating tumor cells are found in the peri-operative 
period, it could be argued that aspirin should be commenced as soon as considered 
clinically appropriate after diagnosis.
In conclusion, we report the novel finding that the survival benefit associated with 
low-dose aspirin use after diagnosis of colon cancer is dependent on intact HLA class I 
expression in the original tumor. Randomized trials of the use of aspirin in the adjuvant 
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setting may provide key information about platelet-tumor interactions and the signal-
ing pathways they elicit.
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SUPPLEMENTARY MATERIAL
Supplementary Table I: Baseline characteristics of the patients included in the population-based registry 
and the patients included in this study
Population-based 
registry (n=3586)
Patients
(n=999)
p-value
Sex
Male
Female
1849 (51.6)
1737 (48.4)
505 (50.6)
494 (49.4)
0.57
Age
1
2
3
1180 (32.9)
1107 (30.9)
1299 (36.2)
342 (34.2)
304 (30.4)
353 (35.4)
0.73
Comorbidity
No
Yes
1627 (45.4)
1959 (54.6)
443 (44.3)
556 (55.7)
0.56
Stage
I / II
III / IV
Missing
1878 (52.4)
1541 (43.0)
167 (4.6)
540 (54.1)
456 (45.6)
3 (0.3)
0.69
Grade
1
2
3
Missing
452 (12.6)
2053 (57.3)
635 (17.7)
446 (12.4)
100 (10.0)
629 (62.9)
193 (19.3)
77 (7.7)
0.12
Localization
Proximal
Distal
Sigmoid
Other
1482 (41.3)
588 (16.4)
1433 (40.0)
83 (2.3)
422 (42.2)
169 (16.9)
395 (39.5)
13 (1.3)
0.25
Supplementary  Table II: primer overview of the primers used for the PIK3CA mutation analysis
Assay Name Primer Name Primer sequence Reporter 1 name Dye Reporter 1 Sequence Reporter 2  name Dye Reporter 2 Sequence
p.E542K* PIK3CA_p.E542K _F AGCTCAAAGCAATTTCTACACGAGAT PIK3CA_p.E542K _V VIC CCTCTCTCTGAAATCA PIK3CA_p.E542K _M FAM CCTCTCTCTAAAATCA
PIK3CA_p.E542K _R GCACTTACCTGTGACTCCATAGAAA
p.E545K* PIK3CA_p.E545K_F TCAAAGCAATTTCTACACGAGATCCT PIK3CA_p.E545K_V VIC CTCTCTGAAATCACTGAGCAG PIK3CA_p.E545K_M FAM CTCTGAAATCACTAAGCAG
PIK3CA_p.E545K_R GCACTTACCTGTGACTCCATAGAAA
p.H1047R* PIK3CA_p.H1047R_F GCAAGAGGCTTTGGAGTATTTCATG PIK3CA_p.H1047R_V VIC CCACCATGATGTGCATC PIK3CA_p.H1047R_M FAM CACCATGACGTGCATC
PIK3CA_p.H1047R_R GCTGTTTAATTGTGTGGAAGATCCAA
Exon 9** PIK3CA_x9_M13F TGTAAAACGACGGCCAGTGGGAAAATGACAAAGAACAGC
PIK3CA_x9_M13R CAGGAAACAGCTATGACCTCCATTTTAGCACTTACCTGTGAC
Exon 20** PIK3CA_x20_M13F TGTAAAACGACGGCCAGTCTGAGCAAGAGGCTTTGGAG
PIK3CA_x20_M13R CAGGAAACAGCTATGACCCCTATGCAATCGGTCTTTGC
*** PR_M13F TGTAAAACGACGGCCAGT
*** PR_M13R CAGGAAACAGCTATGACC
* Hydrolysis probes assays,  ** Genomic PCR,  *** Sanger sequencing, F=Forward primer, R=Reverse primer.
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Exon 20** PIK3CA_x20_M13F TGTAAAACGACGGCCAGTCTGAGCAAGAGGCTTTGGAG
PIK3CA_x20_M13R CAGGAAACAGCTATGACCCCTATGCAATCGGTCTTTGC
*** PR_M13F TGTAAAACGACGGCCAGT
*** PR_M13R CAGGAAACAGCTATGACC
* Hydrolysis probes assays,  ** Genomic PCR,  *** Sanger sequencing, F=Forward primer, R=Reverse primer.
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ABSTRACT
Colorectal cancer (CRC) is the most commonly diagnosed cancer in Europe. Because CRC 
is also a major cause of cancer-related deaths worldwide, a lot of research has been 
dedicated to the discovery and development of biomarkers to improve the diagnostic 
process and to predict treatment outcomes.  Up till now only a few biomarkers are rec-
ommend by expert panels. The currently used TNM criteria, however, cause substantial 
under- and overtreatment of CRC patients. Consequently, there is a growing need for 
new and efficient biomarkers to ensure optimal treatment allocation. The ideal bio-
marker is one that can easily be introduced in clinical practice, able to identify patients 
who can be spared from treatment or capable of identifying patients who will benefit 
from therapy, ultimately resulting in precision medicine in the future. With this review 
we aimed to provide an overview of a number of frequently studied biomarkers in CRC 
and at the same time we will emphasize the difficulties and controversies that with-
hold the clinical introduction of these biomarkers. We will discuss both prognostic and 
predictive markers of chemotherapy, aspirin therapy as well as overall therapy toxicity. 
Currently, only mutant KRAS, mutant BRAF, MSI and the Oncotype DX Colon Cancer As-
say are used in clinical practice. Other biomarker studies showed insufficient evidence 
to introduce these biomarkers in clinical practice. Divergent patient selection criteria, 
absence of validation studies, and a large number of single biomarker studies are pos-
sibly responsible. We therefore advice future studies to focus on combining key markers 
rather than analyzing only one marker, standardizing study protocols and to validate the 
results in independent study cohorts followed by prospective clinical trials.
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INTRODUCTION
Colorectal cancer (CRC) is the most frequently diagnosed type of cancer in Europe and 
is one of the major contributors to cancer-related deaths worldwide 1;2. In 2008, 436.000 
new cases of CRC were diagnosed in Europe and was therefore the most frequently 
diagnosed cancer with 13.6% of all diagnosed cancers 1. Worldwide, the percentage 
of total cancer burden contributable to CRC was 9.7% with 1.23 million cases, after 
lung (1.61 million) and breast cancer (1.38 million) 3. In Europe, CRC was responsible 
for 212.000 (12.2%) deaths in 2008, representing the second most common cause of 
death by cancer after lung cancer (19.9%) 4;5. Approximately 20-25% of patients with 
CRC already have metastatic disease at the time of diagnosis and 20-25% of patients 
will develop metastases during disease progression as well, resulting in a 40-45% high 
mortality rate 4;5.
Studies aiming at optimizing the diagnostic process and treatment of this disease are 
increasing, which probably caused CRC to be one of the most studied and best charac-
terized processes of tumorigenesis. Through more biological knowledge of tumorigen-
esis in CRC, more emphasis on early detection and development of new and improved 
treatment regimens, mortality decreased with almost 5 percent over the last decade 2;6;7. 
Unfortunately, overall mortality and morbidity rates in CRC still remain high 2.
Survival of CRC patients largely depends on the disease stage at diagnosis and varies 
widely between stages. Five-year survival for stage I is 93.6%, which drops drastically 
to 8.1% for stage IV patients 8. Treatment of CRC comprises (radical) tumor resection 
and, depending on tumor stage, radio-or chemotherapy 9. Treatment choices nowadays 
are influenced by the tumor, node and metastasis (TNM) classification of the Union for 
International Cancer Control (UICC) 10. The TNM classification aims to provide an exact 
prediction system for prognosis, to guide therapy choices and to form an understand-
able and uniform ‘cancer language’ 11;12. Over the past decades, this TNM staging has 
changed continuously. In 2009, the seventh edition of the TNM stage was published, 
replacing the sixth edition from 2002 13. Regrettably, the seventh TNM edition did not 
provide greater accuracy in predicting colorectal cancer patients’ prognosis, but resulted 
in a more complex classification for daily clinical use 14.
Unfortunately, besides making tumor classification more complex over the past years, 
the TNM staging system was not able to provide the clinician with the optimal staging 
tool it was designed for. Furthermore, possible under-treatment or over-treatment of 
some patients groups might arise when using the TNM staging system for treatment 
allocation 10;15-17. Studies have shown that approximately 20% to 25% of patients with 
lymph node-negative stage II colon cancer will suffer from recurrent disease within 5 
years of follow-up 18;19. These patients, also identified as high risk-stage II patients, might 
have benefited from adjuvant therapy, which they did not receive as this was not recom-
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mended based on their defined TNM stage. Therefore, the use of TNM stage falls short 
in daily clinical practice, especially in identifying high-risk stage II patients, and needs to 
be supplemented with additional biomarkers that can improve the current staging and 
treatment allocation criteria substantially. The American Society of Clinical Oncology’s 
Tumor Markers Expert Panel (ASCO TEMP-2006), The European Group on Tumor Markers 
(EGTM-2007) and The European Society of Medical Oncology (ESMO) have all reviewed 
the clinical applicability of widely studied biomarkers 20-23. Interestingly, in spite of a 
tremendous amount of available literature on biomarkers in CRC, only a few biomarkers 
are used in daily clinical practice nowadays, like KRAS, BRAF, MSI and the Oncotype DX 
Colon Cancer Assay (Table I). A possible explanation could be that most prognostic or 
predictive biomarkers are not validated in other (large) cohorts, or because there is lack 
of consensus in performing these studies, such as different antibodies used or different 
scoring methods, which makes their results incomparable 20. Furthermore, the handling 
of tissues has been well recognized in contributing to assay variability and issues in assay 
validation 24. Previously, a five step program for the introduction of biomarkers in clinical 
practice was developed with the first step being biomarker development in a preclinical, 
exploratory setting, subsequently followed by verification of this biomarker in a large 
retrospective study, validation and finally confirmation in a prospective randomized 
controlled trial 25.
In this review we aim to give an overview of the most studied biomarkers in CRC and 
we will emphasize on some difficulties and controversies studying these biomarkers. 
The main goal is to identify key biomarkers, which might have the potential to identify 
patients who can be spared from further treatment or for whom additional treatment 
is advised (prognostic biomarkers), and to identify which patients will benefit from 
therapy (predictive biomarkers), ultimately resulting in the use of precision medicine in 
the future.
Table I: Biomarkers used in clinical practice
Biomarkers Clinical use
KRAS Identification of resistance to anti-EGFR moAB in 
metastatic CRC patients
BRAF Identification of resistance to anti-EGFR moAB in 
metastatic CRC patients
Exclusion of Lynch Syndrome
MSI Identification of Lynch Syndrome
Oncotype DX Colon Cancer Assay Inform treatment planning in stage II and II colorectal 
cancer patients
Abbreviations: MSI= Microsatellite Instability
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PROGNOSTIC BIOMARKERS IN CRC
Microsatellite instability
Most cancers of the colon and rectum display a phenomenon termed genomic instabil-
ity. There are two forms of genomic instability that reflect different genetic pathways of 
tumorigenesis.  One form, called microsatellite instability (MSI), refers to a clonal change 
in the number of repeated DNA nucleotide units in microsatellites caused by deletions 
or insertions, and appears in tumors with deficient mismatch repair (MMR) 26. The mo-
lecular phenotype of MSI was first described in CRC by an independent research group 
showing MSI as the hallmark of Lynch Syndrome, although it was not solely restricted 
to hereditary CRC 27. The biochemical basis of this phenotype can be explained by 
strand-specific mismatch repair defects and was initially linked to germline mutations 
of the mismatch repair (MMR) gene hMSH2 followed by the identification of mutations 
in another MMR gene, hMLH1. Only a short period here after, mutations in PMS2 and 
hMSH6 were found in Lynch Syndrome, completing the biological background of this 
MSI phenotype 27;28.
Currently, there are a few clinical criteria for MSI testing in CRC to select potential Lynch 
Syndrome patients to be candidates for molecular MSI testing (Bethesda Guidelines): 1: 
three or more relatives with CRC across ≥ 2 generations with one first-degree relative 
and one with a cancer age below 50 years; 2: CRC in a patient younger than 50 years of 
age; 3: synchronous or metachronous CRC regardless of age; 4: CRC with high-density 
tumor-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-
ring differentiation or medullary growth pattern, patient age ≤ 60 years; 5: CRC in ≥ one 
first-degree relative with CRC, with one cancer diagnosed in a patient with age ≤ 50 
years; and 6: CRC in ≥ two first-/second-degree relatives with CRC at any age 29;30. If there 
is a clinical suspicion of Lynch Syndrome, MSI testing with molecular screening and/
or immunohistochemistry has been recommended by the ESMO Consensus Guidelines 
for management of patients with colon and rectal cancer and has been performed in 
clinical practice as well 23.
Contrary to Lynch Syndrome, a different mechanism causes the sporadic type of MSI to 
develop in CRC. This phenotype is associated with hMLH1 promotor hypermethylation, 
resulting in lack of hMLH1 expression and subsequently loss of mismatch repair system 
function 27. If loss of hMLH1 is observed by MSI testing, somatic hypermethylation of the 
hMLH1 promotor should be considered. This sporadic type of MSI could be investigated 
through testing for a BRAF V600E mutation that is strongly associated with a sporadic 
origin or by analysis of hMLH1 promotor hypermethylation 31.
It has been shown that MSI CRC is associated with a better prognosis than non-MSI 
CRC 32-36. Therefore MSI might be introduced as a standard pathological assessment for 
patients not included in these guidelines as well. Unfortunately, results from studies 
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have been equivocal concerning the proposed survival benefit 37-41 and resulted in not 
routinely clinical testing for sporadic MSI CRC up till now. There are several reasons that 
prevent the introduction of MSI testing into standard pathological assessment. First, 
the prognostic effect of MSI is better appreciated for disease-specific survival than for 
overall survival 42. This could be explained by the better prognosis of young patients 
(<50 years) with MSI CRC, as probably more young patients are likely to have Lynch 
Syndrome 33. Including older patients with sporadic CRC, who can die of other diseases, 
might result in loss of positive prognostic effect of MSI in overall survival. Inclusion or 
exclusion of various age groups will likely influence the prognostic significance of MSI 
analysis. Nonetheless, several studies reported a favorable outcome for patients with 
MSI 37-41. Second, the survival advantage of MSI might also be the result of less distant 
metastases at diagnosis, lower prevalence of advanced stage tumors, high prevalence 
of early stages at diagnosis and for the largest part by younger Lynch Syndrome cases 43. 
In conclusion, MSI is a marker for better clinical outcome, but appears to be more pro-
nounced for Lynch Syndrome 42.
The reluctance to introduce routine testing of MSI in clinical practice is also based on 
several other factors. First, clinicians may not be aware of the criteria and conditions re-
quiring genetic screening and mutational analysis. Second, availability of a standardized 
laboratory test might not be sufficient. MSI testing in molecular pathology laboratories 
is becoming increasingly available, but requires expertise and experience in testing 
and interpretation. Nowadays, immunohistochemistry (IHC) shows high sensitivity and 
specificity in detecting MSI and could therefore offer a relatively cheap, easy to perform, 
and universally available test for MSI instead of a more complex polymerase chain reac-
tion (PCR)-based MSI test 44. Lastly, there are also socioeconomic issues to resolve, like 
ethical, legal and health care-related issues, before introducing MSI testing in clinical 
practice. Clearly, MSI has been used successfully in clinical practice for Lynch Syndrome 
diagnosis and also shows great clinical potential for routine testing of non-Lynch Syn-
drome CRCs, but first more research has to be performed on MSI in sporadic as well as 
hereditary CRC to truly understand the better clinical outcome of MSI.
KRAS
The RAS-family of oncogenes consists of three principal members, KRAS, HRAS and 
NRAS, which are all involved in tumor development 45. KRAS is a proto-oncogene en-
coding a small 21 kD guanosine triphosphate/guanosine diphosphate binding protein 
modulating cellular proliferation and differentiation 46. Active KRAS mutations are found 
in 35-42% of CRCs and are thought to occur early in CRC carcinogenesis. Almost 97% of 
all observed genetic events within KRAS are caused by seven different DNA base pair 
substitutions within codon 12 and 13 of exon 2, resulting in an amino acid substitution 
in the protein 47. KRAS mutation was associated with a significantly higher risk of recur-
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rence in the QUASAR study compared with wild-type KRAS, but not in the PETACC-3 
study 23;47. Other studies performed were also conflicting, with some finding a prognos-
tic value of mutated KRAS alone, others finding this value concomitantly with mutated 
TP53 or PIK3CA and some reporting no prognostic value of mutated KRAS at all 47-51.
Differences in KRAS mutations at codon 12 and 13 may result in different biological 
and functional consequences that could influence the prognosis of CRC 52. Initially, KRAS 
was found to be a strong prognostic factor in CRC, but this finding was later restricted 
to a codon 12 mutation, leading to a glycine to valine substitution (G12V) 53;54. Therefore, 
larger studies are required to confirm whether a specific mutation is responsible for a 
clinically relevant prognostic effect.
An important reason for the discrepancies between the studies could be the study 
design of the individual studies. Data based on prospective analysis of a homogenous 
cohort treated and followed according to the highest clinical standards, as performed 
in a registration trial, are more robust and reliable than those arising from similar sized 
meta-analyses or retrospective studies. Therefore, well-performed clinical trials should 
be used to validate results on KRAS in order to resolve discrepancies.
In conclusion, the available data contradicts each other at this moment and does not 
support standard testing for KRAS mutations in clinical practice to identify patients with 
a worse prognosis, who might require more aggressive treatment. However, in a predic-
tive setting, mutated KRAS has shown differentiation resistance to anti-EGFR monoclonal 
antibodies (135-139) and since then has been used in clinic for this purpose.
BRAF
The BRAF gene encodes a serine/threonine protein kinase belonging to the RAS-RAF-
MEK-ERK kinase pathway regulated by KRAS protein activity and involved in CRC devel-
opment 55;56. Nearly all oncogenic transformations of BRAF are the V600E mutations 57. 
A lot of studies investigated and confirmed the potential adverse prognostic impact 
of BRAF mutations 47;58-60. Yokota et al. identified BRAF as an independent prognostic 
factor for survival in a retrospective cohort of 229 patients with advanced and recur-
rent CRC. Presence of this mutation was associated with a significantly higher risk of 
cancer–related death, independent of other confounding factors 60. These findings were 
consistent with those of other recent studies using patients with both stage II and III 
disease and with studies including all stages 47;58;59;61.
The PETACC-3 and QUASAR studies showed no increased risk of relapse in stage II 
and III CRC patients, but PETACC-3 did show a worse overall survival (OS), particularly in 
patients with MSI-L or MSS tumors 34;47. Two large retrospective studies are in accordance 
with these findings 57;59. Samowitz et al. reported that the BRAF V600E mutation in MSS 
colon cancer was associated with a significantly poorer survival in stage II to IV colon 
cancer, but did not have an effect on the excellent prognosis of MSI tumors 57. Some 
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patients in these trials were treated with cetuximab after relapse. Patients with mutated 
BRAF may not have benefitted from the survival advantage offered by this agent 62;63. 
Therefore, the prognostic relevance of mutated BRAF on OS may have been overesti-
mated. However, the outcome of patients with CRC having BRAF mutations is worse than 
that of patients with wild-type BRAF CRC, independent of treatment with cetuximab 64, 
which further strengthens BRAF as a marker for a worse chance of survival.
TP53
TP53 is a tumor suppressor gene on the short arm of chromosome 17 encoding a protein 
important in regulating cell division. P53 is normally expressed in case of DNA damage, 
resulting in growth arrest and apoptosis (programmed cell death) in rapidly dividing 
cells. In this way TP53 functions as a tumor suppressor gene by aborting growth of 
potentially malignant cells 65. Mutations of the TP53 gene are detected in up to 85% of 
CRCs, usually occurring during the adenoma to adenocarcinoma transition66.  Over the 
years TP53 has been intensively studied as the genome guardian marker 67;68. The im-
munohistochemical expression may have prognostic value in patients with CRC. Higher 
expression has been shown in tumors with lymph nodal involvement and 5-year survival 
is lower for patients with positive p53 staining 69. In normal cellular conditions, synthesis 
and degradation of p53 are tightly regulated and the expression level is kept very low. In 
such conditions, p53 expression is generally not detectable by immunohistochemistry. 
Mutations in TP53 lead to disruption of normal TP53 function and  accumulation of 
mutant p53 levels that are high enough to be detected by immunohistochemistry 70. 
Lack of p53 staining with immunohistochemistry has been associated with wild-type 
TP53, indicating a functionally active TP53. On the contrary, high expression of p53 
staining was associated with mutated TP53 71.  However, there is still debate on the use 
of mutational analysis or immunohistochemistry as a reliable marker for p53 dysfunc-
tion. Lack of consensus on antibodies and scoring might possibly be responsible for 
this 72;73. Studies have shown that immunohistochemistry does not always match with 
mutation studies and that expression of mutant forms of p53 are not simply correlated 
to loss of TP53 function 70. Cripps et al. reported that approximately 33% of the CRCs 
who do not show positive immunohistochemical staining of p53 do not have a detect-
able TP53 mutation 74. Also, a scattered positive immunohistochemical staining of p53 
might represent a functionally active non-mutated TP53 gene and must therefore be 
analyzed separately 73. Most studies in the past, however, only analyzed positive stain-
ing versus negative staining 69;75-77. Recently, Nyiraneza et al. investigated the value of 
immunohistochemistry of p53 in CRC 71. In this study immunohistochemistry revealed 3 
distinct staining patterns of p53 expression; complete negative staining associated with 
truncating TP53 mutations, diffuse overexpression associated with missense TP53 muta-
tions and restricted overexpression associated with wild-type TP53. Furthermore, muta-
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tion analysis by Lopez et al. showed that TP53 mutations were only present in 79.6% of 
positively stained p53 tumors 70. In 30.8% of the tumors with negative p53 staining TP53 
mutations were found as well, indicating no complete correlation between immunohis-
tochemistry and mutation analysis based on RNA expression.
In summary, TP53 could not be used as a prognostic marker so far. Lack of consensus 
on antibodies and scoring methods in immunohistochemical staining, lack of correla-
tion between immunohistochemical overexpression and clinical data, and discrepancies 
between immunohistochemistry and mutation analysis, are responsible for contradict-
ing results and are therefore important reasons for not justifying the use of TP53 in 
clinical practice.
Apoptosis-related biomarkers
One of the most important hallmarks of cancer is their ability to evade programmed 
cell death or apoptosis 78. During tumor development tumor cells can be triggered 
by lymphocytes of the patient’s immune system, by accumulation of DNA damage, or 
by stress factors like growth factor deprivation, to undergo apoptosis 79;80. The actual 
apoptotic cell death machinery, the part of the pathway responsible for the execution of 
apoptosis that results in the morphologic features characteristic for apoptosis, consists 
of a very complex cascade of interacting proteins. The key components are the caspases. 
Caspase-3 is activated at a point where the intrinsic and extrinsic apoptosis induction 
pathways converge. The level of activated caspase-3 should therefore give a reliable 
measure of ongoing apoptosis 81 and is widely used in studies for detection of apoptotic 
cells. Another marker often used and specific for apoptotic epithelial cells is M30, which 
recognizes a caspase-specific cleaved product of cytokeratin-18 82.
Several publications have described the relevance of apoptosis for the clinical out-
come in CRC patients with contradicting results 82-85. Differences between these studies 
might have been caused by a different patient selection, a different method used and 
a different study design of these publications. There are also reasons to believe that 
differences exist as a result of microsatellite status of the tumor, location of the tumor 
in the bowel or biological differences between rectal and colon cancer 82-84;86. Dolcetti 
et al. reported a high frequency of apoptosis in MSI tumors 86. Jonges et al. described 
a higher expression of cleaved caspase-3 expression in right-sided tumors 84. In some 
rectal cancer studies, low expression of apoptosis was related to more local recur-
rences 82;83. In CRC, however, results were different with high expression of apoptosis 
related to more local recurrence 84. Reasons for these discrepancies are unclear. As most 
rectal cancers are MSS, microsatellite status might possibly explain these differences. 
Location of the tumor might also have an important influence on apoptosis. Recently, 
the Cancer Genome Atlas Network attempted to find biological differences between 
colon and rectal cancer, but they only found differences in the anatomical tumor site 
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with more hypermethylation in right-sided tumors, which might be explained by the 
different embryonic origins of the right-and left-sided tumors 87. Additional research 
on apoptosis, keeping the microsatellite status and the location of the tumor in mind, 
needs to be performed.
Furthermore, it might not be sufficient to study apoptosis on its own. A key factor 
in tissue homeostasis is the balance between the level of cell death and the level of 
proliferation. Two important hallmarks of tumorigenesis can cause disturbance of this 
balance; deregulation of the proliferative signaling pathway and deregulation of the 
apoptotic pathway 88;89. Michael-Robinson et al. previously reported on a cohort of 100 
colorectal cancer patients in which they determined an AI:PI ratio 90. This Apoptotic 
Index: Proliferation Index was based on M30 IHC for the apoptosis level and Ki67 IHC for 
the proliferation index. They were able to relate their AI:PI index significantly to patient 
outcome. Preliminary data from our center also showed a better prognosis for patients 
with high levels of proliferation and apoptosis, especially in right-sided tumors (Reimers 
MS, Zeestraten ECM et al., in progress). Therefore, further studies also need to be per-
formed, which will focus on apoptosis as well as proliferation.
Ki67
Proliferation is one of the most important hallmarks tumor cells must acquire for tu-
morigenesis 78. The proliferation activity of a tumor can be estimated by determining 
the expression levels of specific cell cycle-related antigens by using IHC. A widely used 
marker is the ki67 antigen, which is expressed in the nuclei during all cell cycle phases 
except during the G0  phase 91. High expression levels of ki67 have been shown to cor-
relate with patient outcome in many types of cancers, such as breast cancer, malignant 
lymphomas and astrocytomas 92;93. However, in colorectal cancer, there are discrepan-
cies in the association of ki67 with prognosis and survival 94-96. Most studies in CRC 
reported an inverse relationship between ki67 expression and patient outcome; thus 
patients with high expression of ki67 in their tumor sections showed a better chance of 
survival 76;90;94;96. Still, discrepancies exist and the reasons for these remain unclear 94;96;97. 
If we consider the balance between the level of cell death and the level of proliferation 
again as previously mentioned above, contradicting results between the different stud-
ies could be the result of differences in apoptosis in the tumor tissues, which were not 
evaluated in these ki67 studies simultaneously. High proliferation might be associated 
with survival advantages because these cells also undergo apoptosis resulting in tissue 
homeostasis. Michael-Robinson et al. showed that there was a significant correlation 
between the apoptotic index and proliferation index, indicating some degree of coordi-
nated regulation 90. However, a high ki-67 index was associated with improved survival 
in MSI tumors only and therefore microsatellite status might influence ki67 expression 
as well. Since most MSI tumors are found on the right side of the tumor, location of the 
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tumor might also influence ki67 expression 98. Other studies on ki67 did not stratify for 
microsatellite status or location of the tumor 76;94;96. In conclusion, contradicting results 
regarding ki67 expression exist. Further research should focus on combined analysis of 
proliferation and apoptosis, as a balance between these two hallmarks of cancer might 
exist. Furthermore, analyses should be stratified for microsatellite status and location of 
the tumor in order to truly understand the prognostic value of ki67.
Immune-related markers
Historically, the immune system has been attributed with an important role in control-
ling tumor growth and metastasis 99-101. Evasion of immune surveillance and suppression 
of the immune system were therefore two important traits cancer cells had to acquire 
during the process of tumorigenesis 102.  Research from the last century has indicated 
that the effects the immune system has on tumor cells, both in the tumor microenviron-
ment as well as during the process of tumor metastasis, can also contribute to tumor 
progression 103.
The first marker of tumor-immunogenicity is the level of HLA class I expression on 
cancer cells. Tumor cells can escape cytotoxic T-cell (CTL) recognition through down-
regulation or complete loss of HLA class I resulting in minimization of tumor-associated 
antigen (TAA) expression and subsequently less destruction of tumor cells by CTLs 100;101. 
HLA class I expression has been shown to be of prognostic value in several types of 
solid cancer 104;105. However, the results in CRC specifically have been contradicting 106-109. 
Downregulation of HLA class I makes tumor cells more prone to Natural Killer (NK) cell 
destruction. Non-classical HLA-E and HLA-G also play an important role in immune 
surveillance by NK cells. Presence of HLA-E and HLA-G cause an inhibitory signal to NK 
cells, resulting in further immune escape 110-112. Furthermore, immune reactivity can be-
come suppressed by the attraction of immunosuppressive regulatory T cells (Tregs) into 
the tumor microenvironment 113;114.  The immunosuppressive effect of Tregs has been 
proven, with a high density of tumor-infiltrating Treg associated with an unfavorable 
prognosis in a wide range of human carcinomas, including breast and lung cancer 115;116. 
However, in colon cancer different results are reported as well, with more Foxp3+ cells 
correlated with a better patient survival 117;118.
Microsatellite instability has been shown to be characterized by a specific immune 
response 119. Accumulation of frameshift-derived-peptides (FSP) may contribute to 
immune recognition and dense lymphocyte infiltration observed in MSI tumors 119. 
However, these tumors grow out to large tumor masses as well, possibly due to loss 
or downregulation of HLA class I, also frequently observed in these tumors 120. Further-
more, MSI tumors showed a high infiltration of Tregs 119. T cell responses in patients with 
MSI CRCs are frequently directed against selected microsatellite instability-induced FSP, 
possibly creating more immune-mediated tumor rejection 119;120. Therefore, immune 
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escape mechanisms may play a role in tumors characterized by microsatellite instability, 
and thus both features should be considered when analyzing clinical prognosis in this 
tumor type.
Besides T cells, innate immune cells orchestrate an inflammatory environment that 
might inhibit or promote CRC development and progression as well, such as macro-
phages. Macrophages are a primary source of secreted pro-inflammatory cytokines, 
which are able to influence and stimulate growth and migration of tumor cells. For 
example, IL-6 released by macrophages directly promotes CRC cell progression. Fur-
thermore, the interaction between IL-6 and IL-10 also influences CRC progression and 
prognosis by manipulating their microenvironment for tumor growth facilitation121.
The interaction between tumor cells and immune cells is complex and multifaceted. 
As shown by our previous studies in breast cancer, immune markers are related to each 
other 104;122. In our opinion, studies based solely on one immune marker are not suffi-
cient. Therefore, more studies need to be performed which focus on combining immune 
markers. Also, contradicting results from previous studies need to be studied further, 
also taking into consideration microsatellite instability.
Genomic signatures
The recognition that molecular features of cancer, including gene expression profiles, 
are connected to clinical outcome has led to the development of molecular tests 
that provide important prognostic and predictive information to aid clinical decision 
making. Genomic Health Inc (Redwood City, CA) has developed four studies in stage II 
and stage III colon cancer, involving more than 1800 patients in total, where genomic 
profiling has identified genes that are predictive of recurrence in resected colon cancer 
patients who were treated with surgery alone or surgery + 5-FU/LV chemotherapy 123. 
The results from these studies enabled the design of the 12-gene colon cancer Recur-
rence Score, which was then validated in a large, independent, prospectively designed 
study in stage II colon cancer patients from the QUASAR clinical trial. In the QUASAR 
validation study, the Oncotype DX® Colon Cancer Assay (the colon cancer Recurrence 
Score) was validated as a predictor of risk of recurrence in stage II colon cancer patients 
following surgery 124. The Recurrence Score predicted recurrence risk independently of 
pathologic T stage, tumor grade, number of nodes examined, lymphovascular invasion, 
and microsatellite status, providing information not captured by the existing markers 
used in clinical practice. The Recurrence Score thus addressed individualized recurrence 
risk information needed for optimal treatment planning in stage II colon cancer. Since 
January 2010, the Oncotype DX Colon Cancer Assay has been offered by the Genomic 
Health clinical laboratory under Clinical Laboratory Improvement Amendments (CLIA) 
standards for clinical use and is now available to support treatment planning for stage II 
and stage III colon cancer patients 125.
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Furthermore, ColoPrint also showed promising results 126. In this study a prognos-
tic 18-gene signature was identified on the basis of unbiased gene selection, searching 
the whole genome for genes that had the highest correlation to a tumor relapse event. 
The signature was validated in an independent set of 206 patients with UICC stage I–III 
colon cancer from Barcelona, Spain, and in 135 clinical samples of patients with stage II 
colon cancer from Munich, Germany, using a diagnostic microarray platform.
Prior attempts have also been made to correlate gene expression profiles with recur-
rence in stage II and III colorectal cancer 127-130. However, these studies have generally 
used fresh frozen tissues, which are less applicable in clinical practice, and have studied 
small patient cohorts and therefore lacked statistical power for convincing proof.
Genomic signatures potentially have a high prognostic value and some are already in 
use in clinical practice, like Oncotype DX. Other genomic signatures need to be validated 
first before introducing them in clinical practice, preferably using tissues from random-
ized clinical trials.
PIK3CA
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been associated 
with the development of a number of human cancers, including CRC 131. The PIK3CA 
gene encodes the p110 alpha catalytic subunit of PI3K 132. Mutations in this gene have 
been identified in CRC, with most mutations localized in exon 9 and 20 133. Mutations 
have shown to activate the AKT-pathway, driving cell proliferation, and are present 
in 10-30% of all CRCs 134.
PIK3CA mutations were related to a worse chance of survival in CRC patients 135;136. 
However, only a mutation in exon 20 might be responsible for this worse chance of 
survival 137. Also, when stratified by KRAS status, a worse colon cancer-specific mortality 
associated with a PIK3CA mutation was only found in KRAS wild-type tumors 136.
18q Loss of Heterozygosity (LOH)
Allelic loss of 18q has been thought to occur late in the process of carcinogenesis and 
occurred in approximately 70% of CRCs. Deleted in Colon Cancer (DCC), SMAD4 and 
many other important candidate genes have been identified on 18q 134. Patients who 
harbored a 18q LOH showed a worse OS 138;139, but other studies showed contradicting 
results 140;141. Jen et al. showed that stage II and III patients with an intact 18q had a 
significantly better 5-years OS compared to patients with allelic loss of 18q, suggesting a 
prognostic role of 18q LOH 138. A meta-analysis also showed that patients with 18q allelic 
imbalance and DCC loss of expression were associated with a worse survival compared 
to patients with an intact 18q and expression of DCC 134.
Unfortunately, some studies did not account for MSI status, which seemed to influ-
ence the association of 18qLOH with survival 47;142. The prognostic effect of 18qLOH was 
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lost in multivariable analysis in these studies when accounted for MSI status. Therefore, 
the prognostic value of 18q LOH remains unclear. Validation is warranted to draw further 
conclusions.
CIMP
In the last few years, the existence of a new pathway for CRC pathogenesis has gained 
attention, which involves the transcriptional silencing of tumor suppressor genes by 
hypermethylation of CpG islands of the promoter region of various genes 143.  
These tumors are classified as having the CpG island methylator phenotype (CIMP) 144. 
One-third to one-half of all CRCs may evolve through this pathway 145. CIMP tumors with 
methylation-induced silencing of MLH1 constitute the majority of sporadic MSI CRCs 146. 
However, most CIMP-positive tumors are associated with microsatellite stability (MSS). 
These CIMP MSS tumors are comparable with MSI CRC on certain clinical and patho-
logical features, including a predilection for females, advanced age of disease onset, 
predilection for proximal colon, poor differentiation and mucinous histology 147. Jover 
et al. showed that CIMP did not influence disease free survival (DFS) and that patients 
with CIMP-positive tumors did not benefit from 5-FU-based adjuvant chemotherapy 147. 
On the contrary, CIMP positive CRCs showed a worse overall survival after surgery alone. 
However, the same study reported that CIMP positive CRCs showed a better response 
to the combination of surgery and 5-FU treatment, which could be caused by aberra-
tions in folate- or methyl group metabolisms in CIMP positive tumors 148. Taken together, 
these studies might support that CIMP could be used as a prognostic marker, but further 
research is necessary to confirm and validate these data.
Chromosomal instability (CIN)
In addition to microsatellite instability and CIMP, the chromosomal instability (CIN) 
pathway is also involved in colorectal cancer pathogenesis. Most CRCs arise through this 
pathway, which is characterized by widespread imbalances in chromosome number (an-
euploidy) and loss of heterozygosity 149. CIN is observed in 65-70% of sporadic colorectal 
cancers. Defects in chromosomal segregation, telomere stability and the DNA damage 
response have been described, but the complete mechanism of CIN remains unclear 149.
The CIN phenotype was associated with a less favorable outcome for patients com-
pared to tumors with MSI. Patients with CIN tumors showed a decreased overall and 
progression-free survival compared to patients with MSI tumors, irrespective of ethnic 
background, anatomic locations and adjuvant treatment with 5-FU 150. In large meta-
analyses the prognostic value of CIN has been established with a HR of 1.45 compared 
to CIN negative tumors 151.
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In the future, the mechanisms that initiate CIN and the relationship between CIN and 
tumor progression need to be better defined in order to implement CIN as a biomarker 
in clinical practice.
PREDICTIVE BIOMARKERS IN CRC
The predictive markers in this review are divided in therapy-related predictive markers; 
chemotherapy- and aspirin-related; and predictive markers for treatment toxicities in 
CRC patients.
Therapy-related predictive biomarkers
Microsatellite instability
In addition to the positive prognostic influence of MSI in CRC, a predictive role for 
microsatellite status has been demonstrated by using data from randomized clinical 
trials of 5-FU-based therapy versus surgery-only control 152;153. In these trials, treatment 
differed by MSI status and patients with MSI-high tumors who were treated with 5-FU-
based therapy had a trend towards a worse outcome compared with surgery-alone 
controls. In contrast, other studies reported similar outcomes for MSI-high patients with 
chemotherapy 154 or even showed a greater benefit from 5-FU-treatment 36;155;156. These 
contradictory results could be explained by the differences in study design, as these 
latest studies included patients who were not randomly assigned to 5-FU therapy versus 
control, thus allowing selection bias or other limitations inherent to nonrandomized 
studies. Also, Sinicrope et al. reported a positive reduction in disease progression rate in 
MSI CRC patients treated with 5-FU, but this was only due to the HNPCC cases 36. There-
fore, these cases need to be separated from the sporadic MSI cases in further studies.
Establishing microsatellite status could be of particular interest for stage II patients, 
where the modest therapeutic effect of 5-FU-based therapy (2-4% in 5-years DFS) 
emphasized the need for prognostic and predictive markers to risk-stratify these pa-
tients 157;158. The favorable prognosis of MSI CRC patients and the lack of benefit from 5-FU 
based therapy in patients with MSI tumors support a non-adjuvant treatment approach. 
Therefore, if we could establish the predictive value of MSI in these patients, a lot of 
patients could be spared from over-treatment, expenses, treatment-related toxicities, 
and reduced quality of life during 5-FU-treatment.
Unfortunately, patients included in the previously mentioned studies were treat-
ed 20-30 years ago in multiple countries. The current standard for adjuvant therapy in 
CRC has changed over time. The current standard for stage III CRC nowadays is infusional 
fluorouracil, leucovorin and oxaliplatin. Preliminary data suggest that adding either 
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oxaliplatin or irinotecan to 5-FU/leucovorin may overcome possible MSI resistance 
to 5-FU treatment and thus even change the predictive value of MSI 159;160. However, 
these recent data need further investigation and the available data so far do not justify 
excluding patients with stage III disease and MSI tumors from treatment according to 
current regiments.
KRAS
A randomized clinical trial conducted by the National Cancer Institute of Canada Clinical 
Trials Group (NCIG CTG) in collaboration with the Australasian Gastro-Intestinal Trials 
Group (AGITG) showed that among CRC patients who did not respond to advanced 
chemotherapy, monotherapy with cetuximab, a monoclonal antibody directed against 
the epidermal growth factor receptor (EGFR), improved their overall survival and 
progression-free survival and preserved their quality of life in comparison to best sup-
portive care alone 161. Cetuximab and panitumumab are registered for CRC patients 
whose tumors express EGFR protein as determined by immunohistochemistry. However, 
it has clearly been demonstrated that this method has no predictive value in terms of 
cetuximab activity in colorectal cancer, since there was no tendency towards a higher 
response rate with higher EGFR expression162;163. Furthermore, resistance to this treat-
ment is common and might be explained by KRAS. KRAS can acquire activating muta-
tions in exon 20 resulting in isolation of this pathway from the EGFR effect and thus 
rendering EGFR inhibitors, like cetuximab, ineffective 164-168. Indeed, previous studies 
showed the ineffectiveness of cetuximab or other EGFR inhibitors for CRC patients bear-
ing mutated KRAS 164-167. Therefore, treatment of CRC patients with cetuximab, with all 
its costs and toxicities, would be most appropriate for CRC patients bearing wild-type 
KRAS only. Furthermore, the addition of EGFR-antibodies to chemotherapy for patients 
with KRAS mutations appeared to be detrimental 169. KRAS mutation has thus emerged 
as the major negative predictor for EGFR therapy efficacy followed by clinical recom-
mendation for use of patients with wild-type KRAS tumors only 170. KRAS mutational 
testing of metastatic CRC has become a routine and is incorporated in many centers 
nowadays. However, not all patients with KRAS wild-type tumors benefit from cetuximab 
and panitumumab and the positive predictive value is low with a sensitivity of 47%. Ad-
ditional markers are necessary to better identify which patients will benefit from EGFR 
therapy. Less frequently observed KRAS mutations beyond the well-studied codons 12 
and 13, mutations in NRAS, BRAF and PIK3CA also showed that they are associated with 
resistance to anti-EGFR therapy 170.
BRAF
As written above, treatment decisions on cetuximab solely based on KRAS, with an oc-
currence of only 30-40% in nonresponsive patients 166;167;171;172, might not be adequate. 
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Therefore, the identification of additional markers of EGFR-targeted therapies in CRC is 
highly needed. Since EGFR triggers two main signaling pathways, the RAS-RAF-MAPK 
axis and the PI3K-PTEN-AKT pathway, resistance to anti-EGFR therapy could also be 
caused by other members of these pathways, like BRAF as part of the RAS-RAF-MAPK 
pathway 165. BRAF is the principal downstream effector of KRAS 173;174. Only a few stud-
ies on the relationship between BRAF and the effect of cetuximab were performed, 
both showing that BRAF mutations were related to resistance for EGFR-targeted 
therapies 62;63. Although evidence is still inadequate to demonstrate a real association 
of BRAF mutations with non-responsiveness to anti-EGFR therapy, it has been recom-
mended by the National Comprehensive Cancer Network (NCCN) for this purpose. 
Combined analysis of both KRAS and BRAF could be used to select patients eligible for 
EFGR-targeted treatment, with evident medical and economic implications. Further 
molecular markers are needed and more studies, especially a randomized controlled 
trial, need to be performed in order to confirm these results. Preliminary data suggest 
that the ineffectiveness of EGFR-targeted therapies could be restored by adding a BRAF 
inhibitor sorafenib concomitantly with cetuximab or panitumumab 63. This treatment 
combination is currently undergoing clinical assessment in CRC in a trial sponsored by 
the National Cancer Institute (NCT00326495) and might be a promising discovery, but 
also requires further investigation. In addition to sorafenib, other compounds targeting 
either BRAF  (PLX4032 and PLX4720) or its downstream effectors (ARRY-162, AZD6244, 
and PD0325901) are in clinical development and could be exploited in combination with 
EGFR-targeted therapy 175. PLX4032 is a V600 BRAF inhibitor which showed promising 
results in melanoma. However, in CRC the clinical activity was modest, with only a 5% 
response rate. On the contrary, PLX4720 caused substantial delays in tumor growth, 
including tumor regression, without toxicities176.
COX-2
Currently, the use of aspirin is gaining interest in CRC treatment. Aspirin and other 
nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to be effective in 
preventing colorectal cancer 177-179. Aspirin inhibits cyclooxygenase-2 (COX-2), which is 
expressed in 70% of colorectal tumors and increases with a more-advanced stage of the 
disease 180;181. COX-2 plays an important role in colorectal carcinogenesis, invasion, angio-
genesis, and metastasis. Several studies have shown that selective COX-2 inhibitors are 
able to reverse this COX-2 effect 182. Recent studies showed that aspirin might also play 
a role as adjuvant treatment in CRC 183;184. Chan et al. showed that regular use of aspirin 
after a CRC diagnosis is associated with a lower risk of colorectal cancer–specific and 
overall mortality, especially for individuals with tumors that overexpress COX-2 180. Also, 
the same group reported that aspirin reduced the risk of CRC exclusively  for individu-
als with elevated COX-2 expression 185. Though these findings were from observational 
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studies, they confirmed experimental data that prostaglandins and non-prostaglandin 
COX-2 products are central to the pathogenesis of CRC. They are also in accordance 
with animal studies in which genetically modified mice had defective APC-genes and 
in which rats had CRC after administration of exogenous carcinogens 186. Elevated COX-
2 expression in genetic APC deficiency was related to enhanced tumorigenesis while 
deletion of the COX-2 gene had the opposite effect 187;188. These data strongly suggest a 
central role of COX-2 in CRC and their inhibition as an effective chemopreventive mea-
sure. Unfortunately, studies investigating COX-2 expression for patients treated with 
aspirin are scarce, prompting the need for further validation of this possible biomarker.
Recent studies showed that aspirin not only influences COX-2 expression, but COX-1 
inhibition might contribute to the antitumor effects of aspirin as well, for example at 
low-dose aspirin 189. Experimental evidence also suggests additional COX independent 
actions of aspirin and other NSAIDs, like modifications of transcription factors (NFkB), 
induction of apoptosis and DNA stabilization 189.
Furthermore, aspirin use, even at low doses appropriate for cardiovascular risk man-
agement, is not without risks and roughly doubles the incidence of gastric bleeding 190. 
These drugs have been shown to enhance cardiovascular risks as well 191. Appropriate 
biomarkers are therefore needed to improve benefit/risk ratio. Since the exact mecha-
nism of aspirin is not known yet, COX-2 tumor expression is not ready to be used as a 
biomarker to select CRC patients for aspirin treatment.
PIK3CA
In addition to the effect of COX-2 expression on aspirin treatment in CRC as written 
above, a recent study showed that only CRC patients bearing a mutation in PIK3CA 
(exon 9 or exon 20) benefitted from aspirin treatment and not patients with wild-type 
PIK3CA tumors 192.
The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays an important role 
in carcinogenesis 133. Mutations in PIK3CA are present in approximately 15 to 20% of 
colorectal cancers 48;193;194. Up-regulation of PI3K enhances COX-2 activity and prosta-
glandin E2 synthesis, resulting in inhibition of apoptosis in colon-cancer cells 195.  Aspirin 
may suppress cancer-cell growth and induce apoptosis by blocking the PI3K pathway 196.
Unfortunately, only one study on the role of PIK3CA mutations in aspirin treatment 
in CRC has been performed so far, which had limited statistical power as well 192. More 
studies are needed to validate these results and to unravel the therapeutic effect of 
aspirin in CRC.
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Toxicity-related predictive biomarkers
DPD deficiency
Capecitabine, 5-fluorouracil (5-FU), and tegafur all belong to the fluoropyrimidines. Fluo-
ropyrimidines are one of the most frequently used anti-cancer treatments in colorectal 
cancer with a good tolerability for most patients. However, in approximately 5-10% of 
the patients severe toxicity arises after treatment has started, which sometimes could be 
life threatening 197;198. The intolerability of fluoropyrimidines is often caused by dihydro-
pyrimidine dehydrogenase (DPD) deficiency, which is present in approximately 4% of 
the western population 199. In 80% of patients with DPD deficiency the use of fluoropy-
rimidines in standard dose resulted in severe toxicity 200. Screening for this intolerability 
could identify ‘at risk’ patients, resulting in less toxicity-related hospital admissions and 
lower medical costs. Also, treatment could be adjusted for these toxicities with lower 
doses or dose titration according to arising toxicities. Titration of the dose in DPD de-
ficient patients could significantly reduce the frequency of severe, potentially deadly 
toxicity caused by fluoropyrimidines 201.
DPD deficiency can be determined by ‘real-time’ PCR, which is a simple technique and 
only requires 1 mL of blood with a sensitivity and specificity of 100% 202. Unfortunately, 
current genotyping of DPD deficiency only detects 25-50% of all DPD deficient patients, 
as only DPYD*2A is detected so far, which has a frequency of 1-2% in the total popula-
tion 203. New mutations, which are related to fluoropyrimidine toxicity, have been identi-
fied, like DPYD 2846A>T and 1236G>A, and could be implemented in genotyping DPD 
deficiency 203;204.  In clinical practice, the lower toxicity associated with modern infusional 
or oral 5-FU based regimens make it impossible to screen the entire population for 30 
polymorphisms associated with DPD deficiency. Despite the clear effect on toxicity, the 
prognostic and predictive value remains unclear with studies reporting contradicting 
results. Possibly, clinicians responded differently on the encountered toxicities. Despite 
well investigated evidence, the pharmocogenetic basis of varied DPD activity needs 
further investigation 151.
UGT1A1 Polymorphism
Irinotecan is a topoisomerase I inhibitor that interrupts DNA replication in cancer cells, 
resulting in cell death 205;206. The irinotecan prodrug is activated by carboxylesterase to 
the active metabolite SN-38, which is 100–1000 times more cytotoxic than the parent 
drug 205. SN-38 is further catalyzed into the inactive glucuronide derivative SN-38G by 
several hepatic and extrahepatic UGT enzymes. One of the major isozymes involved in 
this catalyzation is UGT1A1 207. A decrease in the level of functional UGT1A1 enzyme 
reduces a person’s ability to metabolize SN-38 to an inactive form and is also associated 
with a higher risk of adverse side effects, like neutropenia and diarrhea caused by high 
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levels or prolonged exposure to the active form 208;209. At least 63 UGT1A1 variants have 
been described, including single base pair changes, frame shift mutations, insertions, 
and deletions in the promoter region, five exons and two introns of the gene. Most vari-
ants are associated with an absent, reduced, or inactive enzyme; one is associated with 
an increased enzyme level, and the effects of some variants are unknown 210. Although, 
several clinical trials have confirmed that patients carrying different genotypes of UG-
T1A1 had varied degrees of tolerance to irinotecan, it is still unclear whether UGT1A1 has 
any influence on treatment efficacy. Three studies investigated the impact of UGT1A1 
isoforms on treatment outcome; however, their conclusions were inconsistent 211-213. 
Many western studies have suggested that UGT1A1*28 is significantly associated with 
irinotecan-induced toxicity 214-216. In particular, patients bearing UGT1A1*28 (TA7/7) had 
a high possibility to develop severe neutropenia and diarrhea. Based on this, doctors are 
warned that patients with UGT1A1*28 (TA7/7) should start with a reduced dose of irino-
tecan, although the details on how to adjust the dose have not been specified 210. On 
the other hand, research in Asian countries has shown a lower incidence of UGT1A1*28 
(TA7/7), while UGT1A1*6 (A/A) is more often found and may replace UGT1A1*28 as a key 
regulator in UGT1A1 expression 217;218.
Palomaki et al. stated a few problems regarding the use of UGT1A1 in clinical practice; 
there seems to be a clear relationship between UGT1A1 genotype and severe neutrope-
nia, but there is no direct or indirect evidence to support the clinical utility of modifying 
an initial and/or subsequent dose of irinotecan for patients with metastatic CRC as a 
way to change the rate of adverse drug events. Also, the data on the clinical validity of 
tests for UGT1A1 variants other than *28 are limited and the analytic validity of UGT1A1 
testing in clinical practice is unknown. Laboratories offering such testing may include 
variants in addition to *28 for which little evidence is available. Furthermore, there are 
limited data on UGT1A1 variants in Hispanic and African American populations. In order 
to recommend UGT1A1 testing in clinical practice, additional studies are needed to 
understand the potential effects of alleles that are rare for Caucasians but more com-
mon for other racial/ethnic groups and studies should focus on all variants of clinical 
significance in the population 210.
DISCUSSION
Nowadays, knowledge about the process of tumorigenesis is increasing. As postulated 
by Hanahan et al. cancer cells must acquire biological capabilities during the multistep 
development of human tumors. Sustaining proliferative signaling, evading growth sup-
pressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
activating invasion and metastasis, reprogramming of energy metabolism and evading 
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immune destruction are all hallmarks of tumorigenesis 78. Recognition of these concepts 
will increasingly affect the development of new treatment modalities in human cancer. 
Currently, recognition of these concepts has led to the identification of a lot of biomark-
ers, which might be of prognostic or predictive value in CRC.
Identifying and understanding molecular markers can improve the effectiveness of 
treatment in several ways; it may lead to the development of marker specific therapies 
and it may also improve the selection of adjuvant therapies by identifying those who 
will benefit most and therefore avoid toxic side effects for patients with the least risk 
of recurrence. The use of biomarkers might also have influence on social economical 
questions, decreasing the economic burden.
In this review we demonstrated the high potential of well-studied prognostic and 
predictive biomarkers in CRC. Only mutant KRAS, mutant BRAF, MSI and the Oncotype 
DX Colon Cancer Assay are currently used in clinical practice for determining whether 
to treat metastatic CRC patients with cetuximab or panitumumab, for the evaluation 
of Lynch syndrome and to inform treatment planning in stage II and III colon cancer 
patients. Implementation of these biomarkers, however, has been beneficial. For 
example screening for MSI resulted in increased identification of patients with Lynch 
Syndrome 219.
Unfortunately, other biomarkers are not ready to be introduced in clinical practice, 
which can be explained by several factors. Firstly, study characteristics of the individual 
investigations on biomarkers varied widely. Sometimes a marker with prognostic signifi-
cance was demonstrated, but only in a highly selected group of patients. Secondly, well-
standardized protocols to detect the biomarker were not applied for any of the markers, 
particularly IHC. Also, there seemed to be no standardized method for quantification 
of the expression level of a certain biomarker. Lack of consensus in performing studies 
may greatly influence the interpretation of the results of these studies. If studies are 
not performed according to standardized protocols, it is extremely difficult to compare 
results of the individual studies. The handling of tissues has been well recognized as 
contributing to assay variability and issues in assay validation as well 24. Some tissues are 
amenable to repeated sampling, without concern of substantial tissue heterogeneity or 
sampling issues, but often tissue-preserving methods cause damage or even destruc-
tion of tissues. New assays make great demands on the tissues , but it is impractical to 
replace the current tissue handling methods entirely. An integrated approach to the 
development and validation of integral biomarker assays might solve this problem. The 
difference between how a biospecimen is handled in a clinical setting and in a research 
setting must be reduced 24. Thirdly, none of these biomarkers are validated in larger 
cohorts or even in prospective trials. Previously, a five step program for the introduction 
of biomarkers in clinical practice was developed with the first step being biomarker 
development in a preclinical, exploratory setting, subsequently followed by verification 
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of this biomarker in a large retrospective study, validation and finally confirmation in a 
prospective randomized controlled trial 25. Unfortunately, this program has not been 
executed so far, which might explain why biomarkers are used so rarely in daily practice. 
Furthermore, most studies did not consider tumor heterogeneity, the influence of tumor 
- stromal interaction and the percentage of tumor in a sample, which also might influ-
ence results gained from molecular or immunohistochemical analyses.  Finally, using 
only one marker to predict the outcome of patients seems inappropriate, as according 
to Hanahan et al. tumor cells acquire multiple capabilities for tumorigenesis 78.  Recently, 
our group has demonstrated that patients with both presence of HLA class I expres-
sion and Treg tumor infiltration had less relapses when treated with chemotherapy 220. 
Combining markers might add more clinical value and gain more information about 
tumor aggressiveness.
In conclusion, the use of molecular markers and other biomarkers in CRC allows the 
identification of genes and biomarkers, which might predict individual prognosis and 
recurrence rate. Also, it might optimize treatment results and minimize treatment tox-
icities resulting in a decrease of economic burden and eventually the use of precision 
medicine in treating CRC patients. Only a few biomarkers are used in clinic nowadays. 
However, in order to introduce more biomarkers in clinical practice future studies need 
to consider the combination of markers, standardizing protocols and avoiding selection 
bias. Furthermore, simple, cheap, automated and standardized assays for the detection 
of molecular markers are necessary and most importantly, studies need to be validated 
in larger studies followed by prospective trials.
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ABSTRACT
Cancer is a leading cause of death worldwide. Great efforts are dedicated to the develop-
ment of prognostic and predictive biomarkers to improve diagnosis and achieve optimal 
treatment selection, thereby, introducing precision medicine in the multimodality treat-
ment of cancer. Genomic aberrations are at the basis of tumor development, represent-
ing excellent candidates for the development of promising clinical biomarkers. Over the 
last decade, single-gene mutations and genomic profiling have been increasingly used 
in multidisciplinary consultations for risk-assessment and subsequent treatment plan-
ning for patients with cancer. We discuss the impact of such genetic-based information 
on surgical decision-making. Single-gene mutations have already influenced surgical 
decision-making in breast, colorectal and thyroid cancer. However, the direct impact of 
genomic profiling on surgical care has not yet been fully established. We discuss the di-
rect and indirect influences of genomic profiling on surgery, and analyse the limitations 
and unresolved issues of a genotypic-approach to the surgical management of cancer.
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INTRODUCTION
Despite early detection of cancer through screening programs and the development 
of new treatment modalities, the overall mortality as a consequence of this disease 
remains high 1. The development of prognostic and predictive biomarkers for use in 
clinical practice has become a crucial part of cancer research. Single-gene mutations, 
which can be linked to cancer, have demonstrated promising prognostic and predictive 
value and have become increasingly used in multidisciplinary consultations for risk-
assessment and subsequent individual treatment planning of patients with cancer 2-8. 
Great examples are mutations within the BRCA1 or BRCA2 genes that are associated with 
a significantly increased risk of breast and ovarian cancer 9,  and mutations in KRAS, which 
are extensively used for adjuvant treatment allocation in patients with colon cancer 2.
However, single-gene mutation analyses alone are unable to completely unravel 
the complexity of cancer. A more-global approach looking at changes in DNA, RNA or 
proteins that contribute to tumor growth and progression, is needed to capture the 
simultaneous interaction of many different mutated genes within malignant cells and 
their surrounding tissues. Genomic profiling, which enables gene expression profiles at 
a genome-wide level to be obtained, has already proven to have an impact on the diag-
nosis and prognostic classification of tumors, as well as on the prediction of response of 
individual patients to specific therapeutic regimens 10-12.
The promise of delivering precision medicine has been an incredibly strong driving 
force for the vast and rapid development of high-throughput genomic technologies. By 
definition, precision medicine is a multi-faceted approach to medicine that integrates 
molecular and clinical research with patient data and outcomes, with the aim of deliver-
ing a treatment targeted to the specific disease characteristics of an individual patient. 
Genomic, epigenomic, and environmental data are studied together with specific 
patient information to understand individual disease patterns and to design personal-
ized preventive, diagnostic, and/or therapeutic solutions. Current regimens of cancer 
treatment are effective in a minority of patients, whereas adverse effects occur in many 
of the treated patients. Genome wide approaches may contribute to increase therapy 
benefit and decreasing adverse events by tailoring treatment decisions 13.
From a clinical perspective, the added value of genetic and genomic approaches is 
clear. However, their impact on surgery, which is still the cornerstone of cancer treat-
ment, is less obvious. This Perspectives article discusses the effect and associated 
limitations of introducing single-gene mutations and genomic profiling in the surgical 
decision-making process in terms of timing, extent and subsequent treatment of the 
patient.
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SINGLE-GENE MUTATIONS AND SURGERY
There are several examples of how single-gene mutations can guide surgical manage-
ment, including mutations in BRCA1 and BRCA2 in breast cancer, adenomatous polyposis 
coli  (APC) in colorectal cancer (CRC), the mismatch repair genes (MMR) in hereditary 
colon cancer and other cancers, and RET in multiple encocrine-relared tumors 3;14-17.
BRCA mutations
Specifically, women carrying mutations in the tumor suppressor genes BRCA1 or BRCA2 
have a high (cumulative risk of 60–80%) lifetime risk of breast cancer 18. The BRCA genes 
are normally expressed in breast cells and other tissues, where they have a crucial role 
in DNA damage repair. If a mutation occurs in one of these genes, DNA damage is 
not repaired properly, resulting in an increased risk of breast and ovarian cancer 19;20. 
Nowadays, bilateral prophylactic mastectomy and oophorectomy are the most effective 
strategy available for risk reduction of breast and ovarian cancer in mutation carriers 15;20-
22. In a recent study, Neuburger et al. 23, showed that in the UK the number of women 
who had a bilateral mastectomy nearly doubled over the last decade, and more than 
tripled among women without breast cancer. Of note, bilateral prophylactic mastec-
tomy has been shown to reduce breast cancer risk by 90% in BRCA1 or BRCA2 mutation 
carriers 24. Despite this great risk reduction, nearly 64% of BRCA1 or BRCA2 carriers in 
the USA choose to avoid surgery as a result of the high sensitivity of MRI that allows 
early tumor detection 25. Since ovarian cancer screening methods are largely ineffective, 
bilateral prophylactic salpingo-oophorectomy remains the standard of care in all BRCA1 
or BRCA2 mutation carriers, leading to a risk reduction of 80-96% in women with BRCA 
associated gynaecologic cancers 26;27.
APC mutations
In CRC, familial adenomatous polyposis (FAP) is a syndrome in which the inherited defect 
in the gate-keeper tumor-suppressor APC gene leads to the development of multiple 
premalignant polyps throughout the colon as a result of uncontrolled growth, and sub-
sequent malignant progression before the age of 40 years 28. Therefore, a colectomy is 
advised after detection of a germ line mutation APC. Depending on the clinical features 
(such as patient age, the number, nature and location of polyps), a rectal or pouch-anal 
anastomosis is recommended 29. Various aspects of surgical decision-making are influ-
enced by both surgeons and patients, whose preferences should be taken into account 
with regard to optimal time for surgical intervention, extent of surgery and the type of 
anastomosis performed. Independent of mutation type, surgery will be recommended 
as soon as FAP syndrome is diagnosed because this is associated with an almost 100% 
risk of CRC 30. However, since cancer is rare before the age of 20, surgery is often deferred 
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to the late teen years or in between major life changes, such as in academic transitions or 
between jobs 29.  The amount of polyps in the rectum are correlated with disease severity 
and are of crucial importance for deciding on the type of anastomosis 31. When fewer 
than five rectal polyps are observed, an ileorectal anastomosis is advised as this corre-
lated with mild disease. Conversely, if 20 or more rectal polyps are identified, indicating 
severe disease, an ileal pouch anal anastomosis will be recommended. Furthermore, 
morbidity quality of life and desired subsequent bowel function should be taken into 
account. Although pouch-anal anastomosis nearly eliminates CRC risk, it is associated 
with worse functional outcome, including an increased daily stool frequency, 24-hour 
incontinence, sexual dysfunction, decreased fecundity in females, impotence in men 
and decreased quality of life when compared to preservation of the rectum 32-35.
MMR mutations
Germline mutations in DNA MMR genes, hMLH1, hMSH2, PMS2 or hMSH6, are responsible 
for another form of hereditary colon cancer, namely non-polyposis CRC (or Lynch Syn-
drome) 36. MMR genes are involved in numerous cellular functions including DNA repair, 
apoptosis, anti-recombination and destabilization of DNA 37. Lynch Syndrome is also 
associated with an increased risk of cancers of the stomach, small intestine, liver, bile 
ducts, upper urinary tract, brain, and skin 38;39. Additionally, women with this disorder 
have a high risk of cancer of the ovaries and the endometrium 39.  Although the need for 
prophylactic surgery is less evident in Lynch syndrome patients than in FAP syndrome 
patients, those with Lynch syndrome who are diagnosed with CRC should consider total 
colectomy rather than a segmental colon resection due to the increased risk of meta-
chronous neoplasia associated with this condition. A large observational study of 382 
MMR gene mutation carriers (172 MLH1, 167 MSH2, 23 MSH6 and 20 PMS2) followed for 9 
years confirmed a high cumulative risk of metachronous CRC for 332 carriers treated 
by segmental resection for their primary CRC. In contrast, there were no diagnoses of 
metachronous CRC for the other 50 MMR gene mutation carriers treated by extensive 
colon resection 16.
RET mutations
Multiple endocrine neoplasia (MEN) are clinical inherited syndromes affecting different 
endocrine glands. The different patterns of MEN syndromes includes MEN1, MEN2A, 
MEN2B and medullary thyroid cancer (MTC) 17,  which is commonly associated with 
pheochromocytoma (PHEO) and/or multiple adenomatosis of parathyroid glands with 
hyperparathyroidism (PHPT). These syndromes have very different clinical courses: 
MEN2B is very aggressive, MTC is almost indolent in most patients, and MEN2A is associ-
ated with variable degrees of aggressiveness 17. Activating germline point mutations 
of the RET protooncogene—a 21-exon gene encoding for a tyrosine kinase transmem-
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brane receptor involved in the transduction of signals for cell growth and differentia-
tion—are present in 95% and 98% of families with MEN2A and MEN2B respectively, and 
in approximately 95% of families with MTC 17. A presymptomatic gene diagnosis aimed 
at detecting the presence of RET mutations in patients with MEN2 syndrome has been 
established to improve morbidity and mortality for patients with this disease. The treat-
ment of choice for primary MTC is total thyroidectomy with central neck lymph nodes 
dissection. However, even after radical surgery for MTC, there is a 30 percent chance of 
recurrence. Therefore, a prophylactic thyroidectomy is advised in patients with MEN2 
carrying mutations in RET in order to guarantee a definitive cure and avoid morbidity of 
a central neck lymph node dissection 17.
The American Thyroid Association task force has suggested four different risk levels— 
from A (the lowest) to D (the highest)— for RET mutations , which are incorporated in 
their most recent management guidelines 40. Specifically, children from families with 
MEN or MTC that carry RET mutations associated with a risk level D-(such as Met918Thr) 
should be surgically treated as soon as possible in the first year of life; whereas patients 
with level B and C risk levels (with RET mutations located in exons 10, 11, 13, 14, and 15) 
should be operated with a total thyroidectomy before 5 years of age; total thyroidectomy 
can be delayed till after the age of 5 or until the calcitonin positivity only for patients 
with a level A risk level (with RET mutations mapping to exon 5 and 8) 41. Removing the 
thyroid in young children has a great impact on the child’s life, as lifetime levothyroxine 
supplementation is required 42.
Recent data have shown that RET mutations carriers with undetectable levels of 
basal calcitonin have an almost no risk of developing MTC 43. Moreover,  serum levels of 
calcitonin <30–40 pg/ml are always associated with intrathyroidal micro-MTC without 
any evidence of lymph node metastases 43. Elisei et al.43 designed a study in which they 
operated on only RET mutation gene carriers depending on their basal and stimulated 
level of calcitonin. Total thyroidectomy was strongly indicated in patients when their 
basal or stimulated calcitonin levels were above 10 pg/mL.  Importantly, this study 
showed that the time of surgical treatment could be personalized and safely planned 
once the positivity to calcitonin is detected at the annual assessment, independent of 
the type of RET mutation and its associated level of risk. This strategy obviously implies 
a high compliance of carriers of RET mutations to the scheduled follow-up if surgery is 
postponed as long as possible. The detection of mutations in the proto-oncogene RET 
has, therefore, become standard practice with surgical implications in MTC, that have 
crucially influenced the timing of surgery 41. Furthermore, Xing et al. 44 have recently 
published an algorithm that incorporates cytology and molecular (RET) testing for the 
management of patients with thyroid nodules presenting with atypia of undetermined 
clinical significance, with the aim of limiting unnecessary and/or extensive surgery. This 
study suggests that in these patients, fine needle aspiration biopsy molecular analysis 
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should be performed for malignancy risk stratification. For example, a BRAF mutation in 
thyroid nodules from this specific patient group tends to be associated with increased 
risk of thyroid cancer and thus need for surgical intervention 44.
GENOMIC PROFILING
In the past decades, the technology for DNA and RNA analysis has evolved rapidly, shift-
ing from single-gene mutation analysis to a genome wide, system-biology approach, 
well placed to assist in unravelling the complexity of cancer 5. Since then, genomic pro-
filing has been increasingly used in multidisciplinary consultations for risk-assessment 
and subsequent treatment planning for cancer patients. In the first part of this section 
the influence of these established RNA-based gene profiles on cancer management are 
discussed. The second part of this section focuses on the impact of genomic profiling on 
surgical decision-making in terms of timing and surgical extent.
Genome sequencing in cancer care
The first genome-wide approaches used to predict clinical outcome in patients with 
cancer were based on RNA microarray analyses 45.  In one study that used microarray 
analysis, a panel of 50 genes identified low-risk and high-risk lung cancer patients with 
significantly different survival outcomes. Since then, many RNA expression profiles have 
been published with varying clinical value (Table 1).
Specifically, the Oncotype DX® profile (Genomic Health Inc., Redwood City, CA) showed 
a promising prognostic value and also proved beneficial for adjuvant treatment alloca-
tion for patients with breast cancer 46. In this assay, the recurrence score is calculated 
using a 21-gene assay, which includes 16 cancer-related genes and five reference genes 
for standardization, and determined a recurrence risk estimate (low, intermediate, or 
high) for each patient 46. In breast cancer, the recurrence score proved to be an indepen-
dent predictor of distant recurrence in patients with node-negative, estrogen receptor 
(ER)-positive breast cancer treated with tamoxifen. The recurrence score was also shown 
to be a predictor of the magnitude of chemotherapy benefit, with patients with high 
recurrence score showing the greatest benefit from chemotherapy 46;47. The recurrence 
score was also found to be prognostic and predictive for postmenopausal patients with 
hormone receptor-positive disease and with positive nodes who were treated with 
tamoxifen. However, these studies showed no benefit from chemotherapy in patients 
with low recurrence scores 10;47.
These results were validated in a separate study, in which the prognostic value of 
the recurrence score for postmenopausal hormone receptor-positive, node-negative 
and –positive patients with breast cancer treated with aromatase inhibitors was also 
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Table 1: Established RNA based prognostic and predictive profiles for breast and colorectal cancer
Breast Cancer Profiles
Test Company Technique Proven value Tissue requirements Output Results Validation References
Oncotype DX Genomic Health, 
Inc.
(Redwood City CA, 
USA)
qRT-PCR
(21 genes)
Prognostic Fresh frozen or FFPE RS:
Low: <18
Intermediate: 18-31
High: ≥31
10-years distant recurrence risk 
for ER+ve, LN- BC patients
Low risk: 6.8% chance of distant 
recurrence (95%CI 4.0-9.6)
Intermediate risk: 14.3% (95%CI 
8.3-20.3)
High risk: 30.5%
(95% CI 23.6-37.4)
High risk &  LN-: significant 
benefit from CT (HR 0.26 (95%CI 
0.13-0.53)). Same is seen for LN+ 
(HR 0.59).
Not seen in low risk patients
Yes
Current Prospective trials:
TAILORx: LN- patients
RxPONDER: LN+ patients
46, 47
MammaPrint Agendia BV
(Amsterdam, 
Netherlands)
Micro-array 
based gene 
expression 
profiling
(70 genes)
Prognostic RNA of fresh tissue cores or frozen 
material or FFPE
Mammaprint risk score:
Low & high risk
to develop metastasis in five 
years follow-up in BC patients
Low vs. High: HR 4.6 (95%CI 
2.3-9.2)
Sensitivity>90%
Yes
Current prospective trial:
MINDACT: LN-/LN+
patients
12, 50, 51
Colorectal Cancer Profiles
Oncotype DX Genomic Health Inc.
(Redwood City CA, 
USA)
qRT-PCR
(12 genes)
Prognostic Fresh frozen or FFPE RS:
Low: <18
Intermediate: 18-31
High: ≥31
10-years distant recurrence risk in 
stage II colon cancer patients
Chance of distant recurrence in 
3 years:
-Low risk: 12%
-Intermediate: 18%
-High risk: 22%
High vs. Low risk: HR 1.47 (95% CI 
1.01-2.14)
Yes 11, 54
ColoPrint Agendia BV
(Amsterdam, the 
Netherlands)
Micro-array 
based gene 
expression 
profiling (18 
genes)
Prognostic Fresh frozen material Coloprint risk score:  low & high 
risk
to develop metastasis in five 
years follow-up for stage II and III 
colon cancer patients
Five years distant metastasis free 
survival:
-Low: 94.9%
-High: 80.6%
High vs. Low risk:
HR 4.28 (95%CI 1.36-13.5)
Yes 55, 56
Abbreviations; CI, confidence interval; CT, chemotherapy; ER+, oestrogen receptor positive; ET, endocrine ther-
apy; FFPE, formaline fixed paraffin embedded; HR, hazard ratio; LN-, lymph node negative; LN+, lymph node 
positive; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; RS, recurrence score.
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Breast Cancer Profiles
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recurrence (95%CI 4.0-9.6)
Intermediate risk: 14.3% (95%CI 
8.3-20.3)
High risk: 30.5%
(95% CI 23.6-37.4)
High risk &  LN-: significant 
benefit from CT (HR 0.26 (95%CI 
0.13-0.53)). Same is seen for LN+ 
(HR 0.59).
Not seen in low risk patients
Yes
Current Prospective trials:
TAILORx: LN- patients
RxPONDER: LN+ patients
46, 47
MammaPrint Agendia BV
(Amsterdam, 
Netherlands)
Micro-array 
based gene 
expression 
profiling
(70 genes)
Prognostic RNA of fresh tissue cores or frozen 
material or FFPE
Mammaprint risk score:
Low & high risk
to develop metastasis in five 
years follow-up in BC patients
Low vs. High: HR 4.6 (95%CI 
2.3-9.2)
Sensitivity>90%
Yes
Current prospective trial:
MINDACT: LN-/LN+
patients
12, 50, 51
Colorectal Cancer Profiles
Oncotype DX Genomic Health Inc.
(Redwood City CA, 
USA)
qRT-PCR
(12 genes)
Prognostic Fresh frozen or FFPE RS:
Low: <18
Intermediate: 18-31
High: ≥31
10-years distant recurrence risk in 
stage II colon cancer patients
Chance of distant recurrence in 
3 years:
-Low risk: 12%
-Intermediate: 18%
-High risk: 22%
High vs. Low risk: HR 1.47 (95% CI 
1.01-2.14)
Yes 11, 54
ColoPrint Agendia BV
(Amsterdam, the 
Netherlands)
Micro-array 
based gene 
expression 
profiling (18 
genes)
Prognostic Fresh frozen material Coloprint risk score:  low & high 
risk
to develop metastasis in five 
years follow-up for stage II and III 
colon cancer patients
Five years distant metastasis free 
survival:
-Low: 94.9%
-High: 80.6%
High vs. Low risk:
HR 4.28 (95%CI 1.36-13.5)
Yes 55, 56
Abbreviations; CI, confidence interval; CT, chemotherapy; ER+, oestrogen receptor positive; ET, endocrine ther-
apy; FFPE, formaline fixed paraffin embedded; HR, hazard ratio; LN-, lymph node negative; LN+, lymph node 
positive; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; RS, recurrence score.
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demonstrated 48. Furthermore, recent findings have also suggested that the recurrence 
score is able to predict locoregional recurrence (LRR) in patients with node-negative 
ER-positive breast cancer treated with tamoxifen 49. This same study further showed 
that patients who underwent a mastectomy had significantly less LRR compared with 
patients who received lumpectomy followed by breast radiotherapy. When subdivided 
by age categories (<50 or ≥50 years), patients aged <50 years with high recurrence score 
seemed to have better clinical benefit from mastectomy than from lumpectomy and 
radiotherapy. On the basis of these results, patients with breast cancer, aged <50 years, 
featuring a high recurrence score should be advised to undergo a mastectomy.
In addition to the Oncotype DX® profile, the MammaPrint® (Agendia Inc. , Amster-
dam, The Netherlands) RNA mini-array was developed for use in the high-throughput 
clinical setting for the diagnosis of breast cancer 12;50;51. Using a supervised classification 
method, the correlation coefficient of the expression for approximately 5,000 genes was 
correlated with disease outcome in a retrospective cohort of 78 patients 12. Classification 
was made on the basis of the correlations of the expression profile of the ‘leave-one-
out’sample with the mean expression levels of the remaining samples from the good 
and the poor prognosis patients, respectively. The accuracy improved until the optimal 
number of marker genes was reached (70 genes). In a validation study, this prognostic 
profile was tested in 295 consecutive patients. The estimated HR for distant metastases 
in the group with a poor-prognosis signature, was 5.1 (95% CI, 2.9-9.0; p<0.001) 51. Mam-
maPrint® is a 70-gene prognosis profile that was reported to be superior to standard 
clinical parameters, such as nodal status and grade, in predicting the occurrence of 
distant metastasis in patients with breast cancer 51. Moreover, the MammaPrint® profile 
also showed predictive value in patients assigned to the ‘high-risk’ subgroup, who 
had a significant benefit of 12% for combined (chemotherapy and hormone therapy) 
treatment when compared with patients in the low risk subgroup 52. Once available, 
the results of the randomized controlled trial  MINDACT (Microarray in Node-negative 
Disease may Avoid ChemoTherapy) will contribute to the validation of the predictive 
role of MammaPrint® 53.
As in breast cancer, one of the clinically established RNA profiles for colon cancer is 
the Oncotype DX® profile. This profile was established from four studies performed in 
over 1,800 patients with stage II or stage III colon cancer 54. Genomic profiling in these 
studies allowed the identification of seven genes associated with tumor recurrence risk, 
six genes associated with chemotherapy benefit and five reference genes, that were 
predictive of recurrence in patients with resected colon cancer who were treated with 
surgery alone or surgery followed by 5-Fluorouracil and Leucovorin chemotherapy. 
This analysis led to the design of a 12-gene colon cancer recurrence score, which was 
validated in the QUASAR clinical trial 11. According to this 12-gene score, predefined risk 
groups are categorized as low, intermediate or high risk for tumor recurrence, which 
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gives the possibility to allocate high-risk stage II colon cancer patients to adjuvant treat-
ment, ultimately protecting patients from costly overtreatment. Of note, currently the 
Oncotype DX® assay has prognostic value regarding outcome in colon cancer, however, 
no predictive value has been established for adjuvant treatment so far.
In addition, the ColoPrint® (Agendia,Amsterdam, The Netherlands), a prognostic 18-
gene signature that was identified through unsupervised hierarchical clustering of a 
whole-genome oligonucleotide high-density microarray leading  to unbiased gene se-
lection, also showed promising results in patients with colon cancer 55. The signature 
was validated in an independent set of patients with stage II colon cancer and identified 
a 5-year distant metastasis-free survival of 94.9 ± 2.2% for low-risk patients and 80.6 
± 6.6% for high-risk patients, (p=0.009) 56. These results support the prognostic value of 
RNA profiling in patients with stage II colon cancer and herewith facilitate the identifica-
tion of patients who may benefit from chemotherapy. Nevertheless, surgical treatment 
will not change at all, using this type of prognostication.
High-throughput genomic analysis have led to the identification of different genomic 
signatures (or profiles) that can be used for cancer management and can contribute 
to the multidisciplenary decision making process for cancer treatment. However, as 
described in the following section, the direct impact of genomic profiling on surgery, 
timing and/or extent of the procedure, is currently less clear.
Impact of genomic profiles on surgery
Breast cancer
Several studies have shown that gene expression profiling of biopsies is a succesful 
tool that can predict response to neo-adjuvant treatment 57;58.  Specifically, Ayers et 
al.57 suggested that transcriptional profiling had the potential to identify a 74-gene 
expression pattern on biopsies of breast cancer that might lead to clinically useful 
predictors of pathological complete response (pCR) to the neo-adjuvant treatment 
regimen of sequential weekly paclitaxel in combination with 5-fluorouracil, doxorubicin 
and cyclophosphamide. However, this small sample study still needs further validation. 
Chang et al.58 analysed core biopsy samples from 24 patients with breast cancer and 
found an association of a 92-gene signature  with treatment response to neo-adjuvant 
monotherapy with docetaxel. These studies suggest that genomic-profiling on biopsies 
represents a clinically relevant progress in cancer management. It can be argued that 
current practice should focus on genomic profiling of the tumor biopsy, before as-
signment of a targeted neo-adjuvant treatment. Although this aspect does not have a 
direct impact on surgery, it could influence the extent and timing of surgery indirectly 
(Figure 1). Targeted neo-adjuvant treatment could potentially lead to downsizing of the 
tumor, with consequently less-extensive surgery or even a delay in surgery in case of 
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a clinical complete response (cCR). By using genomic profiling to tailor neo-adjuvant 
treatment, response rates may increase. This will result in lower mastectomy rates.
In breast cancer, there is already a shift from mastectomy to breast-conserving surgery 
after tumor shrinkage by neo-adjuvant chemotherapy, which proved to be oncologi-
cally safe in terms of survival outcomes 59;60. This decrease of mastectomy rates is a result 
of response to chemotherapy. Although this response can be predicted by molecular 
profiling of the tumor, the surgical planning in itself is not directly influenced by any 
gene expression signature. For local control, the studies by Cho et al.59 and Shin et al. 60, 
investigating the oncologic safety of conservative surgery versus mastectomy after neo-
adjuvant chemotherapy also improved outcome in terms of local recurrence. However, 
the number of patients included and the number of local events were too small to draw 
a significant conclusion in terms of therapeutic safety. These studies imply that through 
Wait-and-see
pCR
Surgery
■ Extent
■ Timing
Downsizing tumour
Targeted neoadjuvant treatment
Genomic profiling
Tumour biopsy
Figure 1: Impact of genomic profiling on surgery.
This figure shows two ways that genomic profiling might impact surgical intervention. Through genomic 
profiling of a tumor biopsy targeted neo-adjuvant treatment can be administered to a patient, possibly 
resulting in pathological complete response (pCR) or downsizing of the tumor. Downsizing of the tumor 
might influence surgery with regards to extent or timing of surgery. In instances of pCR a wait-and-see ap-
proach can be followed, where surgery is no longer necessary and a strict follow-up is advised.
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targeted neo-adjuvant treatment, based on biopsy profiling, further downsizing of the 
tumor could occur and result in less invasive surgery. Today there are no known genomic 
profiles that guide surgical planning directly for breast cancer. Perhaps in the future, the 
risk of local regional recurrences can be predicted on the basis of genomic profiling in 
such a way that even after excellent response to neo-adjuvant therapy, a mastectomy 
is advised.
Pancreatic cancer
An other example of the potential impact of genomic profiling of biopsies is pancreatic 
cancer. Neo-adjuvant chemotherapy with gemcitabine and docetaxel in patients with 
borderline resectable cancer of the pancreatic head showed that operative exploration 
was associated with curative intent in 48% of the patients investigated 61. Of the patients 
that underwent surgery, 87% had a R0 resection and 10% had a complete pathological 
response. This treatment was associated with a low perioperative morbidity and favour-
able survival: 81% of patients with resected cancers were alive at a median follow-up 
of 21.6 months 61. Although this result was not directly based on genomic profiling, it is 
expected that genomic analysis of these tumors (both mutation analysis and expression 
profiling) will better identify ‘treatment sensitive’tumor characteristics, which may lead 
to optimization of allocation of directed neoadjuvant treatment per individual patient.
In the future, a more curative surgical intervention could be achieved for patient 
groups with limited resection options, as a result of genomic profiling of the tumor 
biopsy, when therapeutic regimens are further optimized by targeted neo-adjuvant 
treatments.
Rectal cancer
As described above, neo-adjuvant treatment sometimes leads to downstaging of the 
primary tumor or even a complete clinical or pathological response. Therefore, more 
R0 resections and less-extensive surgeries can be achieved. With the use of genomic 
profiling on biopsy samples, followed by targeted neo-adjuvant treatement, the impact 
on surgical intervention can be striking, possibly leading to the omission of surgery. One 
can argue that based on specific genomic profiles from tumor biopsies, a wait-and-see 
approach might be indicated following complete clinical response after tailored neo-
adjuvant therapy 62. With this wait-and-see approach surgery can be delayed or even 
omitted. In patients with rectal cancer, this wait-and-see approach, however, is under 
debate. Curative total mesorectal excision after preoperative chemoradiation is the cur-
rent standard of care in rectal cancer, in which pCR is observed in nearly 14% of these 
patients 63. This example highlighted the rationale of a wait-and-see policy, which was 
further suggested by the results from a series of retrospective studies from Brazil. The 
Brazilian studies reported similar survival rates in patients that after complete clinical 
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response following neo-adjuvant treatment underwent radical resection or observation 
only 64-68. Furthermore, Maas et al. 69 showed that a wait-and-see policy with strict selec-
tion criteria, up-to-date imaging techniques and follow-up is feasible with promising 
rates of 89% and 100% for cumulative probabilities of 2-year disease-free survival and 
overall survival, respectively, in patients with rectal cancer showing a complete clinical 
response. However, this study was small with a low local event rate, making clinical sig-
nificance debatable. Recently, a study investigating criteria for determination of residual 
disease after neo-adjuvant chemotherapy showed that the majority of patients with a 
complete clinical response still had pathological residual disease 70. For maximal benefit 
from a wait-and-see approach in rectal cancer, we should aim for better identification of 
patients with pathological complete response.
Oesophageal cancer
In oesophageal cancer, neo-adjuvant treatment can downstage tumors, thereby increas-
ing R0 resections 71. In one study, patients were randomly assigned to surgery alone or 
to chemoradiotherapy with carboplatin and paclitaxel followed by surgery 71. Complete 
resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92% 
of patients in the chemoradiotherapy-surgery group versus 69% in the surgery group 
(p<0.001). A pCR was achieved in 47 of 161 patients (29%) who underwent resection 
after chemoradiotherapy. In this scenario, targeted neo-adjuvant therapy based on the 
genomic profile of a biopsy was shown to influence surgery by improving the R0 resec-
tions and pCR rates.
In patients with locally advanced oesophageal cancer, the benefit from neo-adjuvant 
chemoradiotion is clear, but the benefit from surgery afterwards is less obvious 72. Some 
patients with oesophageal cancer will have a pCR after neo-adjuvant chemoradiation 
and some of these patients would be able to forego surgery, but unfortunately evidence 
to guide treatment is scarce. For patients with squamous cell oesophageal cancer, those 
with a good clinical response after neo-adjuvant chemoradiation do not have a worse 
survival when undergoing observation only compared to surgery after chemoradia-
tion 73. The absolute benefit from surgery after neo-adjuvant chemoradiation seems to 
be relatively modest for patients with a good clinical response 72. In selected patients 
with a complete clinical response following neo-adjuvant treatment, 3-year survival 
rates of 50% are seen irrespective of subsequent surgical intervention 74. The accurate 
prediction of response to neo-adjuvant therapy can, therefore, have a direct influence 
on the surgical management of cancer. As treatment regimens improve and detection 
of earlier-stage disease increases (resulting in higher percentages of pCR), alternative 
approaches for patients at high risk of morbidity from surgery should be sought 75. 
Even though evidence is not derived from randomized controlled trials, it might be 
reasonable to forego surgical intervention in patients with a complete clinical response, 
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especially in elderly with comorbidities who are less fit to undergo surgery and more 
likely to experience adverse events. On the basis of these results, one can imagine that 
genomic-profiling could have an additional role in targeting the tumor with the most 
optimal neo-adjuvant treatment, possibly leading to an even better local control and 
survival outcome. However, in current clinical practice, this approach has not been 
routinely established yet.
FUTURE DEVELOPMENTS
Genomic profiling is gaining importance in the multidisciplinary treatment of cancer. A 
direct impact on surgical oncology, however, cannot yet be claimed. Genomic testing 
on biopsies could potentially affect surgical management, but some important issues 
still remain unresolved and warrant further investigation before genomic profiling on 
biopsies can truly influence surgical decision-making.
First, several studies in different types of cancer have shown that in most cases sufficient 
tissue can be obtained from biopsies for performing genomic profiling 76;77. However, 
in 20% of the cases limited tissue quantity is available from a biopsy, precluding further 
analysis 76. Furthermore, low tumor content may need more in-depth sequencing or 
even a repeated biopsy to obtain more material for analysis, which is undesirable from 
the patient perspective. Therefore, improvement of profiling techniques is necessary to 
allow the identification of a valid profile in these more complicated circumstances.
Second, the risk of tumor seeding while performing the biopsy should not be under-
estimated. Case reports of malignant seeding following needle-biopsy have in fact been 
described in several tumors 78-80. However, the clinical significance of this seeding is not 
known. In breast cancer, although data are limited, no increased morbidity has been 
observed as a consequence of tumor seeding 81.
Third, the heterogeneous nature of the tumor could contribute to unreliable prog-
nostication and prediction. Genomic and epigenomic factors, among others, contribute 
to this heterogeneity and, consequently, newly developed targeted anti-cancer drugs 
will only be effective in a subset of patients, and perhaps only at a specific stage of their 
disease. A biopsy represents only a small fraction of the primary tumor, and owing to the 
heterogeneity of the tumor, important information could be missed, possibly resulting 
in a misleading phenotype. A solution for this issue is to obtain multiple biopsy samples 
from several locations throughout the tumor, although a higher risk of tumor seeding 
may be a consequence of this increased sampling.
Finally, the interactions of the tumor with the micro-environment influence tumor de-
velopment and maintenance 82. These patient-specific factors challenge adequate tumor 
sampling for biomarker discovery, warranting the use of techniques such as laser capture 
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microdissection for separate analysis of tumor and normal tissue for biomarker profiling. 
Some profiles, such as MammaPrint®, were derived from the analysis of tissue sections 
containing both the tumor and its closely surrounding micro-environment, whereas 
others, such as Oncotype DX® , analysed only cancer cells. The different gene signatures 
identified from these approaches reveal a great variety of differentially expressed genes, 
with minimal overlap between the signatures identified. For example, Varga et al. 83 
showed that nearly 18% of breast cancer patients showed major-discrepancy between 
Endopredict and Oncotype DX® assay. In current clinical practice, the use of these tech-
niques would require highly trained personnel and are associated with high costs and, 
therefore, is not advisable. It is important to implement sample handling, processing 
and data analysis into a routine standardized practice, thereby increasing quality of the 
array and decreasing costs and inter-laboratory variability 84.
Lack of clarity regarding how to assess a pCR, the ideal timing for a clinical, radiologi-
cal and pathological assessment of response, the uncertainty of the long-term efficacy 
of this strategy and new follow-up protocols are all factors that currently influence the 
surgical  implication of genomic profiling 85. Of note, the decision of when to have sur-
gery after chemoradiation is still an important issue. Patients should be given adequate 
time to recover from chemoradiation-associated toxic effects and sufficient time should 
be allowed for the tumor to respond to treatment. The optimal time-frame between 
neo-adjuvant treatment and surgery remains unclear and is most probably dependent 
on the specific tumor as well as on the individual patient. However, retrospective data 
in patients with rectal cancer and oesophageal cancer indicate that, in general, delaying 
surgery after neo-adjuvant therapy improves neo-adjuvant treatment response and 
decreases surgical complications 86;87. These studies reported an increased pCR rate 
among patients who had a greater time frame between neo-adjuvant treatment and 
surgery 86;87, and an improved 5-year survival and a lower recurrence rate 88.
Finally, an important issue is that if genomic profiling is performed on tumor biopsies 
prior to the targeted neo-adjuvant treatment, the genomic signature identified might 
not be factual as the treatment could alter the genomic profile of the remaining tumor, 
possibly resulting in unreliable prognostication and prediction of adjuvant treatment 
benefit owing to this prespecified genomic profile 62. Hannemann et al.62 analyzed 
changes in gene expression patterns of breast tumors induced by chemotherapy, 
and compared  the profiles of the pretreatment tumor-biopsy with the profiles of the 
remaining tumors after treatment. The researchers found that major changes in gene ex-
pression in locally advanced breast cancer were observed in responders to neo-adjuvant 
treatment, defined as patients with a tumor shrinkage >50%, but not in patients with 
resistant tumors 62. Furthermore, Buchholz et al.89 showed that genomic profiles of 
biopsies obtained from one patient before treatment or 24h and 48h after initiation of 
treatment clustered together more than samples obtained from different patients with 
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comparable tumor stage 89. The fact that no differences were observed before and after 
treatment in the study from Buchholz et al.89 might be due to the time-points chosen for 
the biopsies. In fact, changes in gene expression might only occur at later time points 
(after 48 h). From a surgeon’s perspective, neo-adjuvant-induced tumor shrinkage is de-
sirable as it leads to less extensive surgery with a higher chance of free surgical margins. 
However, not knowing the blueprint of the tumor left behind when radical surgery is 
avoided still leaves us in the dark. Overall, the value of this prespecified genomic tumor 
biopsy profile before neo-adjuvant treatment is largely unknown, owing to the fact 
that redetermination of the genomic profile of the remaining tumor after neo-adjuvant 
treatment cannot be ruled out.
CONCLUSION
The multimodality treatment of cancer has witnessed an increasing influence of genomic 
profiling in clinical decision-making. The complex interplay of genetic and epigenetic 
alterations in our genomes leads to disrupted biochemical interactions in multiple path-
ways, which are responsible for tumor development (Box 1). Ultimately, identifying 
these genomic abnormalities will lead to accurate prediction of tumor recurrence or to 
cancer-related death, non-responsiveness to therapy, and might even provide potential 
new targets for cancer therapy.
Box 1: Impact of epigenetic changes on surgery
Epigenetics, including DNA methylation 
and histone modifications, is defined as 
the study of inherited changes in gene 
expression or cellular phenotype, caused 
by mechanisms other than changes in 
the underlying DNA sequence. Epigen-
etic changes have shown to be critical 
for the development and progression 
of all cancer types 93-95. Of note, these 
changes are intrinsically reversible and are 
therefore attractive targets for therapeutic 
intervention 93;96-98. Drugs for both DNA 
methyl transferases (DNMTs) and histone 
deacetylases (HDACs), involved in addi-
tion of methylgroups to DNA and removal 
of acetyl groups on histone tails, are avail-
able 99;100. DNMT inhibitors have shown 
promising results in cancer therapy, but 
unfortunately their activity is genome-
wide rather than targeting specific 
genes 101. A number of HDAC inhibitors 
have been designed to drive re-expression 
of aberrantly silenced genes, leading to in 
hibition of cell proliferation, hormone re-
ceptor reactivation and/or apoptosis 102. In 
the future, these directed epigenetic treat-
ments could potentially have the same 
impact on surgery as seen with targeted 
’
’
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In current clinical practice, surgery still is the cornerstone of cancer treatment and 
the most valuable outcome predictor. Whereas some single-gene mutations described 
here have successfully impacted on cancer surgery, genomic tumor profiling has no 
direct impact on surgical decision-making, thus far. Today’s research, however, is show-
ing promising results, in particular genomic profiling of tumor biopsies, before and/or 
after targeted neo-adjuvant treatment, may result in less-extensive surgical techniques 
owing to optimal tumor shrinkage, or even lead to a wait-and-see approach.
The data disscussed in this Perspectives article are mainly derived from retrospec-
tive analyses in prospectively designed studies. These studies were not conducted in a 
randomized setting; therefore, confounding may be present. Furthermore, patient num-
bers were often limited, thereby decreasing statitiscal power and clinical significance. 
Currently, two large randomized controlled trials in the adjuvant setting are ongoing, 
where according to risk stratification using Oncotype DX® or MammaPrint®, patients 
are randomly assigned for adjuvant chemotherapy in the TailorX or Mindact Trial, re-
spectively 53;90. The results of these trials will help define the true surgical implication of 
genomic profiling.
More comparable trials, for example, in the neo-adjuvant setting, are needed with the 
aim of limiting the extent of surgery.
neo-adjuvant chemotherapy after biopsy 
profiling. Furthermore, epigenetic chang-
es can be detected in tumor-derived DNA 
in stool, tissues or blood 103-105, allowing 
the use of epigenetic markers in a clinical 
setting. This advance could lead to earlier 
tumor detection with an indirect impact 
on surgical care, influencing extent and 
timing of surgery with less delay in surgi-
cal intervention 106.
In prostate cancer, DNA hypermethylation 
of glutathione S-transferase pi 1 (GSTP1) 107 
can be detected in urine, serum and ejacu-
late 108, which was able to increase sensi-
tivity of prostate cancer diagnosis 109 and 
distinguish between primary cancer tissue 
and benign tissue 110.
In CRC, identification of hypermethylation 
of P16 111 , DAPK (death associated protein 
kinase)112, RUNX3 113 and ALX4 (aristaless 
like homeobox-4) 114 in blood or stool 
also served as a screening tool. Recently, 
a panel of highly sensitive and specific 
biomarkers for methylated DNA in plasma 
was identified, which resulted in three 
genes (TMEFF2, NGR2 and SEPT9) specific 
in discriminating healthy subjects from 
patients with colorectal neoplasia 115.
It is hoped that these screening methods 
will lead to earlier tumor detection, 
however, this will not necessarily translate 
to increased survival and reduced mortal-
ity. Future studies, especially randomized 
controlled trials are warranted to tackle 
these issues and increase sensitivity of this 
exciting diagnostic field.
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Molecular targeted therapy might radically alter cancer treatment in the future and 
have the potential to greatly improve cancer survival by delivering the most effective 
drugs to the right patients 91. Nevertheless, the treatment of cancer, especially in older 
patients or in patients with multiple comorbidities, should also take into account these 
comorbid conditions, quality of life, patient resilience, and preferences. Despite the 
great contribution of genetics and genome profile to cancer therapy, considering only 
the sum of genetic aberrations in cancer is insufficient for developing and deciding ade-
quate cancer treatment, especially in elderly patients. In the USA, the estimated number 
of cancer patients older then 65 years of age will rise from 850,000 cases in 2012 to 1.3 
million in 2025 92. This population is characterized by a great heterogeneity in terms 
of comorbidities, quality of life and patient preferences. These factors are as crucial as 
the molecular signature of the tumor in the multidisciplinary approach to cancer. Thus, 
phenotypic profiling must be part of the vanguard of cancer research (Figure 2).
In conclusion, genomic profile-directed cancer therapy is still in its infancy. Much more 
is expected from this field of research, which might contribute to precision medicine in 
the future of cancer treatment. Currently, it is not clear if genomic profiling will ever gain 
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Figure 2: Global overview of the effect of genomic profiling on precision medicine.
This figure shows the effect of genomic profiling on precision medicine. (Epi)genetic tissue changes and 
patient characteristics influence tumor growth, invasion and metastasis. Genomic profiling can result in 
targeted neo-adjuvant treatment and adjuvant treatment through profiling of tumor biopsies or primary 
tumors consecutively, with the main goal of targeted treatment of the individual patient, better known as 
precision medicine. However, a patient’s phenotype, for example, comorbidities, frailty and poly-pharmacy, 
must be taken into account for optimal targeted treatment and to reduce therapeutic morbidity, as written 
in the discussion session.
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full ground in direct surgical decision-making. It might contribute to improved informed 
decision and better outcome, however, surgery still is, and will remain the most impor-
tant cornerstone in cancer management.
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SUMMARY AND GENERAL DISCUSSION 
Over the past decades, major advances have been made in the treatment of CRC pa-
tients. The introduction of new surgical techniques and (neo) adjuvant therapies has 
greatly improved clinical outcome in CRC patients. A great example is the introduction 
of the total mesorectal excision (TME) technique and pre-operative radiotherapy in 
rectal cancer, which decreased the local recurrence rate from 11 to 6% 1.  In colon cancer, 
the introduction of adjuvant chemotherapy with fluorouracil and levamisole greatly re-
duced the mortality rate by 33% among stage III patients 2. The addition of oxaliplatin to 
this regimen further improved clinical outcome in stage II and III colon cancer patients 
with a three years disease-free survival of 78% in the MOSAIC trial 3. Final results of this 
trial reporting on 5-year disease-free survival and 6-year overall survival also proved that 
adding oxaliplatin to fluorouracil and levamisole was associated with survival benefits. 
However, significant difference in survival between these two regimens was lost in stage 
II colon cancer patients 4. Therefore, the role and benefit of adjuvant chemotherapy in 
stage II colon cancer patients still remains controversial 4;5. Altogether, this has led to 
current recommendations in the Netherlands where patients with stage III and high-risk 
stage II colon cancer, e.g. those with T4 tumor extent or vascular invasion, are offered 
adjuvant chemotherapy with the FOLFOX regimen, consisting of oxaliplatin, fluorouracil 
and leucovorin 3.
In addition to stage II colon cancer patients, the role of adjuvant chemotherapy in 
rectal cancer remains debatable as well. Up till now, studies have failed to show sig-
nificant survival benefits for adjuvant chemotherapy in rectal cancer patients, who are, 
according to current guidelines, treated with preoperative radiotherapy 3;6-8. Adjuvant 
chemotherapy in rectal cancer is therefore not implemented in daily clinical practice in 
the Netherlands.  
Even though major advances in treatment of CRC have been made, mortality still 
remains high. In the Netherlands, each year approximately 9000 patients are diagnosed 
with CRC and 4000 deaths occur as a consequence of this disease (www.cijfersover-
kanker.nl). Morbidity associated with current treatments should not be underestimated 
as well. For example, studies in rectal cancer have evaluated the short- and long term 
morbidity of radiotherapy, where preoperative radiotherapy was associated with faecal 
incontinence, urgency, anal blood loss and sexual dysfunction 9. A significant number 
of (neo)adjuvant treated patients will not show any treatment benefit or not even need 
treatment to increase prognosis, and approximately 30% of stage II colon cancer pa-
tients suffer from recurrent disease within 5 years after surgery 10. Nowadays, prognos-
tication and treatment allocation are majorly influenced by tumor location and tumor 
stage (TNM). However, tumor classification has become more complex over the past 
years since the TNM staging system failed to provide clinicians with the optimal staging 
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tool it was designed for. Patient survival varies widely within each stage and positive 
lymph nodes, which determine tumor stage, are easily missed in routine pathological 
assessment. Under-treatment and over-treatment of some patients exists when using 
this system for treatment allocation 11-14. Therefore, the use of TNM stage falls short in 
daily clinical practice and needs to be supplemented with additional biomarkers that 
can improve current staging and treatment allocation criteria substantially. Predicting 
the clinical behavior of a tumor through a combination of clinical, pathological and bio-
logical characteristics might lead to a well-targeted treatment in the individual patient, 
thereby increasing treatment benefit and limiting negative side effects. In this thesis 
we therefore evaluated prognostic and predictive biomarkers in CRC for improved risk 
stratification and treatment benefit in the individual patient, with the introduction of 
precision medicine in the near future as ultimate goal. This thesis is divided in three 
parts. In Part one we investigated biomarkers related to important hallmarks of can-
cer, which were able to adequately assess prognosis in CRC patients. In Part two we 
established a survival benefit in colon cancer patients treated with low dose aspirin after 
diagnosis and investigated predictive biomarkers, which were able to predict which 
patients would benefit from aspirin treatment after a colon cancer diagnosis. Finally, 
in Part three we discussed the use of prognostic and predictive biomarkers in clinical 
practice, its utility and the road to precision medicine. 
PART ONE: PROGNOSTIC BIOMARKERS IN COLORECTAL CANCER
In 2000, Hanahan and Weinberg published an important article about ‘ the hallmarks of 
cancer’, which are six biological capabilities tumors have to acquire during the multistep 
development of human cancers. These hallmarks are sustaining proliferative signaling, 
evading growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis and resisting cell death 15. In 2011, they added 
two emerging hallmarks; reprogramming of energy metabolism and evading immune 
recognition and recognized the importance of the tumor-microenvironment in tumor 
development. The hallmarks constitute an organizing principle for rationalizing the 
complexities of neoplastic disease. Recognition of these hallmarks will increasingly 
affect prognostication and the development of new means to treat human cancer 15. 
In this part we investigated biomarkers related to some of these hallmarks, such as 
sustaining proliferative signaling, resisting cell death and evading immune recognition.
The last decades, research has indicated a substantial influence of the immune system 
on tumor growth, which showed to be both tumor suppressing and promoting 16. In 
Chapter 2 and 3 we investigated the prognostic value of important immune recogni-
tion evading mechanisms in colon cancer and in rectal cancer separately by analyzing 
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HLA class I tumor expression, tumor expression of non-classical HLA class I molecules 
(HLA-E and HLA-G) and tumor infiltration with immunosuppressive regulatory T cells 
(Tregs). The goal of these studies was to establish a tumor profile based on biomarkers 
that reflect a tumor’s immune susceptibility status and to determine its relationship to 
patient outcome. 
In 285 colon cancer patients (Chapter 2), loss of HLA class I was significantly associ-
ated with a better overall survival and disease-free survival, which could be explained by 
elimination of tumor cells by natural killer (NK) cells once these tumor cells metastasize to 
the bloodstream 17-19. When the immune markers were combined, three distinct survival 
patterns based on immune surveillance were identified. Patients with tumors showing 
loss of HLA class I and negative HLA-E and –G expression, irrespective of Treg tumor 
infiltration, showed the best prognosis. Absence of HLA-E and -G expression possibly 
made these tumors, who have lost their HLA class I expression, even more susceptible to 
NK cell elimination, further explaining their favorable prognosis 20;21. In contrast, patients 
showing the worst prognosis were patients with tumors with HLA class I downregula-
tion and low Treg infiltration, irrespective of HLA-E and –G expression. Since tumors are 
thought to be ‘immunoedited’ through a Darwinian selection process into poorly im-
munogenic tumor cell variants invisible to the immune system 16, we hypothesized that 
these poorly immune-recognized tumors are already edited by Cytotoxic T-cells (CTL), 
because they partly lost their HLA class I expression. Consequently, these tumors will 
elicit a minimal CTL attack, resulting in tumor progression. The absence of Tregs in the 
tumor micro-environment of these tumors further strengthens our hypothesis. Because 
of the opposing actions of Tregs and CTL in tumor immunity, Tregs will not be needed 
for immune escape when CTL presence is scarce 22. In summary, this study showed a 
complex and multifaceted interplay between different immune escape mechanisms, 
highlighting the need for combined immune marker analysis to better reflect patient 
outcome. We were able to determine three distinct survival patterns in colon cancer 
based on immune surveillance (Figure 1), which represented significant independent 
clinical prognostic value in colon cancer patients. 
208 Chapter 10
In Chapter 3, we investigated the prognostic relevance of the same immune markers, 
independently and combined, in 495 rectal cancer patients. In this study, HLA class I 
tumor expression and a high Treg tumor infiltration were related to a better clinical 
outcome in these rectal cancer patients. Interestingly, strong HLA-G expression was 
also significantly related to a better survival. These results are remarkable since HLA-G 
expression can inhibit NK cells from lysing tumor cells that have lost or downregulated 
classical HLA class I expression as a secondary immune escape 23;24. The reason for this 
seemingly opposing effect of HLA-G expression remains unclear. Immune regulation in 
cancer still remains complex and multifaceted, and not all immune-related mechanisms 
are completely clear. Possibly, HLA-G expression does not play an influential role in 
rectal cancer when HLA class I expression is still present. 
When the immune markers were combined, again three distinct patterns in patient 
survival based on immune surveillance were identified. Prognosis increased with a 
decrease in negative prognostic markers, thus patients with tumors bearing two or 
three negative prognostic markers, e.g. loss of HLA class I tumor expression, weak HLA-G 
Figure 1: Global overview of immune escape mechanisms based on literature and results we established in 
a cohort of 285 colon cancers in which HLA class I tumor expression, HLA-E tumor expression, HLA-G tumor 
expression and Treg infiltration were investigated
The tumors with a certain phenotype in the gray, dashed and black circle indicate tumors that are high, 
intermediate or low immune susceptible with a good, intermediate and worse prognosis respectively. Treg, 
immunosuppressive regulatory T cell; CTL, Cytotoxic T cell; NK, natural killer cell.
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tumor expression and low tumor infiltration with Tregs, showed a worse prognosis and 
therefore qualified as very low immune susceptible. Furthermore, patients with tumors 
showing loss of HLA class I expression, low Treg infiltration and strong HLA-G expression 
showed the worst outcome perspectives. We hypothesized that these patients probably 
had tumors which were highly ‘immunoedited’, since these tumors have lost their HLA 
class I expression, causing a minimal CTL attack and subsequently attracted little to no 
Tregs. Because of strong HLA-G expression they probably were able to escape further 
immune recognition through inhibition of NK cell recognition 23;24. Interestingly, in 
contrast to what we have reported above, HLA-G expression is in this subset of poorly 
immune-recognized tumors associated with a worse survival. HLA-G expression might 
only play an influential role during this phase of ‘immuoediting’ as second immune 
escape mechanism, when HLA class I expression has already been lost. 
These two chapters have provided us with some confusing and opposing results, as, 
compared to colon cancer, some different immune escape mechanisms seem to occur 
in rectal cancer. In colon cancer, loss of HLA class I was significantly related to a better 
survival. In rectal cancer, best survival outcomes were seen for patients with tumors 
showing expression of HLA class I. This might suggest biological differences between 
colon and rectal tumors. One of these biological differences might be the microsatellite 
status of the tumor. Approximately 50% of all proximal colon tumors show microsatel-
lite instability (MSI), whereas almost all distal colon and rectal cancers are microsatellite 
stable (MSS) tumors 25;26. MSI has been associated with loss of HLA class I as well as a 
better prognosis, possibly influencing prognostic results when analyzing HLA class I 
in colorectal tumors 27;28. Unfortunately, in our colon cancer cohort the number of MSI 
tumors that was successfully determined was too small to perform separate analyses in 
MSI and MSS tumors. 
When all immune markers were combined, differences in immune escape mechanisms 
became even clearer. In colon cancer, patients with tumors showing loss of HLA class I 
and negative HLA-E and -G expression, irrespective of Treg infiltration, were related to a 
better survival. In contrast, tumors with the same characteristics were related to a worse 
outcome in rectal cancer. Again, microsatellite status might influence these results. 
Recently, the Cancer Genome Atlas Network investigated biological differences be-
tween colon and rectal cancer, but only established differences in anatomical tumor 
site with more hypermethylation in right-sided tumors, possibly explained by different 
embryonic origins of right-and left-sided tumors 29. Therefore, the question still remains 
if there are true biological differences between colon and rectal cancer and further stud-
ies should focus on separate analyses of these tumors.
In Chapter 4, we performed a combined analysis of biomarkers of proliferation and 
apoptosis in colon cancer, namely Ki67 and cleaved caspase-3. A key factor in tissue 
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homeostasis, especially of the intestinal mucosa, is a balance between the level of cell 
death and cell proliferation 30-32. Disturbance of this balance could contribute to initia-
tion and maintenance of tumor growth and development 15;33. Previous studies in CRC 
showed contradicting results with respect to the association between apoptosis and 
proliferation in tumor resection specimens and patient outcome, especially when com-
paring tumors originating from the colon and rectum 32;34-39. Also, the prognostic value of 
apoptosis and proliferation seems to be influenced by tumor location and microsatellite 
status 37;40;41. 
The contradicting results derived from these studies strengthened our hypothesis 
that a balance between both these processes determines patient’s clinical outcome. 
Our study showed that a combined analysis of the level of tumor cell proliferation and 
apoptosis was significantly related to patient outcome in 285 stage I-IV colon cancer 
patients with respect to disease-free survival and overall survival. Patients with a strong 
proliferation and presence of apoptosis in their tumors showed the best survival out-
comes. Interestingly, the impact of this combined analysis of proliferation and apoptosis 
on patient outcome varied with tumor location and therefore highly likely with tumor 
microsatellite status, since significantly more MSI tumors were located on the right side 
of the colon. Unfortunately, the number of MSI tumors in our cohort was too small to 
perform stratified survival analysis for microsatellite status. 
In the left-sided cohort the patients with a balance between proliferation and apop-
tosis in their tumors performed better with respect to outcome. As you would expect 
from high proliferative tumors, patients with left-sided tumors showing high prolifera-
tion levels and absence of apoptosis had the worst outcome perspectives.  In contrast, 
right-sided tumors with high proliferation levels and absence of apoptosis performed 
significantly better. Based on these results we hypothesized that it is either tumor mic-
rosatellite status or tumor location, which influences the prognostic value of the balance 
between tumor cell proliferation and apoptosis. It is not unlikely that the tumor micro-
satellite status influences the balance between tumor cell proliferation and apoptosis. 
MSI tumors are known to have high levels of proliferation and tend to accumulate gene 
mutations leading to increased production of abnormal peptides 40;41. This might result 
in an immune reaction leading to higher levels of apoptosis, which possibly explains 
the favorable prognosis of patients with right-sided tumors showing high proliferation 
levels 42. However, further studies investigating these two important hallmarks are nec-
essary and should focus on separate analyses of colon- and rectal cancers, where tumor 
microsatellite status and location are be taken into account as well. 
In Chapter 5, we performed a validation of the 12-gene Colon Cancer Recurrence Score® 
Assay as a predictor of recurrence risk in stage II and III rectal cancer patients treated 
with surgery alone from the Dutch TME trial 1. The Oncotype DX Colon Cancer Recurrence 
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Score (RS) (Genomic Health, Redwood City, CA, USA) was developed by using tumor gene 
expression data from 1851 patients with resected colon cancer from four independent 
clinical trials 43. This was followed by the design of the 12-gene colon cancer Recurrence 
Score (RS), which was validated in the QUASAR clinical trial beyond other clinical covari-
ates 44. Predefined risk groups were categorized as low, intermediate or high risk for 
tumor recurrence according to patients’ RS values, which gave the possibility to specifi-
cally allocate cancer patients for (adjuvant) treatment regimens. In this validation study 
performed in rectal cancer, RS predicted risk of recurrence, risk of distant recurrence, 
and rectal cancer-specific survival. The effect of RS was most prominent in stage II rectal 
cancer and attenuated with more advanced stage. RS may be clinically useful in stage II 
rectal cancer patients, where RS can help identify high-risk patients who could benefit 
from -- and low-risk patients who may forego -- adjuvant chemotherapy (Figure 2). 
Up till now trials failed to show a survival benefit with adjuvant chemotherapy for 
pre-operatively treated rectal cancer patients 6-8. However, efforts are underway to study 
reduced-intensity approaches, including those that spare radiation or even surgery. 
Incorporation of the Recurrence Score assay into clinical trials, such as the TAILORx and 
RxPonder trials in breast cancer 45;46, may enable these efforts through improved patient 
stratification for risk-adapted treatment strategies. 
Figure 2: Cumulative incidence of recurrence in 297 rectal cancer patients.
Predefined risk groups were categorized as low, intermediate or high risk for tumor recurrence according to 
patients’ Recurrence Score (RS) values based on the 12-gene Colon Cancer Recurrence Score® Assay, giving 
the opportunity to specifically allocate adjuvant treatment in the individual patient. This figure is derived 
from Reimers et al., Validation of the 12-gene Colon Cancer Recurrence Score as a predictor of recurrence 
risk in stage II and III rectal cancer patient, J Natl Cancer Inst 2014 Sep 26:106(11)
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PART TWO: TREATMENT OF COLON CANCER AND PREDICTIVE BIOMARKERS
Aspirin and other nonsteroidal anti -inflammatory drugs have shown to be effective 
in preventing CRC 47-49. More recently, aspirin has also shown promising results when 
used after CRC diagnosis 50-52.  In Chapter 6 we performed a subanalysis in elderly colon 
cancer patients of the cohort used by Bastiaannet et al. 50 to investigate the benefit of 
low-dose aspirin (80mg) treatment after diagnosis. Patients with rectal cancer were ex-
cluded from analysis as these patients did not show any benefit from aspirin treatment. 
In this study, aspirin use after diagnosis was significantly associated with an improved 
survival of 40% in older colon cancer patients (≥ 70 years of age) compared to nonusers. 
This study implicates that aspirin could be an effective adjuvant agent in the treatment 
of colon cancer, especially in older, chemo-naïve colon cancer patients. Demonstration 
of a significant therapeutic effect of a well-tolerated, inexpensive drug would be a major 
clinical advancement.
The exact mechanism by which aspirin exerts its anti-cancer effect still remains largely 
unknown. It might be that the anti-inflammatory and chemopreventive effects of aspirin 
are mediated through direct inhibition of COX-1 and COX-2 53-55. COX-1 is responsible 
for platelet aggregation through production of TXA2 in platelets 56. COX-2 plays an im-
portant role in colorectal carcinogenesis, invasion, angiogenesis and metastasis 54 and 
approximately 70% of colorectal tumors express COX-2 51;57. Studies have shown that 
this COX-2 effect can be reversed by selective COX-2 inhibitors 54. COX-2 independent 
pathways, such as suppression of IL-4, NF-ĸB, insulin-like growth factor 1 (IGF-1), and 
the inhibition of Wnt-signaling and stem cell growth possibly as the result of enhanced 
beta-catenin phosphorylation have also been described to contribute to the anti-cancer 
effects of aspirin 58-62. Recently, several studies on aspirin benefit in CRC were performed 
on data from the Nurses’ Health Study in the USA. First, Chan et al. reported a survival 
benefit for aspirin use after diagnosis in CRC patients, which seemed to be dependent on 
COX-2 expression of the tumor. A much lower risk of CRC-specific and overall mortality 
with tumors that overexpress COX-2 was found 51. A second study of the same research 
group showed that the survival benefit from aspirin use after diagnosis was restricted 
to patients with mutant PIK3CA tumors. Patients with wild-type PIK3CA tumors did not 
benefit from aspirin treatment 63. The phosphatidylinositol 3-kinase (PI3K) signaling 
pathway plays an important role in carcinogenesis 64. Mutations in PIK3CA are present 
in approximately 15 to 20% of CRCs 65-67. Up-regulation of PI3K enhances COX-2 activ-
ity and prostaglandin E2 synthesis, resulting in inhibition of apoptosis in colon-cancer 
cells 68. Aspirin might suppress tumor development and induce apoptosis by blocking 
this PI3K pathway 69. 
As it is desirable to reduce overtreatment of patients and lower incidental side effects 
of aspirin treatment, we also tried to find predictive biomarkers for aspirin treatment in 
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colon cancer. The metastatic potential of cancer cells that are shed into the bloodstream 
can be modified by environmental conditions, including platelets and bone marrow-
derived cells in the vasculature 70. As soon as cancer cells enter the bloodstream they 
interact with platelets 71. Through tumor cell coating, platelets are thought to protect 
disseminating tumor cells from lysis by immune cells such as NK cells. Tumor cell coating 
leads to platelet activation and degranulation followed by release of a variety of factors 
capable of influencing NK reactivity 72. The interaction between platelets and tumor 
cells is also thought to transfer HLA class I from the platelet onto the tumor cell surface 
resulting in a HLA class I-positive phenotype, or ‘pseudoself’. This platelet-derived HLA 
class I blocks NK cell activity. Because platelet-derived HLA class I presents self-peptides, 
reflecting the normal ligandome of the megakaryocyte lineage, CTLs are not activated 
as well 72. 
Aspirin influences platelet aggregation through COX-1 inhibition 56. Most likely tumor 
cell coating and platelet-tumor cell interaction are affected as well. In case of aspirin 
use, tumor cells are now prone for lysis by immune cells. NK cells preferentially recog-
nize and eliminate cells with low or absent expression of HLA class I 21;23, We therefore 
hypothesized that the survival benefit associated with low dose aspirin use after a 
cancer diagnosis would be associated with tumors that have low or absent HLA class I 
expression. In Chapter 7 we showed that aspirin use after a colon cancer diagnosis was 
associated with improved survival if tumors expressed HLA class I on their cell surface, 
contrary to the original hypothesis. There are two possible explanations for this intrigu-
ing observation. First, the disruption of platelet aggregates with aspirin that shield HLA 
class I expressing, circulating tumor cells might make these cells more susceptible for 
T-cell mediated immune surveillance. Second, direct contact of platelets and tumor cells 
results in secretion of TGF-β and activation of the NF-ĸB pathway, which, in synergistic 
action, prime circulating tumor cells for subsequent metastases 70. Aspirin might inhibit 
platelet-tumor cell signaling and prevents epithelial-mesenchymal transition in circulat-
ing tumor cells, thereby reducing the metastatic potential. HLA class I expression might 
be necessary for this platelet mediated NF-ĸB signaling in circulating tumor cells result-
ing in an epithelial-mesenchymal-like phenotype with enhanced metastatic potential 
(Figure 3).
Our data was not able to confirm the previously published results from the USA group, 
which demonstrated that the benefits of aspirin after a colorectal cancer diagnosis were 
associated with strong COX-2 expression in the original tumor and the presence of 
mutations in PIK3CA 51;63. In our cohort, there was no difference in benefit from aspirin 
use after a colon cancer diagnosis when the survival analyses were stratified for COX-2 
expression and PIK3CA mutation status. Interestingly, research performed by an English 
group recently confirmed the survival benefit of aspirin in PIK3CA mutated CRCs, how-
ever, the predictive value of COX-2 expression was again not validated in this cohort 73. 
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The contradicting results might be pharmacologically explained, since different dosages 
of aspirin are investigated in these studies (USA group 325 mg, English group 100 mg, 
our group 80 mg). Data on aspirin indicate that systemic concentrations of aspirin 
reached with low-doses are inadequate to permanently acetylate COX-2, but are optimal 
for platelet inhibition 74. This might explain why in our cohort, where low-dose aspirin 
was investigated, strong COX-2 expression and PIK3CA mutations were not validated as 
predictive biomarkers. Furthermore, there may be more than one mechanism of action 
that accounts for the anti-cancer effects of aspirin; a direct anti-platelet effect due to 
inhibition of COX-1, that is responsible for the reduction in metastases and only requires 
Figure 3:
In this model direct contact of platelets and tumor cells results in secretion of TGF-β and activation of 
the NF-ĸB pathway, which, in synergistic action, prime circulating tumor cells for subsequent metastases. 
Aspirin might inhibit platelet-tumor cell signaling (which is dependent upon intact HLA expression) and 
prevents epithelial-mesenchymal transition in circulating tumor cells, thereby reducing the metastatic po-
tential.
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a dose of aspirin that inhibits platelets; and a second mechanism activated with higher 
or more frequent dosing that inhibits the COX-2 pathway in systemic tissues. 
Reflecting on the results derived from this thesis the apoptotic pathway could also 
be a potential field of interest for studying the anti-cancer effects of aspirin. Aspirin 
has shown to promote apoptosis, either through suppression of IL-4 gene expression, 
which is essential for the resistance to DNA damage-induced apoptosis of colon cancer 
stem cells (CSCs) 58;75, or through inhibition of NF-ĸB or COX-2 expression 61;68. Research 
has shown that MSI confers cell resistance to apoptosis 76. Consequently, microsatel-
lite status might influence benefit from aspirin treatment. In vitro studies investigating 
long term aspirin exposure have already shown the selection for MSS and reduction 
of the MSI phenotype in colorectal and gastric cancer cell lines 77;78. Goel et al. previ-
ously showed that aspirin treatment increased mismatch repair protein expression and 
apoptosis in CRC cells. Interestingly, growth inhibition of all human colon cancer cell 
lines was independent of microsatellite status, however, different growth regulatory 
mechanisms were responsible for this inhibition 79. A recent study also confirmed that 
aspirin treatment induced NF-ĸB-driven apoptosis was independent of p53 expression 
and microsatellite status, suggesting that microsatellite status is not the predominant 
pathway responsible for aspirin anti-tumor activity 76. In the preventive setting, for 
example in Lynch Syndrome families, aspirin could have an important influence on 
microsatellite status, thereby reducing MSI phenotype and thus cancer progression. 
However, since the MSI phenotype has been associated with improved survival 80, the 
survival benefit caused by aspirin will probably not be influenced by the microsatellite 
status of the primary tumor.
In summary, results from the above mentioned studies still keep us in the dark concern-
ing aspirin’s anti-cancer effects. Pooling of data from the different cohorts to improve 
statistical power in subgroup analyses followed by validation studies and random-
ized controlled trials are therefore eagerly awaited. In the Netherlands, a randomized 
placebo-controlled trial investigating low-dose aspirin (80 mg) after surgery in older 
colon cancer patients will start soon (Aspirin Trial, NTR 3370; EudraCT2011-004686-32). 
Possibly, more than one mechanism is responsible for the anti-cancer effects of aspirin. 
Different pathways should therefore be combined, also taken into account that the 
molecular mechanisms responsible for the anti-cancer effects of aspirin in the adjuvant 
setting may differ from the ones in the preventive setting.
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PART THREE: PRECISION MEDICINE IN COLORECTAL CANCER AND FUTURE 
PERSPECTIVES
The TNM stage proved to fall short in clinical practice and needs to be supplemented 
with additional biomarkers to improve current staging and treatment allocation criteria 
substantially. A lot of research has been dedicated to the discovery and development 
of clinical prognostic and predictive biomarkers to improve diagnosis and to allocate 
optimal treatment modalities, introducing precision medicine in the multimodality 
treatment of cancer. By definition, precision medicine is a multi-faceted approach to 
medicine that integrates molecular and clinical research with patient data and clinical 
outcome, and places the patient at the center of all elements. Genomic, epigenomic, 
patient- and environmental data are studied together to understand individual disease 
patterns and to design preventive, diagnostic, and therapeutic solutions.
Unfortunately, in spite of a vast amount of available literature on biomarkers in CRC, 
only a few biomarkers are used on request in clinical practice nowadays, like KRAS, 
BRAF, MSI and the Oncotype DX Colon Cancer Assay for determining whether to treat 
metastatic CRC patients with cetuximab or panitumumab, for the evaluation of Lynch 
syndrome and to inform treatment planning in stage II and III colon cancer patients.
In Chapter 8 we have given an overview of a number of frequently studied biomark-
ers in CRC and emphasized on the difficulties and controversies that withhold clinical 
introduction of these biomarkers. In this review we have stated that there is insufficient 
evidence to introduce other biomarkers in clinical practice. Possible explanations are 
the use of divergent patient selection criteria, lack of consensus in performing studies 
and absence of validation studies. 
Previously, a stepwise program for the introduction of biomarkers in clinical practice 
was developed with the first step being biomarker development in a preclinical, explor-
atory setting, subsequently followed by verification of this biomarker in a large retrospec-
tive study, validation and finally confirmation in a prospective randomized controlled 
trial 81. Future studies should focus on following this program and standardized methods 
for performing studies, according to Good Clinical Practice recommendations, have to 
be developed. Furthermore, since tumor cells may acquire multiple capabilities during 
tumor development 15, the combination of biomarkers may provide greater prognostic 
and predictive value than the use of one single marker. 
Over the last decade genomic profiling demonstrated its promising prognostic and 
predictive value in precision medicine and is therefore increasingly used in multidis-
ciplinary consultations for risk-assessment and subsequent treatment planning of the 
individual cancer patient. The added value of genomic profiling for systemic therapy 
seems clear. In Chapter 9 we have focused on the impact of genomic profiling on surgi-
cal decision-making. Apart from some single-gene mutations, genomic tumor profiling 
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in current clinical practice merely impacts surgical decision-making indirectly, as ge-
nomic tumor profiling of the biopsy might influence timing, extent and type of surgery 
by means of optimal tumor shrinkage through targeted neo-adjuvant therapy. Possibly, 
this may also lead to a wait-and-see approach in case of a pathological complete re-
sponse (pCR). However, some issues should be resolved before genomic profiling has a 
clear influence on surgery, such as lack of clarity how to assess a pCR, the ideal timing 
of clinical, radiological and pathological assessment of response, the uncertainty of the 
long-term efficacy of this strategy, new follow-up protocols and the question of when to 
have surgery after neo-adjuvant treatment. 
To achieve precision medicine in the future some important steps have to be taken. 
First, to increase clinical applicability, studies investigating biomarkers should focus on 
using standardized methods and comparable patient selection criteria in order to vali-
date the results. Second, as current cancer research mainly focuses on the genotypical 
approach of cancer treatment, which is believed to alter cancer treatment radically in 
the near future, the phenotype of the cancer patient is ignored. In our greying society, 
cancer patients often suffer from one or more comorbid conditions, which should be 
Figure 4: Precision medicine in the multimodality treatment of cancer.
By definition, precision medicine is a multi-faceted approach to medicine that integrates molecular and 
clinical research with patient data and outcomes and places the patient at the center of all elements.
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taken into account when making cancer treatment decisions. Both a direct effect of 
comorbidity (competing risk of mortality) as well as the interaction with cancer must 
be weighed in these treatment decisions. Thus, parallel to the existing TNM stage for 
treatment allocation and the exciting new developments of the epigenetic and genetic 
fingerprint of the tumor, phenotypic profiling must be incorporated in the treatment ap-
proach of an individual patient. Finally, specialists involved in cancer management need 
to join forces and create a collaborative multidisciplinary approach to provide the most 
efficient and tolerated treatment in order to achieve precision medicine as ultimate goal 
(Figure 4). 
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Het carcinoom van de dikke darm en endeldarm (colorectaal carcinoom, CRC) staat op 
de derde plaats van meest voorkomende tumoren wereldwijd en is tevens een van de 
grootste veroorzakers van kanker-gerelateerde sterfte 1;2. Ongeveer 20-25% van de pati-
enten presenteren zich al met een gemetastaseerde ziekte tijdens diagnose en 20-25% 
van de patiënten ontwikkelen metastasen tijdens de progressie van deze ziekte, wat 
resulteert in een mortaliteit van 40-45% 3;4.
CRC ontstaat meestal spontaan, in 5% van de gevallen is het erfelijk, via een staps-
gewijs proces van maligne ontaarding van gezonde cellen tot carcinoom, ook wel de 
adenoma-carcinoma sequentie genoemd 5. Een aantal jaar geleden werd duidelijk dat 
tumorcellen voor deze maligne ontaarding zes biologische eigenschappen moeten 
verkrijgen, de zogenaamde ‘hallmarks of cancer’6. Deze eigenschappen zijn autonomie 
van groeisignalen, ongevoeligheid voor groei-remmende signalen, invasieve groei en 
metastasering, immortaliteit, aanhoudende vaatnieuwvorming en ongevoeligheid 
voor apoptose (geprogrammeerde celdood). Recentelijk werden nog 2 belangrijke 
aanvullende eigenschappen erkend; reprogrammeren van het energiemetabolisme en 
ontsnappen aan herkenning door het immuunsysteem 7. Tevens werd de rol van het 
micromilieu rondom de tumor, die verantwoordelijk is voor het verkrijgen van deze 
eigenschappen, erkend. Genetische instabiliteit in een cel is verantwoordelijk voor het 
verkrijgen van deze tumoreigenschappen.
De belangrijkste pijler van behandeling van CRC is chirurgische verwijdering van de 
tumor met meenemen van bijbehorende lymfeklieren. De laatste decennia heeft de 
behandeling van colorectaal carcinoom zich sterk ontwikkeld. Mede door de introductie 
van nieuwe operatietechnieken, zoals de Totale Mesorectale Excisie (TME) bij rectumcar-
cinoom, preoperatieve radiotherapie bij rectumcarcinoom en adjuvante chemotherapie 
is de overleving van patiënten met CRC sterk verbeterd. Recent zijn er ook aanwijzingen 
gevonden dat behandeling met aspirine een remmende werking op tumorvorming en 
een positieve invloed op de overleving van patiënten met CRC heeft 8-15.
Tegenwoordig wordt de keuze voor een bepaalde operatie en aanvullende therapie 
sterk beïnvloed door tumorstadiëring en locatie van de tumor.  Echter, ongeveer 20-25% 
van de patiënten, die door een lage tumorstadiëring geen aanvullende therapie hebben 
gekregen, krijgen toch terugkeer van de ziekte binnen vijf jaar na diagnose 16. Tevens 
kunnen de nieuwe aanvullende behandelingen voor aanzienlijke bijwerkingen zorgen 
en weten we uit onderzoek dat niet iedere patiënt baat heeft bij een bepaalde aan-
vullende therapie. Deze tekortkomingen in het huidige gebruik van tumorstadiëring 
kunnen resulteren in zowel onderbehandeling als overbehandeling van patiënten. 
Tumorstadiëring is daarom niet een optimaal beslismodel om de prognose van een 
patiënt te voorspellen en patiënten te selecteren voor aanvullende therapie. Huidige 
inzichten laten zien dat de onderliggende biologie van CRC ook invloed heeft op de 
prognose van de patiënt en het slagen van een aanvullende behandeling. Op basis van 
228 Chapter 11
zogenaamde biomarkers, die een weergave vormen van de onderliggende biologie en 
daarmee de kans op tumorgroei en metastasering reflecteren, kan een accurate voor-
spelling worden gedaan over de prognose van de patiënt (prognostische biomarkers) of 
het slagen van een behandeling (predictieve biomarkers). De groei van een tumor zou 
optimaal voorspeld kunnen worden door een combinatie van klinische, pathologische 
en biologische tumorkarakteristieken, resulterend in een optimale gepersonaliseerde 
behandeling.
Dit proefschrift richt zich op sleutelbiomarkers vanuit de moleculaire biologie van 
CRC, waarmee een voorspelling kan worden gedaan over de prognose van een patiënt 
en het slagen van een behandeling.
DEEL EEN: PROGNOSTISCHE BIOMARKERS IN COLORECTAAL CARCINOOM
Met behulp van prognostische biomarkers, die betrokken zijn bij maligne ontaarding 
van darmepitheelcellen en progressie van tumoren,  kan een voorspelling worden 
gedaan over de prognose van een patiënt na resectie van de primaire tumor. Om dit te 
onderzoeken hebben we enkele biomarkers geselecteerd die behoren tot de ‘hallmarks 
of cancer’, zoals hierboven beschreven.
In hoofdstuk 2 en 3 hebben we de prognostische waarde van belangrijke biomarkers, 
die gerelateerd zijn aan het immuunsysteem, in zowel coloncarcinoom als rectumcarci-
noom onderzocht. Door middel van immunohistochemische kleuringen werd de tumo-
rexpressie van Humaan Leukocyt Antigeen (HLA) klasse I, HLA-E en HLA-G en tumorin-
filtratie van immunosuppressieve regulatoire T-cellen (Tregs) in kaart gebracht, met als 
doel het ontrafelen van ontsnappingsmechanismen van de tumor aan herkenning door 
het immuunsysteem. Er zijn aanwijzingen dat door genetische instabiliteit varianten 
van tumorcellen ontstaan, die een grotere kans hebben om aan het immuunsysteem te 
ontsnappen (‘immunoediting’). Deze tumorcellen kunnen vervolgens verder uitgroeien 
en metastaseren 17-20 . Een aantal mechanismen zijn daarvoor verantwoordelijk. HLA 
klasse I moleculen presenteren antigenen aan cytotoxische T-lymphocyten (CTL), die 
hierdoor schadelijke cellen voor het lichaam, zoals tumorcellen, kunnen herkennen 
en opruimen. Verminderde expressie van HLA klasse I op tumorcellen kan er dus voor 
zorgen dat deze cellen niet meer worden herkend en ontsnappen aan vernietiging door 
CTL 21. Tumorcellen kunnen naast het verminderen van de HLA klasse I expressie op 
hun celmembraan HLA-G tot expressie brengen. HLA-G komt zelden voor in gezonde 
weefsels, maar vertoont wel expressie in tumoren 22. HLA-E is daarentegen wel aanwe-
zig op verscheidene gezonde weefsels en correleert met expressie van HLA klasse I 23. 
Onderzoek heeft aangetoond dat tumorexpressie van HLA-E en HLA-G ervoor zorgt dat 
natural-killer (NK) cellen niet geactiveerd worden, waardoor tumorcellen nog verder 
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kunnen ontsnappen aan het immuunsysteem 23-25. Tenslotte kan infiltratie met Tregs in 
het micromilieu rondom de tumor zorgen voor remming van de activiteit van CTL 26;27.
In 285 ‘stadium I-IV’ patiënten met coloncarcinoom (hoofdstuk 2) was totale tumo-
rafschakeling van HLA klasse I gerelateerd aan een betere overleving. Deze bevinding 
zou kunnen worden verklaard doordat deze tumorcellen, zodra ze metastaseren naar 
de bloedbaan, opgeruimd worden door NK-cellen 28;29. Wanneer we de immuunmarkers 
combineerden in de statistische analyse zagen we 3 verschillende overlevingsgroepen 
ontstaan, die van significant prognostische waarde waren. Totale afschakeling van HLA 
klasse I in combinatie met afwezigheid van HLA-E en HLA-G op de tumor was geasso-
cieerd met de beste overleving. Door afwezigheid van HLA-E en HLA-G op de tumorcel 
werden deze tumoren waarschijnlijk nog beter opgeruimd  door NK-cellen 24;25. Patiënten 
met tumoren met verminderde expressie van HLA klasse I en weinig infiltratie van Tregs 
waren geassocieerd met de slechtste overleving. Deze tumoren zijn waarschijnlijk door 
activiteit van CTL veranderd in een tumorvariant met verminderde expressie van HLA 
klasse I, zodat ze verder kunnen ontsnappen aan herkenning door het immuunsysteem. 
Hierdoor kunnen deze tumorcellen nu niet goed meer door CTL opgeruimd worden, 
resulterend in verdere groei of metastasering van de tumorcellen. De afwezigheid van 
Tregs in deze tumoren versterkt onze hypothese aangezien CTL en Tregs tegengestelde 
werkingsmechanismen vertonen 30. In deze tumoren met een slechte prognose zijn 
Tregs waarschijnlijk niet noodzakelijk, omdat de aanwezigheid van CTL activiteit schaars 
is. Doordat er nog partiële expressie van HLA klasse I aanwezig is kunnen deze tumoren 
mogelijk ook niet goed opgeruimd worden door NK-cellen.
In hoofdstuk 3 hebben we de prognostische waarde van dezelfde biomarkers, 
wederom onafhankelijk van elkaar en gecombineerd, in 495 rectumtumoren van de 
Nederlandse TME-studie onderzocht.  Zowel expressie van HLA klasse I als een hoge 
Treg infiltratie was geassocieerd met een betere overleving.  Interessant was dat ook een 
sterke HLA-G expressie geassocieerd was met een betere overleving. Dit resultaat is op-
merkelijk, aangezien expressie van HLA-G als secundair ontsnappingsmechanisme NK-
cellen kan remmen om tumorcellen met verminderde expressie of totale afschakeling 
van HLA klasse I op te ruimen 24;25. De reden hiervoor is onduidelijk. Immuun-regulatie in 
tumorcellen blijft een complex fenomeen, waarvan nog niet alle immuun-gerelateerde 
ontsnappingsmechanismen in kaart gebracht zijn. Mogelijk speelt HLA-G geen grote 
rol in rectumcarcinoom. Wanneer de immuunmarkers werden gecombineerd in de 
statistische analyse, zagen we wederom 3 overlevingsgroepen ontstaan. De prognose 
van de patiënt nam toe bij toename van het aantal markers die waren gerelateerd aan 
een goede prognose, zoals expressie van HLA klasse I, hoge Treg infiltratie en expressie 
van HLA-G. Interessant was dat patiënten met tumoren met totale afschakeling van 
HLA klasse I, expressie van HLA-G en weinig infiltratie met Tregs de slechtste prognose 
hadden. Deze tumoren hebben zich mogelijk zodanig aangepast dat ze goed kunnen 
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ontsnappen aan het immuunsysteem. Door verlies van HLA-expressie is er geen herken-
ning door CTL en door expressie van HLA-G ook geen opruiming van de tumorcellen 
door NK-cellen. HLA-G lijkt in deze fase van ‘immunoediting’, wanneer HLA klasse I totaal 
afgeschakeld is, wel een belangrijke rol in de overleving van tumorcellen te spelen.
De uitgevoerde studies tonen aan dat er waarschijnlijk verschillen bestaan tussen co-
loncarcinoom en rectumcarcinoom. De meeste studies die onderzoek hebben gedaan 
naar de relatie tussen immuunmarkers en prognose hebben deze studies uitgevoerd 
in patiënten-cohorten met zowel rectumtumoren als colontumoren 31;32. Deze studies 
laten vaak zien dat totale afschakeling geassocieerd is met een betere overleving. 
Echter, in rectumcarcinoom was HLA-expressie gerelateerd aan een betere overleving. 
Mogelijk zijn biologische verschillen tussen rectum en colon verantwoordelijk voor deze 
verschillen. Een van de biologische verschillen tussen rectum- en colontumoren is het 
fenomeen microsatellietinstabiliteit (MSI). Ongeveer 50% van de proximale coloncarci-
nomen vertonen MSI, terwijl bijna alle tumoren in het rectum juist microsatellietstabiele 
(MSS) tumoren zijn 33;34. MSI is geassocieerd met totale afschakeling van HLA klasse I en 
een betere overleving, wat de resultaten kan vertroebelen 35;36. Daarom is het noodzaak 
om, wanneer naar HLA klasse I expressie gekeken wordt in colorectale tumoren, de 
microsatellietstatus van de tumor in acht te nemen. Helaas was het aantal patiënten 
met MSI-tumoren in ons coloncarcinoomcohort te klein om separate analyses in MSI- en 
MSS-tumoren uit te voeren.
In hoofdstuk 4 hebben we de prognostische waarde van biomarkers die gerelateerd 
zijn aan apoptose en proliferatie onderzocht. Een disbalans tussen deze twee processen 
kan bijdragen aan het ontstaan en onderhouden van tumorgroei en –ontwikkeling 6;7. 
Verschillende studies laten tegenstrijdige resultaten zien wanneer gekeken wordt naar 
de prognostische waarde van apoptose of proliferatie, met name tussen tumoren 
afkomstig van het colon of rectum 37-40. Ook lijkt er sprake te zijn dat de microsatel-
lietstatus van invloed kan zijn op deze processen 39;41;42. In 285 ‘stadium I-IV’ patiënten 
met coloncarcinoom hebben we de mate van apoptose en proliferatie onderzocht door 
middel van immunohistochemische kleuringen met antilichamen tegen respectievelijk 
actief caspase-3 (een apoptose-inducerend enzym) en ki67 (proliferatiemarker).  Deze 
studie liet zien dat patiënten met tumoren met zowel een sterke tumorcelproliferatie 
als apoptose de beste overleving hebben. Interessant was echter dat de uitkomst van 
deze studie varieerde met de locatie van de tumor en waarschijnlijk met de microsatel-
lietstatus van de tumor. Helaas was het aantal MSI-tumoren in ons cohort te klein om 
separate analyses uit te voeren. Echter, MSI werd wel significant meer waargenomen 
in rechtszijdige tumoren. Een balans tussen apoptose en proliferatie (aanwezigheid 
van een sterke tumorcelproliferatie en aanwezigheid van apoptose, of afwezigheid van 
beide processen) was geassocieerd met een betere overleving in linkszijdige colontumo-
ren. Zoals je kan verwachten van sterk prolifererende tumoren, hadden patiënten met 
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linkszijdige tumoren waarin sprake was van een sterke proliferatie en afwezigheid van 
apoptose de slechtste overleving. In de rechtszijdige tumoren daarentegen, lieten de 
tumoren met een sterke proliferatie en afwezigheid van apoptose een betere overleving 
zien. Locatie van de tumor of tumormicrosatellietstatus hebben dus mogelijk invloed op 
de prognostische waarde van deze markers gezamenlijk. Eerder onderzoek heeft laten 
zien dat MSI-tumoren vaak veel proliferatie laten zien. Tevens vertonen MSI tumoren 
veel genmutaties, waardoor sprake is van een verhoogde productie van abnormale 
eiwitten 41;42. Dit leidt mogelijk tot een sterke immuunreactie met als gevolg toename 
van apoptose in de tumoren. De betere prognose van deze patiënten met rechtszijdige 
tumoren met een sterke proliferatie zou hierdoor kunnen worden verklaard 43. In de 
toekomst zullen deze resultaten gevalideerd moeten worden, waarbij rekening moet 
worden gehouden met de locatie en de microsatellietstatus van de tumor.
In hoofdstuk 5 hebben we een validatie uitgevoerd van de 12-gene Colon Cancer 
Recurrence Score® Assay in 297 patiënten met rectumcarcinoom uit de Nederlandse 
TME-trial die een operatieve verwijdering van hun tumor hebben ondergaan, zonder 
preoperatieve bestraling. Deze test, die de expressie meet van 12 genen, was eerder al 
gevalideerd in meerdere trials in patiënten met stadium II coloncarcinoom 44;45. Geba-
seerd op de expressie van de genen worden patiënten ingedeeld in 3 groepen; een laag 
risico, gemiddeld risico en hoog risico op terugkeer van de ziekte. In deze validatiestudie 
in rectumcarcinoom voorspelde de Recurrence Score® (RS) het risico op terugkeer van de 
ziekte, het risico op afstandsmetastasen en rectumcarcinoom-specifieke overleving. Het 
effect was het meest zichtbaar in stadium II rectumcarcinoom. RS zou in de toekomst 
mogelijk in de kliniek gebruikt kunnen worden om patiënten met een hoog of laag risico 
op terugkeer van de ziekte te selecteren voor respectievelijk wel of geen adjuvante 
chemotherapie.
DEEL TWEE: BEHANDELING VAN COLONCARCINOOM EN PREDICTIEVE 
BIOMARKERS
Onderzoek toont aan dat aspirinegebruik na de diagnose de overleving en mortaliteit 
van patiënten met CRC sterk verbetert 9-11;46.  In hoofdstuk 6 hebben we het effect 
van aspirinegebruik (80 mg) na de diagnose op de overleving onderzocht door een 
subanalyse te verrichten in ouderen (≥ 70 jaar) met coloncarcinoom uit het cohort dat 
eerder is gebruikt door Bastiaannet et al.46. In deze studie was aspirinegebruik na de 
diagnose significant geassocieerd met een sterk verbeterde overleving in ouderen met 
coloncarcinoom vergeleken met niet-gebruikers. Al deze studies impliceren dat het 
goed getolereerde en goedkope aspirine mogelijk gebruikt kan worden als een nieuwe 
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adjuvante therapie, wat zeker bij ouderen met colon carcinoom een grote klinische 
doorbraak zal zijn.
Het exacte mechanisme achter dit fenomeen is nog niet bekend. Mogelijk spelen 
bepaalde enzymen en genen daarbij een rol, waaronder het enzym COX-2 (cyclooxy-
genase-2), COX-1 (cyclooxygenase-1) en het gen PIK3CA. COX-1 is verantwoordelijk 
voor trombocytenaggregatie door productie van TXA2 in trombocyten, waarop aspirine 
aangrijpt 47. COX-2 is een enzym dat betrokken is bij de prostaglandine productie en 
maligne ontaarding van epitheliale cellen, wat kan worden geremd door aspirine 48;49. 
Ongeveer 70% van de CRCs vertonen expressie van COX-2 9 . Recent onderzoek liet 
echter ook zien dat aspirine mogelijk tumorgroei remt en apoptose induceert door het 
blokkeren van de phosphatidylinositol 3-kinase (PIK3CA) signaleringroute, die verant-
woordelijk is voor de aansturing van COX-2 50. Deze route speelt een belangrijke rol 
in tumorgroei en progressie 51. In 15-20% van de CRCs worden mutaties in het PIK3CA 
gevonden. Aspirine zou mogelijk alleen een positieve invloed hebben op de overleving 
van patiënten met een CRC indien er sprake is van een PIK3CA-mutatie in de tumor 52 of 
verhoogde expressie van COX-2 9.
Omdat aspirinegebruik gepaard kan gaan met negatieve bijwerkingen bij de patiënt 
en mogelijk kan resulteren in overbehandeling, hebben we in hoofdstuk 7 onderzoek 
gedaan naar predictieve biomarkers die kunnen voorspellen welke patiënten met co-
loncarcinoom baat hebben bij aspirinetherapie na de diagnose. In de bloedbaan kan het 
metastaseringsvermogen van tumorcellen worden beïnvloed door omgevingsfactoren, 
waaronder trombocyten en cellen afkomstig van het beenmerg 53. Zodra tumorcel-
len de bloedbaan binnen dringen, komen ze in contact met trombocyten 54. Er wordt 
gedacht dat trombocyten metastaserende tumorcellen in de bloedbaan beschermen 
tegen immuuncellen, zoals NK-cellen. Doordat trombocyten als het ware een schild 
vormen rondom tumorcellen wordt de NK-reactiviteit beïnvloed 55. De interactie tussen 
tumorcellen en trombocyten resulteert in verplaatsing van HLA klasse I expressie van 
de trombocyt naar het celmembraan van de tumorcel, resulterend in een HLA klasse I 
fenotype. Hierdoor wordt NK-cel activiteit geblokkeerd. Doordat HLA klasse I afkomstig 
is van de trombocyt, wat niet als lichaamsvreemd herkend wordt, worden CTL ook niet 
geactiveerd 55.
Aspirine remt de trombocytenaggregatie 47 en aannemelijk is dat het schild van 
trombocyten rondom de tumorcel ook geremd wordt, met als gevolg dat trombocyten 
de metastaserende tumorcellen niet meer kunnen beschermen tegen afbraak  door im-
muuncellen, zoals de NK-cellen. NK-cellen herkennen en elimineren bij voorkeur cellen 
met totale afschakeling of verminderde expressie van HLA klasse I 55. De hypothese van 
deze studie was dan ook dat de overlevingswinst van aspirinegebruik na de diagnose 
coloncarcinoom geassocieerd is met tumoren met totale afschakeling of verminderde 
expressie van HLA klasse I. Echter, in strijd met onze hypothese, vonden we in deze 
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studie, waarbij tumorweefsel van 999 patiënten met coloncarcinoom beschikbaar was, 
dat aspirinegebruik na de diagnose alleen een positieve invloed heeft op overleving 
indien er sprake is van HLA expressie op de tumor. Er zijn twee mogelijke verklaringen 
voor dit fenomeen. Ten eerste zou aspirinegebruik kunnen zorgen voor verstoring van 
trombocyten, waardoor tumorcellen met HLA klasse I nu meer toegankelijk worden 
voor CTL activiteit. Ten tweede zorgt direct contact tussen trombocyten en tumorcellen 
voor secretie van TGF-β en activatie van de NF-ĸB signaleringsroute, wat resulteert in 
een epitheliaal-mesenchymaal fenotype met een verhoogd metastaseringsvermogen 
van de circulerende tumorcellen 53.  Aspirine zou de NF-ĸB signalering tussen trombo-
cyten en tumorcellen, die mogelijk afhankelijk is van een intacte HLA klasse I expressie, 
kunnen remmen. Hierdoor kan de epitheliale-mesenchymale transitie in circulerende 
tumorcellen worden voorkomen met als gevolg een vermindering van het metastase-
ringsvermogen.
Onze studie heeft niet kunnen bevestigen dat aspirinegebruik alleen een positief ef-
fect heeft op de overleving van patiënten met coloncarcinoom wanneer er sprake is van 
verhoogde COX-2 expressie of een PIK3CA mutatie. Een farmacologische oorzaak kan 
daaraan ten grondslag liggen. Farmacologische studies naar het gebruik van aspirine 
tonen aan dat een lage dosis (80 mg), die gebruikt is in onze studie, niet genoeg is om 
permanent COX-2 te acetyleren, maar wel de optimale dosis is voor trombocyten rem-
ming 56. In de studies die hebben aangetoond dat PIK3CA en COX-2 expressie predictieve 
biomarkers zijn voor de positieve invloed van aspirinegebruik in CRC was de dosis 325 
mg 57;58.
Mogelijk heeft aspirine meerdere werkingsmechanismen in CRC;  een direct effect op 
trombocyten door remming van COX-1, nodig voor het remmen van metastasering en 
waarvoor een lage dosering aspirine genoeg is; en een tweede mechanisme dat in de 
weefsels COX-2 expressie remt, waarvoor een hogere en meer frequente dosering nodig 
is.
DEEL DRIE: GEPERSONALISEERDE BEHANDELING VAN COLORECTAAL 
CARCINOOM
De huidige classificering middels de TNM stadiëring, waarbij rekening wordt gehouden 
met de tumor zelf (T), de betrokken lymfeklieren (N) en metastasering op afstand (M), 
blijkt niet een optimaal handvat te zijn voor artsen om een bepaalde behandelings-
strategie te bepalen. Het is daarom belangrijk om additionele biomarkers te vinden 
die de huidige tumorstadiëring kunnen verbeteren. Met gebruik van biomarkers 
naast de bestaande tumorstadiëring zou de prognose van een patiënt beter kunnen 
worden ingeschat en de behandeling worden geoptimaliseerd. Het uiteindelijke doel 
van de ontdekking en ontwikkeling van al deze klinische prognostische en predictieve 
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biomarkers is een optimaal multidisciplinair bepaalde behandeling gericht op de indivi-
duele patiënt. Deze gepersonaliseerde behandeling integreert moleculaire en klinische 
tumoreigenschappen met patiëntkarakteristieken. (Epi)genetische eigenschappen en 
externe factoren worden samen met patiëntkarakteristieken bestudeerd, waardoor 
de ziekteprogressie van een individuele patiënt beter in kaart kan worden gebracht 
en betere preventieve, diagnostische en therapeutische methoden kunnen worden 
ontwikkeld.
Helaas worden, ondanks een enorme overvloed aan gepubliceerd onderzoek naar 
biomarkers, in de praktijk op aanvraag slechts enkele biomarkers gebruikt. Voorbeelden 
hiervan zijn KRAS en BRAF om te bepalen of een patiënt met gemetastaseerd CRC ge-
schikt is voor behandeling met cetuximab of panitumumab, MSI voor het bepalen van 
het erfelijke Lynch syndroom en de Oncotype DX Colon Cancer Assay om te bepalen 
of aanvullende behandeling in stadium II en III coloncarcinoom wenselijk kan zijn. In 
hoofdstuk 8 hebben we een overzicht gemaakt van de meest bestudeerde biomarkers 
in CRC. Echter, de meeste biomarkers worden, ondanks de mooie resultaten die zijn 
gepubliceerd, niet gebruikt in de kliniek. Het gebrek aan consensus in de patiënten 
selectiecriteria en het uitvoeren van studies, en de afwezigheid van validatie studies zijn 
mogelijke oorzaken die hieraan ten grondslag liggen. De moeilijkheden en controverses 
die gepaard gaan met de klinische introductie van een biomarker worden verder in 
dit hoofdstuk besproken.  Uit dit overzicht hebben we moeten concluderen dat er op 
dit moment onvoldoende bewijs is om naast KRAS, BRAF, MSI en Oncotype DX andere 
biomarkers in de kliniek te gebruiken.
In de toekomst zou een stappenplan voor de klinische introductie van een biomar-
ker kunnen worden gebruikt om dit probleem op te lossen 59. De eerste stap van dit 
programma zou bestaan uit ontwikkeling van een biomarker in een preklinische explo-
ratieve setting, gevolgd door verificatie van de biomarker in een grote retrospectieve 
studie, validatie en uiteindelijk bevestiging van de waarde van de biomarker in een 
prospectieve gerandomiseerde trial.  Tevens zou een combinatie van biomarkers meer 
prognostische en predictieve waarde kunnen bieden dan het gebruik van één enkele 
biomarker.
De laatste jaren heeft genotypering ook een veelbelovende voet aan de grond 
gekregen in de behandeling van CRC, waarbij met name de risicopredictie en de behan-
delingsstrategie van de individuele patiënt centraal staan.  Alhoewel de toegevoegde 
waarde van genotypering voor het bepalen van systemische therapie duidelijk lijkt, 
zoals ook beschreven in hoofdstuk 5, is de impact van genotypering op chirurgisch vlak 
onduidelijk. In hoofdstuk 9 wordt de rol van genotypering in de chirurgische besluit-
vorming bediscussieerd.  Behoudens enkele afzonderlijke genetische mutaties die een 
directe invloed hebben op chirurgisch ingrijpen, zoals BRCA mutaties in borstkanker 
waarvoor een profylactische bilaterale mastectomie wordt geadviseerd, is er tot op he-
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den geen directe relatie tussen genotypering en chirurgische besluitvorming. Indirect 
kan genotypering echter wel invloed hebben op de chirurgische besluitvorming. Geno-
typering van een preoperatief biopt kan leiden tot een gerichte neo-adjuvante therapie, 
leidend tot een mogelijke tumorregressie, met als gevolg dat de timing en omvang 
van de operatie worden beïnvloed. Indien door een gerichte neo-adjuvante therapie 
complete remissie van de tumor optreedt, zou zelfs een ‘wait-and-see’ benadering tot 
de mogelijkheden behoren. Echter, voordat genotypering een duidelijk rol zal spelen 
in de chirurgische besluitvorming zal er eerst meer duidelijkheid moeten zijn over hoe 
een complete remissie wordt vastgesteld, hoeveel tijd er tussen de gegeven gerichte 
therapie en het vaststellen van het therapie effect moet zitten, wat de lange termijn 
effecten van deze strategie zijn en wanneer de operatie na deze gerichte neo-adjuvante 
therapie moet plaatsvinden.
Om uiteindelijk de veelbelovende gepersonaliseerde behandeling met behulp van 
biomarkers en genotypering van kankerpatiënten te bereiken, moeten belangrijke 
stappen worden genomen. Ten eerste is het, zoals hierboven beschreven, voor de ont-
wikkeling en validatie van biomarkers en genotyperingsprofielen belangrijk om gestan-
daardiseerde methoden en vergelijkbare patiëntcohorten te gebruiken, waarmee de 
integratie in de kliniek verbeterd kan worden. Ten tweede is het in onze vergrijzende po-
pulatie ook niet onbelangrijk om het fenotype van een patiënt in acht te nemen. Zowel 
de comorbiditeiten van oudere patiënten als de invloed van deze comorbiditeiten op de 
tumor moeten worden meegenomen in een gewogen patiëntgerichte behandelings-
strategie. Tenslotte is het  van groot belang dat alle specialisten die betrokken zijn bij 
kankerbehandeling hun krachten nog verder bundelen, waardoor de reeds bestaande 
multidisciplinaire behandeling van tumoren verder uitgebreid kan worden met kennis 
op het gebied van tumorbiologie. Door inachtneming van deze belangrijke factoren zal 
in de toekomst aan iedere individuele patiënt de meest efficiënte en draaglijke behan-
deling kunnen worden geboden.
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